

# **AMUNDI ALTERNATIVE FUNDS PLC**

(An umbrella fund with variable capital and segregated liability between sub-funds)

**ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

REGISTRATION NUMBER: 492331

# AMUNDI ALTERNATIVE FUNDS PLC

<b>TABLE OF CONTENTS</b>	<b>PAGE</b>
COMPANY INFORMATION	2
DIRECTORS' REPORT	3-6
INVESTMENT MANAGER'S REPORT	7-29
DEPOSITARY'S REPORT	30
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF AMUNDI ALTERNATIVE FUNDS PLC	31-33
STATEMENT OF FINANCIAL POSITION	34-37
STATEMENT OF COMPREHENSIVE INCOME	38-39
STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES	40-41
STATEMENT OF CASH FLOWS	42-43
NOTES TO THE FINANCIAL STATEMENTS	44-95
SCHEDULE OF INVESTMENTS	96-110
APPENDIX A: SCHEDULE OF PURCHASES AND SALES OF INVESTMENTS (UNAUDITED)	111-114
APPENDIX B: TOTAL EXPENSE RATIO (UNAUDITED)	115-116

# AMUNDI ALTERNATIVE FUNDS PLC

## COMPANY INFORMATION

### Directors

Mr. Vincent Dodd\* (Irish)  
Mr. Bryan Tiernan\* (Irish)  
Mr. Moez Bousarsar (French)  
Mr. Declan Murray (Irish)  
Mr. Paul Weber (Irish) resigned on 21 November 2023  
Mr John O'Toole (Irish) resigned on 21 November 2023  
Mr. Colm Callaly (Irish)

\*Independent Director  
All Directors are non-executive Directors

### Registered Office

70 Sir John Rogerson's Quay  
Dublin 2  
Ireland

### Manager, Promoter and Global Distributor

Amundi Asset Management S.A.S.  
91-93, Boulevard Pasteur  
75015 Paris  
France

### Depositary

CACEIS Bank, Ireland Branch  
Bloodstone Building  
Sir John Rogerson's Quay  
Dublin 2  
Ireland

### Company Secretary

Matsack Trust Limited  
70 Sir John Rogerson's Quay  
Dublin 2  
Ireland

### Sub-Fund

Amundi Tiedemann Arbitrage Strategy Fund  
Amundi Sandler US Equity Fund

The following abbreviated names for the Company's sub-funds were used in the Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares, Statement of Cash Flows and on the tables in the Notes to the Financial Statements and the Unaudited disclosure sections of the financial statements:

### Sub-Fund Full Name

Amundi Tiedemann Arbitrage Strategy Fund  
Amundi Sandler US Equity Fund

### Administrator

SS&C Financial Services (Ireland) Limited  
*(Effective from 3 November 2023)*  
3rd Floor,  
Bishop Square,  
Redmond's Hill,  
Dublin 2  
D02 TD99

*(Effective until 2 November 2023)*

La Touche House  
Custom House  
Dock  
IFSC  
Dublin 1  
Ireland

### Investment Manager

Amundi Asset Management S.A.S.  
91-93, Boulevard Pasteur  
75015 Paris  
France

### Legal Adviser

Matheson  
70 Sir John Rogerson's Quay  
Dublin 2, Ireland

### Independent Auditors

PricewaterhouseCoopers  
Chartered Accountants and Statutory Audit  
Firm  
One Spencer Dock  
North Wall Quay  
Dublin 1  
Ireland

### Registrar and Transfer Agent

CACEIS Ireland Limited  
One Custom House Plaza  
IFSC  
Dublin 1  
Ireland

### Sub-Investment Manager

TIG Advisors LLC  
Sandler Capital Management

## **AMUNDI ALTERNATIVE FUNDS PLC**

### **DIRECTORS' REPORT**

**For the year ended 31 December 2023**

The Directors submit their report together with the audited financial statements of Amundi Alternative Funds PLC (the "Company") for the year ended 31 December 2023.

#### **Background**

The Company is an investment company with variable capital constituted as an umbrella fund with segregated liability between Sub-Funds. The Company was incorporated on 7 December 2010 under the laws of Ireland pursuant to the Companies Act 2014 and is authorised by the Central Bank of Ireland (the "Central Bank") as an Undertaking for Collective Investment in Transferable Securities ("UCITS") pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (as amended) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (collectively the "UCITS Regulations").

As at 31 December 2023, the Company comprised of the following active Sub-Funds: the Amundi Tiedemann Arbitrage Strategy Fund and the Amundi Sandler US Equity Fund.

Amundi Asset Management S.A.S acts as the investment manager (the "Investment Manager") of the Company.

#### **Investment Objectives**

##### **Amundi Tiedemann Arbitrage Strategy Fund**

The investment objective of the Sub-Fund is to be exposed to the Amundi Tiedemann Arbitrage Strategy (the "Strategy") during the life of the Sub-Fund. The Strategy is based on two components, being (i) a proprietary discretionary trading strategy which has been developed by the Sub-Investment Manager (the "Trading Strategy") and (ii) an allocation of any excess cash to liquid assets pursuant to a process defined and implemented solely by the Investment Manager (the "Cash Allocation Process").

The Trading Strategy shall consist, primarily, of global equity investments in announced merger and acquisition transactions, based on analysis of the probability that the transactions will be consummated. In limited cases and under specific circumstances, positions in securities of companies not yet currently involved in such transactions but the price of which is or can be affected by anticipated acquisition or restructuring may also be taken from time to time.

The Sub-Fund will seek to achieve its investment objective by providing Shareholders with a return obtained from exposing up to 100% of the Sub-Fund's net assets to the performance of the Trading Strategy.

##### **Amundi Sandler US Equity Fund**

The investment objective of the Sub-Fund is to be exposed to the Amundi Sandler US Equity Strategy (the "Trading Strategy") during the life of the Sub-Fund. The Trading Strategy is based on two components, being (i) a proprietary discretionary trading strategy which has been developed by the Sub-Investment Manager (the "Trading Strategy") and (ii) an allocation of any excess cash to liquid assets pursuant to a process defined and implemented solely by the Investment Manager (the "Cash Portfolio").

The Trading Strategy's investment objective is to achieve capital appreciation across shifting economic and market environments, through both long and short positions in equities which are mainly but not exclusively listed on North American Recognised Markets.

The Sub-Fund will seek to achieve its investment objective by providing Shareholders with a return obtained from exposing up to 100% of the Sub-Fund's net assets to the performance of the Trading Strategy.

## **AMUNDI ALTERNATIVE FUNDS PLC**

### **DIRECTORS' REPORT (continued) For the year ended 31 December 2023**

#### **Investment Objectives (continued)**

#### **Statement of Directors' responsibilities**

The Directors are responsible for preparing the annual report and the financial statements in accordance with Irish law and International Financial Reporting Standards (IFRS's), as adopted by the European Union.

Irish company law requires the Directors to prepare financial statements for each financial year. Under Company law, the Directors must not approve these financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial year end date and of the profit or loss of the Company for that year. In preparing those financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from these standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements are prepared in accordance with IFRS's as adopted by the European Union and comply with the Irish Companies Act 2014, the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the "Central Bank UCITS Regulations" or collectively the "UCITS Regulations"). They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The Directors, together with Amundi Asset Management S.A.S., the Investment Manager, are responsible for the maintenance and integrity of the publication of these financial statements online. Legislation in the Republic of Ireland governing the presentation and dissemination of the financial statements may differ from legislation in other jurisdictions.

Under the UCITS Regulations, the Directors are required to entrust the assets of the Company to a Depositary. CACEIS Bank Ireland Branch have been appointed as the Depositary.

## AMUNDI ALTERNATIVE FUNDS PLC

### **DIRECTORS' REPORT (continued)** **For the year ended 31 December 2023**

#### **Adequate accounting records**

The measures taken by the Directors to secure compliance with section 281 to 285 of the Companies Act 2014 to keep adequate accounting records are the use of appropriate systems and procedures and employment of competent persons. The accounting records are kept at the following address: SS&C Financial Services (Ireland) Limited, 3rd Floor, Bishop Square, Redmond's Hill, Dublin 2, D02 TD99 (effective from 3 November 2023) and La Touch House, IFSC, Dublin 1, Ireland (effective until 2 November 2023).

#### **Review of the business and future developments**

A detailed review of the business and any future developments are included in the Investment Manager's Report.

#### **Corporate governance**

The Company has adopted in full the voluntary Corporate Governance Code for Irish domiciled Collective Investment Schemes and Management Companies (the "Code") as published by Irish Funds, the text of which is available from the Irish Funds website, [www.irishfunds.ie](http://www.irishfunds.ie). The Company has been fully compliant with the Code for the financial year ended 31 December 2023 (31 December 2022: same).

#### **Companies Registration Office ("CRO")**

Investment companies are now required to file the statutory financial statements, statutory auditor's report and directors' reports with the CRO not later than 11 months after the end of each financial year which commenced on or after the 1 January 2018. Such documents will be publicly available on the CRO's website.

#### **Risk management objectives and policies**

The main risks arising from the Company's financial instruments are market risk (including market price risk, currency risk and interest rate risk), credit risk and liquidity risk, as set out in Note 10.

#### **Results and dividends**

The results for the year are set out in the Statement of Comprehensive Income. The Directors do not propose the payment of dividends during the year.

#### **Political donations**

No political donations were made during the year (31 December 2022: NIL).

#### **Directors**

The Directors at 31 December 2023 are set out below. All served for the year covered by the audited financial statements unless otherwise stated.

Vincent Dodd* (Irish)	Declan Murray (Irish)
Bryan Tiernan* (Irish)	John O'Toole (Irish) resigned on 21 November 2023
Moez Bousarsar (French)	Paul Weber (Irish) resigned on 21 November 2023
Colm Callaly (Irish)	

\*Independent Director

#### **Directors' and Secretary's interests**

The Directors and Secretary and their families had no interest in the shares of the Company as at 31 December 2023. No Director had, at any time during the year, a material interest in any contract of significance, subsisting during or at the end of the year, in relation to the business of the Company. All Directors' fees are borne by the Manager.

## AMUNDI ALTERNATIVE FUNDS PLC

### **DIRECTORS' REPORT (continued)** **For the year ended 31 December 2023**

#### **Connected person transactions**

The Manager is satisfied that: (i) there are adequate arrangements in place, to ensure that the obligations set out in Regulation 41 (1) of the Central Bank UCITS Regulations are applied to all transactions with connected persons; and (ii) transactions with connected persons entered into during the year complied with the obligations set out in that paragraph.

#### **Directors' compliance statement**

The Directors acknowledge that they are responsible for securing the Company's compliance with the relevant obligations as set out in Section 225 of the Companies Act 2014.

The Directors confirm that:

1. A compliance policy statement has been drawn up that sets out policies that, in our opinion, are appropriate to the Company, respecting compliance by the Company with its relevant obligations;
2. Appropriate arrangements or structures are in place that, in our opinion, are designed to secure material compliance with the Company's relevant obligations; and
3. During the financial year, the arrangements or structures referred to in (2) have been reviewed.

#### **Audit information**

In accordance with Section 330 of the Companies Act 2014, each of the Directors believes the following to be the case:

- So far as the Directors are aware, there is no relevant audit information of which the Company's statutory auditors are unaware; and
- The Directors have taken all steps that they ought to have taken as Directors in order to make themselves aware of any relevant audit information and to establish that the Company's statutory auditors are aware of that information.

#### **Significant events during the year**

Refer to Note 20 of the financial statements for the details of significant events during the year.

Russia's invasion of Ukraine caused a closure of the Moscow stock exchange and then the closure of the market for Global Depositary Receipts replicating Russian assets and has had an impact on energy and other commodity costs. Although this has not had a material effect on the fund, we have seen bouts of volatility arising as a result. We continue to monitor developments in this crisis and its impact on the management of the fund.

#### **Subsequent events**

Refer to Note 21 of the financial statements for the details of subsequent events.

#### **Independent auditors**

PricewaterhouseCoopers have expressed their willingness to continue in office in accordance with Section 383(2) of the Companies Act 2014.

Signed on behalf of the Board of Directors:

\_\_\_\_\_  
Bryan Tiernan  
Director

29 April 2024

\_\_\_\_\_  
Vincent Dodd  
Director

29 April 2024

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund

Over the full year 2023, the Fund posted a positive performance of 8.35 % (I USD). The Amundi Tiedemann Arbitrage Strategy Fund was down -0.25% for the month of January. In **January**, we started to see signs of market stabilization as the S&P 500 was up +6.60% and the Nasdaq composite was up +11.52%. As a result, there was some pickup in deal activity, specifically the hostile takeover approach from Emerson for National Instruments and the Bain Consortium counterbid for Caverion. However, the antitrust environment and credit markets continue to be a counterforce to new deal flow. As we have mentioned in past letters, the regulatory review process has been as difficult as it has ever been, as frequent intervention from government entities has been viewed as “random acts of violence.” In the US, Senator Elizabeth Warren has recently written letters to the Federal Trade Commission (FTC) and Department of Justice (DOJ), asking for careful scrutiny of the Activision, Tegna, Aerojet, Horizon Therapeutics, Spirit Airlines and Albertsons mergers. Outside the US, the European Commission seems to be willing to accept behavioral remedies, but the Competition and Markets Authority seems to align with the FTC on its progressive agenda. This has impacted position sizing across our portfolio, as only 15% of capital is involved in complex antitrust M&A. Lastly, credit markets seem to be improving as “hung debt” from previous LBO transactions is being offloaded by banks. Currently, the hung debt is approximately \$15 billion, down from \$70 billion. Until the loans are offloaded, banks’ capacity to underwrite new large buyout financing is limited, leading to a stall in M&A activity. There is a strong appetite to do deals, however CEOs are concerned about doing large acquisitions given the macro uncertainty. The three biggest winners of the month were Sierra Wireless, Altra Industrial Motion, and Shaw Communications. Heading into 2023, Semtech’s acquisition of Sierra Wireless was in the midst of a Second Request with the DOJ. The second request completely caught the companies, and the market, by surprise, potentially risking dragging the deal past the end date of March 4. The second request caused the gross spread to go from 0.80% to a wide of 9%. However, we were confident that there was no reasonable antitrust case and doubled the position size from 1.5% to 3% following the issuance of the second request. In mid-January, the companies announced it received early termination of the second request, and the deal closed. We started the month with a 3.5% of capital position in AIMC and 3.8% gross spread. We also bought 35 bps of Regal Rexnord, the acquirer, following a decline of 20% from the deal announcement over concerns of leverage, giving up more value in market cap than the premium paid for AIMC. On January 19, SAMR accepted the RRX deal filing under a simplified procedure, causing the spread to compress to 1.6% gross. Further, RRX stock price recovered 15% as investors became comfortable with management stress testing a reduction of leverage in a recessionary environment. We ended the month with 3.75% of capital in AIMC and exited our position in RRX. Shaw was the third largest contributor for the month following the Competition Tribunal ruling in favor of the merging parties on December 29. As a result, we reduced our position substantially to circa 1%. In the early days of January, the spread widened 2% as Competition Bureau Canada filed for an appeal and a Temporary Restraining Order was issued, preventing the merger from closing pending a hearing on a stay. We were surprised to learn during a conference management hearing at the appellate court that the Judge would rule on the appeal by the end of the month, therefore opening a path to a 0-30 day event. In advance of the trial, we had increased our position to 3% of capital. We further increased the position to 4.5% on January 24 as the hearing played extremely well in the favor of the merging parties. The judge ruled that same day to uphold the decision. The three largest losers of the month were Tegna, Horizon Therapeutics, and 1Life. Healthcare. We entered January with 3.75% of capital in Tegna. The stock traded up in December after the parties’ put commitments on the docket to resolve concerns voiced by commenters. The Federal Communications Commission (FCC) opened a pleading cycle running to January 20 to solicit feedback from commenters about the sufficiency of the commitments. While the feedback from the cable companies was receptive, the unions remained opposed to the transaction. The stock then traded down on the news that Gigi Sohn, who is expected to be skeptical of the transaction, was renominated to fill the open FCC commission seat. A media-only press conference held by Standard General was viewed as a negative signal by the market. Reports also suggested that the DOJ still had concerns about the transaction, putting further downward pressure on the stock. We started the month with a 5% of capital position in Horizon Therapeutics. As we became more comfortable with the antitrust concerns, we increased the position to 6%. On January 26, four days before the expiry of HSR, Senator Elizabeth Warren wrote a letter to the Chairwoman of the FTC asking for scrutiny of the Horizon Therapeutics/Amgen which caused the gross spread to widen from 3.1% to a high of 7.8%. The day before the letter, we had reduced the position by 25 bps and sold another 50 bps in the days following to bring the position to 5%. We ended the month with 5.25% of capital in Horizon at a 6% gross spread. For 1Life Healthcare, we started the month with 2.5% of capital invested and 41% putted with January and February \$15 strike puts to limit our downside. On January 12, the FTC announced they were going to hold a closed-door meeting on January 19, and we started to reduce the position to 2% and increased the put position to 65%. By the end of the month, we increased the position to 2.25% of capital and 35% of the position putted. The top 3 detractors in January were all impacted by regulatory challenges. Given the ultra-aggressive nature in the FTC, DOJ, and other regulators, and the actions they have recently taken on Activision/Microsoft and other deals that have been sued, we continue to be very cautious about the regulatory environment and the risk reward presented.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

One of the factors impacting position sizing in the portfolio is that deal timing is being pushed out; a second request from the FTC or DOJ naturally requires additional time to fulfill the request for more information. We feel well positioned going forward having reduced our exposure to long duration, complex regulatory deals and will continue to focus on 0-30 day events.

The Amundi Tiedemann Arbitrage Strategy Fund was down -0.21% for the month of **February**. In February, the extreme regulatory environment continued to weigh on performance. We are seeing the U.S. government utilize all agencies available to them, including the Federal Communications Commission (FCC) and more recently, the Department of Transportation (DOT) to hinder mergers with perceived anticompetitive behavior. As a result of the intense regulatory scrutiny in the United States and Europe, more deals are ending up in court causing mergers to be in purgatory for a long period of time and spreads to widen. Ultimately, we believe this sets our team up for attractive opportunities to short deals and generate alpha as we have two dedicated regulatory analysts with years of experience attending trials. Meanwhile, the credit environment is improving as the hung debt from 2021 LBOs continues to trend downward. While our exposure is low compared to historical levels, our focus is on preserving capital and identifying 0-to-30-day events. The three biggest winners of the month were 1Life Healthcare, Atlas Corporation, and Caverion. 1Life Healthcare was a roller coaster of a process. Although the deal presented no reasonable antitrust concern, it attracted a great deal of attention because of Amazon's involvement and the recent crusade by the Federal Trade Commission (FTC) under Lina Khan. Reports indicated that a suit was coming, and we had recently seen the FTC sue to block mergers with very questionable antitrust issues. The stock traded as low as \$15 as these concerns mounted. However, at the last moment, the FTC dropped the case due to lack of evidence and the deal closed. We held a 200 bps position heading into the news. We believed that the 1Life Healthcare stock would drop on a deal break; as a result, we defined our downside with the strike put options. Atlas was the second largest contributor in February. From the beginning of the year, fear began to circulate that China may force the deal into a full SAMR review which could extend the timeline by five months. We were also still waiting on a condition to close the merger regarding the refinancing of the 2026 bonds. We were confident in the consortiums commitment to the deal and our research indicated that the bonds would be dealt with and would not impede the transaction. In addition, China announced that the deal would be dealt with in a simplified review which dramatically shortened the time to close. Caverion was the third largest contributor of the month. At the eleventh-hour, Triton announced an \$8 per share competing bid for Caverion that was in the midst of a deal with Bain for \$7 per share. In January, Bain matched Triton's offer and set a February 28 close date for the deal. Leading into that date, we were confident that Triton had more money to contribute and grew the position to 85 bps. On February 23, Triton announced an increased offer of \$8.95 per share and the stock traded to \$9. The three largest losers of the month were National Instruments, VMware, and Tegna. ational Instruments was a rare hostile strategic process. Emerson announced a hostile bid for National Instruments in January at \$53 per share, up from \$39 unaffected. National Instruments already rejected the bid but did announce the start of a formal strategic review. Numerous high-profile companies were publicly mentioned as possible buyers (Honeywell, Rockwell Automation, Fortive, Keysight) and all research indicated National Instruments would run a full and fair process. Since then, the bidder pool has shrunk to Emerson, Keysight, and Fortive. Emerson has continued to reiterate its commitment to own the asset but has put in a strict limit of less than \$60 per share. Questions remain around where National Instruments will agree on price. We are optimistic about the process as competitive strategic up for sales have historically yielded attractive outcomes. VMware lost ground in February due to a continuing difficult regulatory environment. In early February, the Competition and Markets Authority (CMA) issued a statement of issues in the Microsoft/Activision merger which indicated continued hostility to behavioral conditions. This proved a drag on VMware, which (like Activision) needs CMA approval. Additionally, on February 28, reports that the European Commission (EC) would issue a statement of objections put further negative pressure on the stock. Tegna was the third largest detractor in February, driven primarily by the February 24 announcement by the FCC that they were designating the matter for a hearing before an administrative law judge. Due to the slow pace at which the Administrative Law Judge (ALJ) process works, it is essentially impossible for the deal to receive FCC approval before the May 22 end date. While the parties reportedly continue to seek ways to get FCC approval, there is no longer a clear pathway to get the deal to close. We continue to be cautious on investment levels, as the macro environment is at a critical juncture with regional banks and Credit Suisse potentially going under. The smooth functioning of credit markets and bank money transactions is key to the M&A business as well as the markets. We continue to be monitoring for stresses in the system. If any of our clients see anything in their different positions, it would be helpful for us to have some feedback.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

**March** has been an eventful month for the global financial markets, with the banking crisis dominating headlines. However, in some ways, the market has moved on as the S&P 500 was up +1.5% for the month. While the banking crisis has caused significant volatility in the market, the impact to our portfolio has been limited and we continue to see the opportunity set improve. In March, we increased position sizes across multiple deals as we are being presented with opportunities to take more risk. Despite no meaningful improvement in debt markets, there was a significant pick up in deal activity with 14 deals (each greater than \$1 billion in value) announced. From a regulatory perspective, our team believes the Department of Justice (DOJ) process has begun to differentiate its approach from the Federal Trade Commission (FTC). One deal we wanted to highlight that was impacted by the Silicon Valley Bank collapse that we did not own was the First Horizon (FHN) / TD Bank deal. This was largely owned by the merger arbitrage community as it was considered a safe deal. However, our team likes to avoid these “cookie cutter” arbitrage plays. The First Horizon gross spread was 0.9% on February 28th and widened to 12.9% as a result of TD stating they will not receive regulatory approval in time for the close date and will likely need a further extension. Following the collapse of SVB, the gross spread widened to 55.8%. The three biggest winners of the month were Life Storage, Oak Street Health, and Shaw Communications. Life Storage (LSI) received a hostile takeover offer from Public Storage (PSA) on February 6 for \$129 per share, all stock. In early March, LSI cancelled out of a large investor conference with no explanation, which is typically a good sign that they are in a sales process. Concurrently, PSA reiterated their commitment towards a transaction. On March 22, Bloomberg reported that Extra Space (EXR) was expected to weigh an offer for LSI and we increased our position from 138 bps to 400 bps. On April 3, LSI announced that they entered into a deal with EXR, valuing LSI at \$145 per share. Oak Street Health (OSH) was the second largest contributor in March. Our research indicated that there was minimal antitrust risk, but the market anticipated a lengthy regulatory review due to the size of the deal. However, on March 27, CVS declared that their deal for Signify cleared antitrust review roughly two months ahead of schedule. Consequently, we substantially increased our position in OSH as the Signify outcome offered positive insights about CVS and the general regulatory environment. As the HSR expiration date passed without CVS disclosing a second request, we continued to add to our position. On March 30, CVS announced the expiration of the HSR waiting period for OSH, causing the gross spread to tighten from 5.4% to under 0.5%. Shaw Communications was the third largest contributor of March following Minister Champagne (Canadian Minister of Innovation, Science and Industry), approving the transfer of spectrum licenses, paving the way for Rogers to close on its 2-year-old transaction. We began the month with 386 bps in Shaw and 20 bps in Rogers Communications Inc., 50% hedged with peers. Throughout the month, we had the opportunity to meet with Rogers, Quebecor and attend events where the Minister and his staff were speaking. We grew confident the approval would follow the Canadian Budget announcement and grew our position to 541 bps in Shaw and 120 bps in Rogers. The deal is set to close on April 4 and we are monetizing the Rogers accretion trade opportunistically. The three largest losers of the month were EMIS Group, Portfolio Hedges, and Allfunds Group. EMIS was the largest detractor of the month. Our research indicated the antitrust issues were still pending following many months of pre-notification talks between the acquirer, UnitedHealth, and The Competition and Markets Authority (CMA). On March 31, the CMA announced they would refer the transaction to a Phase 2 review, a surprising outcome to the parties and the market. EMIS share price closed down 15%. We bought shares opportunistically as we believe the market is being too punitive and the risk/reward remains compelling. Portfolio hedges were the second largest detractor of the month. Due to the banking crisis, we increased the portfolio level hedge. However, the high volatility cost us as the S&P 500 ended the month up 1.5%. AllFunds was the third largest detractor of the month. On February 22, Euronext publicly announced it was in talks to acquire Allfunds. We bought 35 bps of capital as we saw the potential for a competitive bidding situation. As time progressed, we became concerned by the decline in Euronext share price and brought our Allfunds position down to 25 bps and went long 15 bps of Euronext as a Texas Hedge. On March 1, Euronext walked away from a potential deal and Allfunds share price declined 12%. We sold our position quickly which paid off as the share price has since declined another 25%. Looking ahead, we are optimistic about the opportunity set, particularly as hostile deal flow improves. In this environment, the market is pricing risk at wide levels and there are several deals that have large spreads. With the decline in interest rates in March, there was a rotation into tech causing the downside in tech deals to improve across the board. While we have not yet increased positions in this area, we believe there will be opportunities to add risk here going forward.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

The Amundi Tiedemann Arbitrage Strategy Fund was up +0.81% for the month of **April** net of all fees and expenses, bringing 2023 year-to-date return to +1.05%. Despite the macroeconomic headwinds presented by the regional banking crisis and difficult regulatory environment, our team generated alpha in April driven by hostile transactions and complex situations. Our team has observed that the market tends to misprice the upside in hostile situations, as highlighted by National Instruments (NATI) and Life Storage (LSI), discussed further below. We remained disciplined in our approach to risk management by utilizing options to define our downside exposure. Throughout the month, our team capitalized on spreads widening and increased position sizes. We are optimistic about the opportunity set and believe there is more alpha to be captured going forward. One deal that exemplifies the regulatory headwinds was Activision (ATVI)/Microsoft (MSFT). While the decision from The Competition and Markets Authority (CMA) was unfavorable, we were able to manage risk by defining our downside ahead of the ruling. We increased the physical long position and bought puts, through which we sought to provide significant upside potential and limited downside. This deal is discussed in further detail below. Going forward, our team expects to continue utilizing puts to define downside risk. The recent rate hikes from The Fed are being interpreted as a signal that peak interest rates are near. This is one metric our team is monitoring as a sign for deal flow to return. However, the regional banking crisis introduced a significant amount of volatility in the market. While our strategy has the ability to generate alpha in both low and high interest rate environments, stability in the market plays a crucial role in dictating the level of confidence that CEOs have on executing M&A. The three biggest winners of the month were NATI, LSI, and Horizon Therapeutics (HZNP). On January 17, Emerson (EMR) went hostile with a \$53 all-cash bid to acquire NATI. This forced NATI to kick off a months' long sales process to see if an adequate proposal could arise. As the process dragged on there was skepticism that there was not enough competitive tension to create an attractive outcome. The stock gradually faded from \$54 on January 26 to \$50 on March 13 as optimism diminished. Our average purchase price was \$52.02, and conviction was driven by numerous sit-down meetings with the management of both EMR and Fortive (FTV). FTV had emerged as a surprisingly competitive bidder and was very strong in their desire to expand in Test and Measurement and outline a plan that would allow them to raise the adequate cash to pay for such a large acquisition. In the meantime, EMR continued to state their desire to own the asset and indicated that their synergy estimates had increased. On April 12, EMR announced its acquisition of NATI for \$60 per share, the limit they had previously stated publicly. FTV had bid \$60 as well but with less secure financing. Another hostile situation was Public Storage (PSA)'s attempted acquisition of LSI for \$129 per share in an all-stock transaction. We grew the position throughout March and early April from 119bps to 391bps, driven by research that indicated that LSI was a willing seller at the right price, and that PSA had shown commitment to offering more to get a deal done. On March 22, Bloomberg reported that Extra Space Storage (EXR), a competitor in the space, was weighing an offer for LSI. Our position was hedged 80% to the terms with PSA, underestimating EXR's ability to pay up for the asset. On April 3, EXR announced an all-stock swap deal for LSI valued at \$143 per share. Originally, it was a suboptimal outcome as EXR traded down on the announcement and LSI was pulled with it, while PSA traded up. We were patient with this market reaction as we believed PSA should only slightly outperform EXR, hence we did not roll the position day one. As time passed, the stocks eventually reverted to the mean, and we ended up making an attractive return. With HZNP we started the month with a 6.5% of capital position at a 6.7% gross spread. In the middle of the month, the spread tightened to 4% gross as Amgen (AMGN) set the Irish Court date for May 22 and calling HZNP notes effective May 25. We traveled to Las Vegas to meet with AMGN senior management to test our theory that they set the Irish Court date because the Federal Trade Commission (FTC) was wrapping up their review. We realized these events were not correlated and reduced the position to 5.8%. Subsequent to month end, on May 16, the FTC sued to block the merger causing HZNP to drop to a low of \$90 per share. We believe the FTC has a weak case and added to our position. The three largest losers of the month were ATVI, Arconic (ARNC), and Catalent (CTLT). We reinitiated our investment in ATVI in late March in advance of the CMA outcome on April 26. Although the preliminary CMA findings from February appeared unfavorable, the CMA provided some optimism that they might clear the deal with behavioral remedies after issuing an addendum to their provisional findings, which concluded that there was no substantial lessening of competition in console gaming. This highly unusual step, combined with reporting that MSFT had multiple meetings with the CMA following receipt of the Remedies Working Paper, gave optimism that the CMA could potentially accept a behavioral remedy for cloud gaming competition concerns. Ultimately, the CMA blocked the deal. While MSFT plans to appeal the decision, they will likely need to negotiate a new merger agreement as the current contract's end date is coming up on July 18. If they do extend the merger agreement, we think there is substantial upside given the fundamentals of ATVI and the gaming industry. ARNC was the second largest detractor in April. Reports in late February noted that Apollo (APO) had put in an acquisition offer. As time passed it seemed that a deal was likely, and that the current APO bid was enough to get a deal done. There were additional stories that other private equity buyers were looking at the asset as well. However, the tone shifted in early April as reports emerged that APO put in an unattractive \$27-\$28 bid. With earnings approaching on May 4, we reduced the position and felt that the risk reward was not attractive.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

CTLT was the third largest detractor of the month. We entered April with 95 bps in CTLT, putted on 20%. As we mentioned last month, one of CTLT's largest gene therapy customers received an Advisory Committee (AdComm) notice from the FDA, a potentially negative regulatory event for the approval of their drug. On April 13, an article came out stating the FDA staff was leaning towards rejecting the new gene therapy drug and we decreased our position significantly while maintaining the puts. On April 14, CTLT issued an unexpected business update stating that the CFO is no longer with the company, and they were going to materially miss earnings due to productivity issues and higher than expected costs at three of their manufacturing facilities. CTLT closed the day down 24%, but we were well protected by our put strategy and had materially reduced our position the day before. A few days later, it was reported Danahar (DHR) had shelved their takeover pursuit of CTLT. Looking ahead, we will continue to closely monitor the banking crisis to see whether the market is pushed into a steeper dislocation. We believe that CEOs will likely have better visibility within the next quarter what the environment will look like longer term, which will help bring stability to the market. The silver lining of the difficult antitrust environment is that we have historically been able to capture alpha when companies go to trial. We remain optimistic that there will be opportunities to add risk going forward. We appreciate your continued support.

The Amundi Tiedemann Arbitrage Strategy Fund was down -2.32% for the month of **May** net of all fees and expenses, bringing our 2023 year-to-date return to -1.30%. Our performance in May was affected by atypical regulatory headwinds, diverging from the precedent set by the last fifty years of antitrust law. There were four positions in the portfolio with losses this month relating to regulatory issues, with aggregated losses of net -158bps. Of these detractors, only one was realized: First Horizon (FHN, discussed further below). The regulatory review process is becoming politicized. Our team is rigorously assessing this evolving regulatory landscape. At the outset of 2023, healthcare and pharmaceutical deals were passing regulatory reviews smoothly. However, the Federal Trade Commission's (FTC) unexpected decision to sue to block the Horizon Therapeutics (HZNP) / Amgen (AMGN) deal marked a significant turn. The resultant lawsuit against HZNP / AMGN drove biotech deal spreads wider, creating a buying opportunity. Our team leveraged this opportunity by allocating circa 2.5% of capital across five different deals. One silver lining in the current regulatory environment is that our team's expertise and proven track record allows us to capture alpha when motivated buyers challenge regulators in court. The case of Spectrum Brands (SPB) demonstrates our approach in litigation research, a topic we will delve into later. The significant losses to numerous funds have resulted in de-risking that is being magnified by the structure of the Arbitrage market, which comprises pods and multi-strategy managers with significantly large positions. This has had a considerable impact on spreads as they look to reduce position size. As of month-end, the portfolio held 11 complex situations with gross spreads ranging from 15% to 40%. These widened spreads present an opportunity for our strategy to capture alpha in these intricate scenarios. The three biggest winners of the month were Prometheus Biosciences (RXDX), SPB, and Activision Blizzard (ATVI). We started the month with 2.64% of capital in RXDX. After the FTC filed a lawsuit against HZNP/AMGN, the RXDX spread moved out to a 4% gross spread from 2.8% and we took the opportunity to add 100 basis points of capital to RXDX since there was no competitive overlap between Merck (MRK) and RXDX portfolios. On May 23, the FTC cleared the transaction and the spread tightened to 70bps with the last milestone the vote on June 15. We ended the month with 4.68% of capital in RXDX. SPB was the second-largest contributor in May. SPB agreed to sell its HHI business unit to Assa Abloy (ASSAB SS) for \$4.3 billion in September 2021. The Department of Justice (DOJ) sued to block the deal in September 2022, alleging a loss in competition for residential smart locks. We did not own this initial event. In response, ASSAB SS agreed to divest its US/Canadian residential smart locks business to Fortune Brands. The DOJ, however, deemed this remedy overly complicated and continued the lawsuit. Due to weaknesses in the DOJ's case and skeptical comments from the judge, we entered May with a 57bps long position in SPB (paired with a collar option strategy), which was trading at \$66. We increased our position to 90bps after an unscheduled pause in the trial led us to suspect that the merging parties might be in settlement talks with the DOJ. On May 5, the DOJ and ASSAB SS reached a settlement, pushing SPB stock price to \$73.50, with further upside expected once SPB officially announces a share buyback with the proceeds of the transaction. ATVI is a position we have maintained since the Competition and Markets Authority (CMA) moved to block its deal with Microsoft (MSFT) in late April. When the CMA decided to block the deal, the general assumption was that the deal would break on the end date, July 18. ATVI traded from \$86 to a low of \$75 following the event, and our position decreased from 400bps to 130bps, largely due to exercising puts. Since then, we have maintained a position due to limited fundamental downside and an expectation that there may be a path forward, albeit unlikely, for the deal. Over the past few weeks, both parties have reiterated their commitment to the deal and have received an expedited appeal schedule in the UK. They have also received clearance in the European Commission (EC) with a high-quality remedy package. It seems likely the parties will decide to extend the deal past July 18 to continue the fight. This will require some form of improved terms for ATVI shareholders, either in the form of a special dividend, an increased deal price, and/or an increased break fee. We like the optionality of this event.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

The stock has begun to trend higher and is now back to \$81; meanwhile, we have increased our position back to approximately 300bps. The three largest detractors for the month were HZNP, FHN, and EMIS Group (EMIS). We began the month with 5.85% of capital in HZNP. As the HSR expiry on May 15 drew closer, our research indicated that HZNP had confidence in closing the transaction, but also had concerns over the opaque FTC process. Given the uncertainty, we purchased May \$100 strike and \$90 strike puts for 40% of our position. On the evening of May 15, the FTC initiated litigation to block the merger, based on a bundling theory. The following morning, we met with AMGN's management, who were committed to litigation and the strategic logic of the transaction. We grew the position to 7.1% due to our confidence that the lawsuit was without merit. The second largest detractor of May, FHN, was a very volatile deal break. TD Bank Group's (TD) proposed acquisition of FHN for \$25 per share seemed to be progressing towards closure when the parties announced a regulatory issue specific to TD, indicating that the deal could not be finalized by the end of May. This announcement led the stock to shift from a 2% spread to approximately 40%, a move partially driven by the concurrent banking crisis. We were not invested during this initial event. However, following this development, we engaged with TD numerous times, and they reiterated their commitment to the deal and spoke optimistically about their ability to resolve the issue. After engaging with TD, we initiated a position at approximately \$17 per share. In retrospect, the underestimated risk was that due to banking regulations, TD could not disclose the nature of the issue to external parties. Thus, we took TD at their word regarding their commitment and ability to resolve the issue. Market expectations pointed towards a deal price reduction as the most likely outcome, along with a lengthy extension to seek approval. Surprisingly, one month before the end date, TD and FHN announced a mutual termination due to the regulatory hurdles, causing the stock to collapse to around \$10 per share. EMIS was the third-largest detractor for the month. The CMA published the long-awaited Phase 1 decision and decided to refer the deal to phase 2, outlining the scope of the issue and the challenges to be addressed in phase 2. Along with the market, we were surprised to find a greater emphasis on UnitedHealth Group Inc's (UNH) re-entry risk, a new theory of harm for a vertical deal. The ability to resolve this issue was perceived as difficult, making the success of the deal contingent upon convincing the CMA that there was no basis for a significant lessening of competition (SLC) in the first place. The share price ended the month 18% lower, reflecting a ~20% probability of closing. When reflecting on the merger arbitrage environment throughout May, the headwinds were global and broad. Looking ahead, our focal points will be to mitigate risk, recoup unrealized losses, and to diligence jurisdictions where there is recourse in the court system. We anticipate that the rising rate cycle is nearing its end, and with that expectation of process clarity, we expect to see a pickup in activity. It is encouraging that our top portfolio positions are expanding across the strategy. We are optimistic that the large number of deals trading with huge alpha will drive returns in the coming months. We appreciate your continued support.

The Amundi Tiedemann Arbitrage Strategy Fund was up +1.41% for the month of **June** net of all fees and expenses, bringing our 2023 year-to-date return to +0.10%. June's performance was driven by a recovery from the volatile events that we encountered in May. It was a follow through on the process we outlined in the past regarding mispriced risk in times of sector stress. On the regulatory front, we are witnessing the protection offered by the US judicial system. Although the Federal Trade Commission (FTC)/ Department of Justice (DOJ) has initiated a new radical merger review process, they have largely failed to successfully defend their cases in court. This much needed clarity has helped deals such as Horizon Therapeutics (HZNP) and Activision (ATVI), and frankly any merger that may encounter abnormal scrutiny by the FTC or DOJ. With that said, we remain cautious in the current regulatory environment and have focused on avoiding long-dated antitrust processes with no near-term catalyst, specifically when non-appealable authorities are involved (UK Competition and Markets Authority (CMA)). It has become crucial to focus on 30-days events with tangible, researchable catalysts. The investable universe is currently extremely complex which has created wide spreads nearly across the board; an environment we feel well equipped to take advantage of. Deal flow continues at a slow pace, largely driven by macro ambiguity for buyers and sellers; all parties are hoping to wait out the uncertain near-term environment. One notable trend we have seen is that once a company is put into play (either via deal or hostile bid), potential buyers are forced to compete for the asset, creating competitive processes. Generally, we are still in capital preservation mode and will focus acutely on situations where we feel our research-based approach can offer an edge. The three biggest winners of the month were Dechra Pharmaceuticals (DPH LN), HZNP, and Network International (NETW LN). We began the month with a 2.5% position in DPH LN. On June 2, EQT announced a firm offer for the company at GBP38.75, a 4.8% price cut from the originally proposed and recommended price of GBP40.70. Shares rallied 7% on the announcement, settling at a 6.7% gross spread. The deal is not conditioned on the CMA; however, the agency could claim jurisdiction to review it. We believe the spread is attractive at the current level and see an opportunity to add if the CMA calls for the transaction to be reviewed later this summer or thereafter. Next up is HZNP which recovered from the surprising decision by the FTC to block the transaction in May. To start June, the deal was trading with a 16% gross spread and we had a 7.0% capital position. In June, the FTC filed their pre-trial briefs that failed to show evidence of incriminating documents necessary to prove the FTC's theory of harm.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

Towards the end of the month, we reduced the position due to concerns around second quarter sales numbers for Tepezza, HZNP's most significant drug, and due to the predicted quarterly numbers, the deal was trading at a 75% implied chance of closing. We continue to find the opportunity very attractive heading into what should be a challenging trial for the FTC. Last up is NETW LN, which was the second UK Put Up or Shut Up (PuSu) process we participated in this month. The outcome was a little disappointing, as both CVC Limited (CVS) and Brookfield (BN) were in the final stage of formalizing offers, but only BN submitted a finalized offer thereby limiting upside optionality. We owned 3.5% prior to the event. The stock rallied 5.6% on the news. This deal highlights the risk-off environment we find ourselves in. This was a competitive bidding process between two parties and when one party dropped out, hence evaporating any upside potential, we still stood to make an attractive return. The three biggest losers for June were Seagen (SGEN), National Instruments (NATI), and Software AG (SOWO GY). For SGEN, we started the month with a 1.81% capital position and the deal trading with a 17.5% gross spread. We increased the position to 4.3% based on research that indicated that Pfizer (PFE) was firmly committed to closing the deal. Further research supported that PFE was anticipating a second request from the FTC for more information regarding the planned merger. Although the parties pulled and refiled their HSR filing with the FTC, PFE continued to communicate that they expected a full second request to follow. We reduced our position as others were buying the hope that the deal would clear following the pull and refile. We ended the month with a 4.0% position and a 19% gross spread. For National Instruments (NATI) we started June with an 8.58% capital position. NATI is in the process of being acquired by Emerson (EMR) for \$60 per share cash, plus \$0.28 quarterly dividend. We anticipate a December close, which equates to ~11% annualized return. The spread moved a bit wider in June due to broader pain in the merger arbitrage universe and a realization the deal will likely require a full review process in China, our expectation all along. Lastly is SOWO GY, which taught us a lesson on how German corporate governance can disenfranchise shareholders. Silver Lake agreed to acquire the company for €30 and signed a hard irrevocable agreement to purchase a ~30% stake from the SOWO GY - Stiftung (the foundation). The board recommended the offer, despite Bain Capital (BCSF) expressing interest in acquiring the company at a higher valuation, €34-36. Following BCSF's conditional proposal, Silver Lake was forced to increase their offer. However, the board refused to engage with BCSF and provide access to due diligence, thereby depriving shareholders of competition from BCSF. We expressed our concerns in a letter addressed to the Board of Directors and the Special Committee, but it went unanswered. At the beginning of the month, we held a 1.3% capital position, with shares trading at €33.4. On June 16, BCSF surrendered and sold the 5% stake they had previously purchased in the company to Silver Lake, closing the chapter and clearing the path for Silver Lake to take full control at €32. The merger arbitrage universe is still in a risk-off mode following the pain in the first half of the year. We agree with some of the caution displayed by investors, but we also continue to see mispriced opportunities driven by unfounded pessimism. Deals that had faced years-long regulatory battles are finally entering the US courts for final decision which will present an attractive opportunity. These court cases are researchable and we have a well-designed system to capitalize on them. The realization that the US courts aren't swayed by the cases that the FTC and DOJ have challenged, should give companies the confidence to pursue new M&A. We are eager to capitalize on the opportunities in the back half of 2023. We appreciate your continued support.

The Amundi Tiedemann Arbitrage Strategy Fund was up +0.88% for the month of **July** net of all fees and expenses, bringing our 2023 year-to-date return to +0.97% net (I USD). July's performance was driven by our ability to research and invest in an evolving litigation environment. A pivotal development in July was the position reversal by the UK Competition and Market Authority (CMA) regarding antitrust investigations. This change became evident in the wake of the CMA's dealings on the Activision Blizzard (ATVI)/ Microsoft merger (MSFT). Previously known for its strident stance on antitrust, the CMA now seemingly aligns with decisions from its European Union (EU) and Federal Trade Commission (FTC) counterparts, diminishing the probability of it standing alone in opposition to a global transaction. This was demonstrated clearly through two recent antitrust investigation outcomes: the first being that iRobot (IRBT)/Amazon (AMZN) was cleared by the CMA on June 16 and second being that VMware (VMW)/Broadcom (AVGO) was provisionally cleared on July 19. Considering these two events and the win in the US Ninth District Court of California where the FTC lost its case for a preliminary injunction on ATVI, we have moved from capital preservation to capital deployment. Throughout the month of July, we have added roughly 6% of capital to the top five deals in our portfolio ; National Instruments (NATI), ATVI, Horizon Therapeutics (HZNP), Seagen (SGEN), and VMW, which we believe are complex in nature and are trading at attractive spreads. Additionally, we increased exposure to certain friendly deals exhibiting wide spreads driven by interest rate levels and pods forced liquidation of some of their positions. Going forward, we plan to add 7.5 – 10.5% of capital to these types of transactions. The three biggest winners of the month were ATVI, NATI, and Black Knight (BKI). ATVI had two major developments this month. Notably, the UK CMA's decision to alter their stance and the US district court decision to deny the FTC a Preliminary Injunction (PI). We felt the United States PI trial in June had gone well for the parties and we decided to increase the position size to own the positive outcome and the inevitable bump MSFT would owe ATVI holders, since the deal was slated to go well past the merger agreement end date of August 19.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

On July 10, the judge released her ruling rejecting the PI and, within an hour, the CMA released a statement saying they had received an incremental offer from MSFT and were willing to alter their decision to prohibit the transaction. This was an indication that the CMA was backing down and did not have the willingness to be the sole regulator responsible for blocking a global transaction. Later in July, we received further evidence of the CMA commitment to allowing the transaction to pass when they indicated to the appellate judge they were “highly confident” that MSFT’s offer would lead to a solution. MSFT compensated ATVI shareholders with a \$0.99 dividend and a \$2 billion increase to the termination fee for the additional time required to close past August 17. We anticipate the deal closing in September. NATI was the second largest contributor of July following the Chinese SAMR decision to review the deal under its simplified procedure. NATI began the month trading at a 5% spread to the \$60 per share deal price (plus dividends). Throughout June and the first half of July, all reports indicated that the deal would have to be filed under normal procedure, which can take up to 180 days. Meanwhile, deals like Silicon Motion (SIMO) and Taiwan Semiconductor (TSM) were going through in-depth SAMR reviews that looked increasingly bleak. To some extent, the market lumped NATI in the same bucket as those transactions and saw SAMR as a universal risk, causing NATI to trade to a low of \$55.90, an 8% spread. We maintained our belief that the NATI/EMR deal posed no viable antitrust concerns and NATI’s technology is far from unique or sensitive. On July 25 there were reports that SAMR had backtracked and planned to review the deal under its simplified procedure, dramatically reducing the timeline to approval to less than 1 month. At month end, NATI was trading at a 1.8% gross spread. BKI was the third largest contributor of the month driven by the parties and the FTC pausing the trial to re-engage in settlement talks. We began the month with no position after covering our previous short position in May and June. In early July, we initiated a position upon hearing comments from a conference we attended that the parties were considering divesting an additional asset, Optimal Blue. Our analysis indicated that the sale of Optimal Blue would eliminate the bulk of the FTC’s concerns with the transaction and make it difficult for the FTC to continue the litigation. On July 17, the parties announced a sale of Optimal Blue to Constellation Software (CNSWF). Concurrently, the parties and the FTC jointly requested that the trial be rescheduled for mid-August so they could re-engage settlement talks. This deal somewhat highlights the risk-off environment we are in and the abnormal spreads it can create. Intercontinental Exchange (ICE)’s willingness to divest Optimal Blue had been disseminated into the market by numerous sources leading into the event, yet the spread only moved from ~\$18 to ~\$15.50. The spread collapsed to \$5 on the announcement of the divestiture. The three biggest losers for July were SIMO, HZNP, and Abcam (ABCM). SIMO began the month trading at a 45% gross spread due to the ongoing SAMR review. We decided to reduce our position from 140 bps to 50 bps due to concerns over the Chinese regulatory approval process pushing the deal past the drop-dead date of August 7. As we unwound our position, the market began to acknowledge these issues and the spread widened to 105% gross. On July 26, SAMR approved the transaction, catching both the market and the merging parties off guard, and the spread tightened to ~10% gross. We debated whether to take the 45 bps PNL win and reduce the position to zero or add to the position as a 10% gross spread still presented an attractive return. Unlike many of our peers who added significant positions, we decided to only add 35 bps because we were concerned that the company had not put out any press release and were unreachable for comments. The market was shocked as MaxLinear (MXL) put out a press release later that day terminating the acquisition; alleging there had been a material adverse development and that the reps and warranties for SIMO had not been satisfied. This led to the spread widening back to 85% gross. We added an additional 30 bps as we believed MXL’s allegations were baseless, and this was a classic case of buyers’ remorse. HZNP was the second largest detractor in July, driven by reduced sales expectations by the sell-side for HZNP’s leading drug, Tepezza. We started the month with a 6.2% of capital position trading at a 13% gross spread. As we started to research the Q2 revenue for Tepezza, we determined that the street models had not updated for Tepezza’s Q1 revenue miss and the street’s consensus was too high at \$500 million revenue for Q2. Given the stock was trading at a 75% implied probability to close, a \$10 change in the downside would impact the spread by ~\$2.50. We reduced the position from a peak 7.3% on June 22 to a low of 5.1% by mid-July and hedged 1/3 of the position with August 18 \$100 strike puts. After a top-tier sell-side firm reduced Q2 Tepezza sales expectations and reduced downside from \$65 to \$55, Horizon ended the month at \$100. ABCM was the third largest detractor of the month. The company reported earnings in early July, reiterating their revenue and operating margin guidance and provided an EBITDA margin guidance for the first time. This drove the sell-side to raise their downside expectations from \$16-\$18 to closer to ~\$20. However, the stock drifted lower during the month given there had been no substantive update on the sale process. We still believe this is an attractive opportunity with the potential buyers being large strategic companies like Danaher (DHR), Thermo Fisher (TMO), and Merck KGaA (MRK). In the second half of the year, we anticipate more opportunistic deal flow, as CEOs become more comfortable with the new regulatory environment and recession views become more discounted. This includes a rise in complex deals, especially hostile deals, which we believe are often underpriced by the market. In addition, MSFT’s victory over the FTC and the change in position by the CMA were game changers. It seems to have encouraged CEOs that there is a path to close deals and M&A interest level has jumped significantly.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

The interest rate environment seems to be playing out as expected, with a hiking cycle that is nearing an end. We are optimistic about the opportunity set and are actively looking to deploy capital to our top 5 positions and select friendly spread arbitrage deals that are priced attractively. We appreciate your continued support.

The Amundi Tiedemann Arbitrage Strategy Fund was up 1.73% for the month of **August** net of all fees and expenses, bringing our 2023 year-to-date return to 2.72%. In August, the regulatory environment continued to shift in a more positive direction. The regulatory headwinds from earlier in 2023 have provided researchable and tradable catalyst events and, as these litigation processes began, our team used these opportunities to recuperate unrealized lost P&L from the initial antitrust challenges. The top three winners for the month were all deals that had faced regulatory setbacks: the first being Horizon Therapeutics (HZNP) being sued by the Federal Trade Commission (FTC), the second being EMIS Group (EMIS) entering into phase 2 UK Competition and Market Authority (CMA) review, and the third being Seagen (SGEN) receiving a 2nd request. VMware (VMW) was also another deal that face regulatory setbacks as it received a 2nd request and entered phase 2 CMA review. These results generated a 4:1 return ratio of the top 5 winners vs. top 5 losers in the UCITS Fund. An indication that we are in a different antitrust environment came from comments that Amgen (AMGN) made at a conference we attended that the FTC reached out to them to initiate settlement talks. Another factor driving this month's performance, that we discussed last month, is our shift to a risk-on capital investing mode. Across our top 5 deals by size (HZNP, SGEN, National Instruments (NATI), VMW, Activision Blizzard (ATVI), we added 10.7% of capital. We have also increased our exposure to rate-of-return trades as pod funds continue to liquidate positions, causing spreads to widen to attractive levels. Going forward, we plan to continue adding capital to these types of transactions. The three biggest winners of the month were HZNP, EMIS, and SGEN. HZNP was the largest contributor in August. We entered the month with 5.77% of capital in the position, ahead of an anticipated September 11 trial date. This position reflected our research that the FTC's case against the deal was weak and not supported by facts or law. We began increasing the position after reporting indicated that the FTC was considering settling the case and allowing the case to proceed. On August 25, the FTC withdrew the case from its own administrative court to consider a settlement. We increased the position to 10.1% of capital in advance of a settlement being announced September 1. EMIS was the second largest contributor of the month. We began August with 1.24% of capital in the position having previously reduced it from 1.8% based on findings from a survey we conducted to Population Health Management (PHM) companies. The survey confirmed the theory of harm behind the Significant Lessening of Competition (SLC) issued in the CMA's phase 2 review. However, after incremental research suggested the National Health Services (NHS) had turned supportive of the deal, we bought back our position to the previous level of 1.8% at a 30% gross spread. On August 11, the CMA provisionally cleared the deal with behavioral commitments. The deal is set to close in early October. SGEN was the third largest contributor of August fueled by the HZNP settlement talks. We began the month with 5.1% of capital in the position driven by research indicating that Pfizer (PFE) and SGEN had relatively minor drug or portfolio level overlaps. Further, there was positive reporting in the press about the nature of the FTC's investigation into the deal, indicating they were not investigating any esoteric theories of harm and were focused on the more traditional drug overlap theories. We increased our position throughout the month to 9.3% of capital in anticipation of a positive outcome in the AMGN/HZNP case. We believed a HZNP win or settlement would prove to be a positive catalyst for SGEN. This was borne out, as SGEN rallied from \$194 at the start of the month to \$206 at the end, driven by the settlement of the Horizon matter. The three biggest losers of the month were Silicon Motion (SIMO), NuVasive (NUVA), and Softwareone (SWON SW). SIMO was the largest detractor in August. Following Max Linear's (MXL) attempted termination of the merger agreement in July, SIMO surprised the market by terminating the merger agreement and seeking damages in lieu of seeking specific performance. The market had reservation about the ability to seek specific performance as the debt commitment letter expired in August. Therefore, the idea of only seeking damages was an eventuality but thought as a recourse after leveraging the threat of seeking specific performance. As a result, SIMO stock price declined 14% in the month of August. NUVA was the second largest detractor of August. We started the month with 1.64% of capital reversed the spread as our research indicated there were possible antitrust issues with the deal. On August 18, we covered 10% of our short position following reports that the companies were optimistic for an early-September close. On August 28, the Nasdaq put out a delisting notice for NUVA and we covered our entire short position and went long the spread. On the morning of August 30, the FTC announced a closed-door meeting, often associated with litigation. This meeting caused the spread to widen from ~\$0.44 to a peak of \$1.70 on the day. We took advantage of this uncertainty in the market to add to our position given our research indicated that the meeting was not about them and ended the day with 145 bps long the spread. We brought the position to 2.01% of capital on August 31 as there was still 40 cents to capture in the spread. The NUVA deal closed on September 1st. SWON SW was the third largest detractor of the month, as the stock lost some premium because the auction process is taking longer to commence. The stock has since recovered these levels. The path to deal flow is being laid out as the CMA and US regulatory agencies ease their aggressive stance.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

As we mentioned last month, ATVI changed the perception of CEOs and bankers by proving that there is a path to victory. As long as companies provide themselves the time to litigate, they can ultimately succeed, which plays into our expertise in complex situations. The current environment reminds us of 2009, where we operated off a stale set of opportunities. While deal flow has yet to increase dramatically, there have been opportunities to identify certain phases that we like, which provide certainty of process but uncertainty of price. We are starting to see green shoots of opportunistic bids, including US Steel (X), Abcam (ABCM), and Hostess Brands (TWNK). We believe that the appetite for M&A is robust, and we are optimistic about the opportunity set in the second half of 2023. We appreciate your continued support.

The Amundi Tiedemann Arbitrage Strategy Fund was up +1.13% for the month of **September** net of all fees and expenses, bringing our 2023 year-to-date return to +3.88%. We are pleased to report a strong performance in September, achieving positive alpha while effectively minimizing losses across the portfolio. Our largest loser in the month of September, Sigma Lithium (SGML), represented an estimated net MTD loss of -4.5bps while our largest winner, VMware (VMW), had an estimated net return of +31.8bps. As we have previously discussed, we have been anticipating an increase in opportunistic and hostile bids as the market cycle evolves, particularly with higher interest rates slowing down. Additionally, we believe that a market correction of 7% to 10% is positive and creates an environment for opportunistic deal flow. In September we started to see the emergence of such opportunities with companies like Hostess Brands (TWNK), US Steel (X), PGT Innovations (PGTI), and Adevinva (ADE NO). Furthermore, the recent easing of the regulatory environment has triggered a noticeable uptick in large-scale M&A, exemplified by the \$60 billion acquisition of Pioneer by Exxon (XOM) and the \$28 billion acquisition of Splunk (SPLK) by Cisco (CSCO). We will continue to look for opportunities to add to spread merger arbitrage positions as higher rates have pushed some of the spreads to attractive levels. The top three performers for the month were VMW, TWNK, and Horizon Therapeutics (HZNP). We started the month with 9% of our capital allocated to VMW at a 10% gross spread. We increased our position in VMW mid-month based on our research which indicated the company was confident it would receive all regulatory approvals and close the merger on October 30. The spread compressed to 5.6% during the month. We continue to monitor the Chinese SAMR process and see it as an opportunity in the month of October. TWNK was the second largest contributor of the month. In late August, it was reported that TWNK was up for sale and numerous large strategic buyers were involved in the process. The stock went from ~\$22 per share to \$27.50 per share on the news. We immediately recognized that TWNK was a unique asset with multiple competing strategic buyers eager to win. After attending an industry conference, it was clear that the situation was live and there were parties beyond those reported that were taking part in the sales process. These factors drove a fast and successful bidding war. We accumulated 1.8% of capital position with an average purchase price of \$27.85. On September 9, JM Smucker (SJM) announced a deal to acquire TWNK for \$34.25 per share. HZNP was the third largest contributor in September. We entered September with 10% of capital in the position, having increased the position substantially in August after the Federal Trade Commission (FTC) withdrew the matter from adjudication at the administrative law judge in order to consider settlement. Early on September 1, the FTC and the merging parties formally announced a settlement of the case, with Amgen (AMGN) agreeing to not bundle certain drugs in negotiations with PBMs. The remedy marks the first time either the FTC or the Department of Justice (DOJ) has taken a behavioral remedy under the Biden Administration. The deal closed on October 6. The three largest detractors were SGML, Silicon Motion (SIMO), and Dechra Pharmaceuticals (DPH LN). SGML was the largest detractor in September. SGML announced a strategic review on September 13 after the company received multiple proposals from industry leaders in the energy, auto, battery and lithium refining industries. We thought it was interesting given the broad array of strategic interest. However, we have been disappointed with the quality of the company and process after meeting with management here in our offices and have reduced the position size to less than 30 bps hedged 40% with Albemarle (ALB). The stock gave up some premium in September in part due to a decline in lithium commodity prices and concerns around the process. SIMO was the second largest detractor, giving up 6% in the month of September as the street waits for SIMO to file for arbitration in Singapore. We continue to hold 90 bps of SIMO hedged 50% with a sector basket based on the arbitration potential and the fact that we think SIMO is trading at its fundamental value. DPH LN was the third largest detractor of September. The stock declined 63 bps during the month as the closing timeline is being pushed out since the parties have not filed at the European Commission (EC) yet. We have increased our position to 5.8% of capital because we see it as a safe spread yielding 15% ARR to a late November close. While our total gross long exposure remained relatively stable for the month, top positions grew near catalyst events which have been playing out in our favor. Historically, we have driven positive returns capturing alpha on large positions backed by research, not by deploying high levels of gross long exposure across the portfolio. The current opportunity set excites us, and we have already seen promising signs of opportunistic and hostile bids, such as X and TWNK. We appreciate your continued support.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

The Amundi Tiedemann Arbitrage Strategy Fund was down -0.79% for the month of **October** net of all fees and expenses, bringing our 2023 year-to-date return to +3.05%. October proved to be a challenging month, driven both by deal-specific and broader market factors. The most significant factor impacting our performance this month came from VMware (VMW), currently in a state of uncertainty due to pending approval from the Chinese regulatory authority, SAMR. As the termination date of November 26 nears, we remain confident in the strategic importance of this deal for Broadcom's (AVGO) future growth and expect to recover unrealized losses once the deal closes. We discuss VMW in more detail below. In contrast, the successful closure of Activision (ATVI) after a 22-month long process is a testament to our team's prowess in navigating complex regulatory environments. The completion of this deal signals a positive catalyst in the M&A landscape as it highlights there is a path to victory in court. Recently, we have seen three mega deals with the announcement of the \$28 billion acquisition of Splunk (SPLK) by Cisco (CSCO), the \$59.5 billion acquisition of Pioneer Natural Resources (PXD) by Exxon (XOM), and the \$53 billion acquisition of Hess (HES) / Chevron (CVX). There has been a notable pickup of activity in the oil sector, however, pre-announcement, these situations are only modestly attractive as they typically consist of all-stock considerations and relatively low premiums. The top three performers for the month were ATVI, Spirit Airlines (SAVE), and Silicon Motion (SIMO). ATVI's volatile 22-month deal process came to an end in October. At the start of the month, the deal was trading at a 1% gross spread and was waiting on final approval by the UK Competition and Markets Authority (CMA) which our research indicated was imminent. We had a 9.4% of capital of position in ATVI when the deal closed on October 16. SAVE was the second largest contributor of the month as the trial brought by the Department of Justice (DOJ) kicked off on October 31. We began the month short 33bps and were long puts in SAVE. Both companies find themselves in very stark financial situations, and a proforma company has questionable viability. Up until October 25, SAVE was trading at \$16-\$17 per share, a nearly 100% spread to the deal terms. As the trial approached, and any hope of a settlement dissipated, the SAVE stock quickly deteriorated and traded \$11.50 by month end. We continue to see considerable downside in SAVE (approximately \$4 per share) due to significantly impaired fundamentals and we believe the DOJ is poised to prevail in court. The trial is expected wrap up at the end of November with a ruling likely to come in late January/early February. We believe if the parties manage to win the trial, there will likely be a significant price cut required to maintain a financially viable proforma company. SIMO was the third largest contributor of the month. We held the position after the termination of the merger agreement with Maxlinear (MXL) on a risk/reward basis backed by strong SIMO earnings, and a belief that SIMO's threat of arbitration against MXL for wrongfully terminating the merger agreement could lead to a substantial settlement. On October 5, SIMO announced that they had commenced arbitration in Singapore against MXL, a process which we anticipate will take 12-18 months. However, the overhang of the arbitration process on MXL's share price means that MXL is still incentivized to settle the case rather than remaining in limbo and waiting for a judgment. We anticipate that we will exit the position if it becomes clear the case will not settle in the near term. The three largest detractors for the month were VMW, CCC Intelligent Solutions (CCCS), and Covestro (ICOV). VMW was the largest detractor in October. The VMW spread widened from 5.7% at the beginning of October to 10.7% on October 17 following an industry report suggesting potential delays in SAMR regulatory approval from China. It widened further (18.5% at the close Friday October 20) as the Monday, October 23 election deadline drew closer, mandating shareholders to lock up their shares. VMW put out a press release on October 30 updating the transaction. The release states that they are keeping the stock election results which means our shares are locked up until the election is changed, or the deal closes or breaks. Since the election deadline has passed, the stock currently reflects the \$142.50 cash option, not the value of the cash and stock election, which represents a deal value of \$177 per share. The election process is artificially pricing the stock below the deal value because any shares bought today will only be eligible to receive the cash option. AVGO has publicly stated they will close before November 26. We maintained our position and await the outcome. CCCS was the second largest detractor of the month. In mid-September it was reported that CCCS was in the midst of a sales process as Advent (ADN), the majority owner of CCCS, looked to offload the investment. Weeks later, Bloomberg reported that Bain (BCSF) and TPG were weighing a deal to acquire CCCS. Following this second report we initiated a position that grew to 140bps at roughly \$12.60 per share. Research continued to indicate that the process was progressing, with the expectation a deal could be reached before earnings on November 6. However, on October 24 it was reported that ADN/CCCS abruptly decided to pull the process and surprised the market, causing the stock to trade down to ~\$11. ICOV was the third largest detractor for the month. We lost 15bps in ICOV, an up for sale, as the chemical sector continued to weaken. We flew to Abu Dhabi to meet with Abu Dhabi National Oil Company (ADNOC) in early October, which affirmed our belief the transaction is of strategic importance and the timing in the chemical sector was key to their investment thesis. Our 2.44% position 50% putted (put spread collar) got hit by ICOV trading down 6% in sympathy with its peers (~5%). We rolled part of our puts to January to extend our protection should the situation drag into next year. We remain constructive on the process and like the risk/reward. Across September and October, there was a peak-to-trough correction of ~10% in the S&P.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

As we have highlighted in past letters, we believe a 7-10% correction is healthy and leads to opportunistic bids which we have begun to see with US Steel (X) and Wyndham (WH). These opportunistic and hostile situations have the potential to create a positive profitability outcome for us as there is certainty of process but uncertainty around price. Furthermore, we continue to hear and observe that credit markets are open for business. As it relates to LBO transactions in October, notable examples include the acquisition of Textainer (TGH) by Stonepeak for \$7.4 billion and the acquisition of EngageSmart (ESMT) by Vista Equity Partners for \$4 billion. We expect the opportunity set to continue to improve as we come to the end of a hiking interest rate cycle and CEOs gain confidence around regulatory process and that we are not headed into a severe recession. We appreciate your continued support.

The Amundi Tiedemann Arbitrage Strategy Fund was up 2.13% for the month of **November** net of all fees and expenses. November's standout performance was driven by the closing of the VMware (VMW)/Broadcom (AVGO) deal on November 22, yielding a remarkable 136 bps of gross P&L. The transaction highlighted a shift on China's State Administration for Market Regulation (SAMR) and the strains of the political process between US and China. VMW does not have a significant amount of revenue in China and had no technological importance to China as it is a mainframe virtualization software, so we had a significant bet that it would get regulatory approval. Going forward, caution will be taken for sizable deals contingent on SAMR approval, which continues to be an opaque process. We discuss VMW/AVGO in more detail below. Our portfolio hedge incurred a higher cost in November, yielding a monthly net performance of -17 bps. The primary factor was the S&P 500's +8.92% MTD surge driven by a substantial reduction in the 10-year treasury yield (-12.18% MTD). We interpret this interest rate shift as a catalyst for broad market momentum and increased M&A activity, given the lowered cost of deal financing. We continue to anticipate a surge in M&A activity based on pent up demand and stability in capital markets. The top three performers for the month were VMW, ImmunoGen (IMGN), and United States Steel Corp (X). VMW was the largest contributor in November, as the deal secured regulatory approval in China on November 21, and the deal closed on November 22. While our position was locked up due to the stock election which took place prior to the previously expected October 30 close, we bought puts in November to mitigate the risk of a poor outcome in China. Our position also benefitted from a significant percentage (~4%) of holders electing to receive cash, giving stock-elected shareholders a small windfall beyond the expected 50/50 cash-stock mix. MGN was the second largest contributor of the month. At the end of October, we attended the European Society for Medical Oncology (ESMO) conference and had several conversations with key opinion leaders (KOL) in oncology that believed IMGN's drug, Elahere, to be a paradigm shift in the treatment of folate receptor-alpha positive, platinum-resistant ovarian cancer. In late October, after ESMO 2023, there was news indicating that IMGN had attracted interest from European pharmaceutical companies.

We bought **December** \$19, \$20, and \$21 strike options which allowed the team to limit downside and capture upside optionality if there was a deal before the JP Morgan Healthcare conference in January 2024. On November 30, AbbVie (ABBV) announced a deal to buy IMGN for \$31.26 per share. X was the third largest contributor of the month. The X sales process continued to pick up momentum in November. There were numerous high-quality reports that final round bids were due on December 1 and that there were at least 5 bidders. We continue to find the process attractive since there are numerous strategic buyers competing to own the asset. The process is one we typically like to own, and the potential upside is usually underappreciated. The three largest detractors of the month were Capri Holdings (CPRI), Origin Energy (ORG), and Spirit Airlines (SAVE). CPRI was the largest detractor of November due to the deal receiving a second request for more information from the Federal Trade Commission (FTC) on November 6. As a result, the gross spread widened to 12.5% from 11% at the start of November. Following CPRI's earnings release, we met with the management team of Tapestry (TPR) who remains fully committed to closing the transaction and were meeting with debt investors to raise debt to finance the deal. We continue to monitor the fundamentals of CPRI and trends in the accessible luxury space. ORG was the second largest detractor of the month. On November 2, the consortium (Brookfield) increased their offer for ORG and made it best and final. Following this amended offer, an Australian fundamental holder came out opposing the new offer. As the stock collapsed, the Australian fund continued to buy shares of ORG. We reduced our position in anticipation that in the event of a failed scheme vote leading to no immediate executable offer alternative, our team would face a long and complicated process. We believed the parties were highly committed and motivated to buying ORG and will present a viable alternative to the scheme of arrangement in the form of an exchange offer. This loss is another reminder to us that Australia is a challenging market for arbitrage. We will remain disciplined as we wait for the consortium's plan B, which we believe may include launching an offer with a 50% acceptance threshold. SAVE was the third largest detractor in November as the trial continued in earnest throughout the month. The Department of Justice (DOJ) was able to show that the merger would raise prices to low-cost customers and elicit testimony that the divestiture buyers (Allegiant (ALGT) and Frontier (ULCC)) would not commit to flying the same routes as SAVE.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund (continued)

However, the judge also made comments suggesting that he viewed JetBlue's (JBLU) expansion as potentially beneficial on a nationwide basis, leaving the trial outcome uncertain. The stock also rallied, as SAVE became a popular retail trade, causing price movements sometimes unrelated to events in the courtroom. In addition to VMW, EMIS Group (EMIS), New Relic (NEWR) and Hostess brands (TWNK) deals all closed in November, representing circa 20% of gross long exposure. We maintain a patient stance for deploying additional risk, concentrating on attractive opportunities where we have significant capital positions as we approach year-end. Looking forward to 2024, as annual meeting season approaches, we expect hostile deal flow to pick up prior to the annual meeting so that hostile acquirers can make change of the board through the annual meeting process.

#### Market Outlook:

During the end of the year 2023 and as early as January 2024, there are some signs of growing demand for M&A activity, buoyed by a gradual easing of regulatory and macroeconomic headwinds. Markets participants begun to see an uptick in hostile deal flow, reinforced by the reduction in US-year treasury rates from just over 5% to under 4%.

This decline bolsters CEOs' confidence that the hiking interest rate cycle is concluding, helping them to better gauge the likelihood of a recession. Additionally, the market has observed outcomes in cases like ATVI/MSFT and HZNP/AMGN that suggest there is a viable path to completing complex transactions. Consequently, the probability of a higher deal flow is significant which should support the opportunity set for merger arbitrage managers.

Annual performance per share class as at 31 December 2023:

A CHF	A EUR	A GBP	A USD	AA USD	C EUR	C USD
4.28%	6.01%	7.07%	7.63%	7.39%	6.22%	7.98%

EB EUR	I CHF	I EUR	I GBP	I JPY	I NOK	I USD
6.92%	5.08%	6.76%	7.82%	3.30%	2.31%	8.35%

IA USD	O EUR	O USD	SI EUR	SI GBP	SI USD	ID GBP
8.22%	6.18%	7.83%	6.74%	7.96%	8.56%	4.10%

TIG Advisors LLC  
Amundi Asset Management S.A.S.  
February 2024

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Sandler US Equity Fund

##### 2023 Market Performance Review

Financial markets started the year strongly in January 2023 with tailwinds from declining inflation and hopes of a soft landing, before high interest rates led to a US regional banks crisis extending to global markets in March. However, the stronger capitalization of banks, quick response from the FDIC, and the source of the issue (US Treasuries) helped contain the market turmoil. Financial markets remained flat in April and May, and rallied over June and July following the release of optimistic economic data. Markets then cooled during the rest of Q3 as the end-of-July Fed meeting and persistent economic challenges drove the narrative of higher-for-longer interest rates. In contrast, financial markets rallied in Q4 over hopes of sooner-than-expected interest rates cuts.

##### Monthly Fund Performance Review

The year started with uncertainty in the U.S. stock market, reflecting global concerns about the post-pandemic recovery and geopolitical tensions. Mirroring this uncertainty, the Fund experienced a net decline of 2.37% in January (I USD share class). During the month, long positions added 3.2% to performance while short positions detracted 5.7%, on a gross basis. At the sector level, positions in Industrials added most to performance during the month, followed by positions in Healthcare, Materials, and Tactical Market Indices. Positions in Financials detracted most from performance during the month, followed by positions in Consumer Discretionary, Real Estate, and Communication Services. The fund had a very difficult month as its short portfolio rallied by 8.5 percentage points more than its long portfolio. The move down in quality and momentum and the associated rally in stocks with short interest seems very extreme to us and we believe it is not indicative of a healthy market. We don't think it's sustainable given our economic outlook. During the month, we increased net exposure by 7 points (8 beta-adjusted) and reduced gross exposure slightly. The biggest changes to sector exposures were to increase net exposure to Consumer Discretionary and Communication Services by approximately 2 points each and to Materials, IT, and Financials by just over 1 point each.

**February** marked a phase of relative stabilization, as growth signals from major economies slightly eased concerns over monetary policies, providing a more stable backdrop for our strategies. The Amundi Sandler US Equity Fund saw a modest uptick of approximately 0.18% during the month. During the month, long positions detracted 0.9% from performance while short positions added 0.9%, on a gross basis. At the sector level, positions in Information Technology added most to performance during the month, followed by positions in Real Estate, Communication Services, and Tactical Market Indices. Positions in Healthcare detracted most from performance during the month, followed by positions in Financials, Industrials, Consumer Discretionary and Materials. Positions in Energy and Utilities had minimal impact on return for the month. The fund had a very quiet month. Longs and shorts essentially offset for the month. By issuer, the biggest contributor and detractor were just 20 bps and 22 bps, respectively. While the market gave back some of its January rally, quality factors didn't make a similar reversion. We've continued to gradually increase net (by 7 points in Jan and by another 5 points in Feb). Most of the shift in net has been short covering (some in January in more crowded names that rallied and some more in February on select profit taking). On a sector basis, net exposure to Industrials increased by 3 points during the month, followed by IT by 2 points, and Financials by 1 point, while we reduced net exposure to Consumer Discretionary by 1.5 points. Other sector net exposures changed by less than a point. We think being slightly net long is a better match with our quality slant for the time being. If upcoming inflation data forces the Fed to be more aggressive, you could see us lean into the portfolio, particularly on the short side. In the meantime, we will be looking to add selectively to both sides of the portfolio.

In **March**, the market exhibited signs of confidence, supported by strong corporate earnings and positive economic indicators, leading to moderate gains. The Fund capitalized on this sentiment, netting a 2.98% increase. During the month, long positions added 1.0% to performance and short positions added 1.8%, on a gross basis. At the sector level, positions in Financials added most to performance during the month, followed by positions in Information Technology, Real Estate, Communication Services, Energy and Tactical Market Indices. Positions in Materials detracted most from performance during the month, followed by positions in Healthcare. The fund had a strong month, making money on both sides of the portfolio. Financial shorts were the standout contributor during the mini regional banking crisis, but the fund made money across most sectors. We didn't lay into the shorts as markets began to falter because there were many moving pieces with the Fed and so forth, and that turned out to be fortunate as the latter part of the month saw stabilization and recovery in many areas.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Sandler US Equity Fund (continued)

Overall net and gross exposures were almost unchanged on the month, as were sector net exposures, with the biggest changes being a 1.4 point add to Communication Services net exposure and a 1.4 decrease to Consumer Discretionary net. We believe the environment should be conducive to quality looking ahead, though not without mini rotations, as the economy faces much uncertainty in the face of persistent inflation pressures and financial tightening.

**April** saw positive market reactions to policy measures addressing inflation, although long-term impacts on economic growth remained a concern. The Amundi Sandler US Equity Fund recorded a slight increase of about 0.15%. During the month, long positions detracted 0.1% from performance while short positions added 0.1%, on a gross basis. At the sector level, positions in Consumer Discretionary added most to performance during the month (37 bps), followed by positions in Healthcare (13 bps), Materials (6 bps), Real Estate (4 bps), and Consumer Staples (2 bps). Positions in Information Technology detracted most from performance during the month (26 bps), followed by positions in Communication Services (19 bps), Financials (14 bps), Tactical Market Indices (3 bps), and Energy (2 bps). Positions in Industrials and Utilities had minimal impact on return for the month. Currency hedging had minimal impact on return for the month. The fund had a very quiet month. Changes to overall exposures during the month were minor, with gross exposure increasing by 5 points and net exposure declining by 1 (and by 3 points on a beta-adjusted basis). At the sector level, we reduced net exposure to IT by about 3 points and to Financials (going more net short) by 2 points. Net exposure increase to Communication Services, Industrials, and Healthcare by about 1 point each.

**May's** market experienced a slight downturn, influenced by ongoing geopolitical uncertainties and renewed inflation concerns. Despite this, the Amundi Sandler US Equity Fund achieved a 1.22% increase. During the month, long positions added 1.6% to performance while short positions detracted 0.3%, on a gross basis. At the sector level, positions in Information Technology added most to performance during the month, followed by positions in Materials, Energy, Industrials, Real Estate, Communication Services and Tactical Market Indices (5 bps). Positions in Consumer Discretionary detracted most from performance during the month, followed by positions in Financials and Healthcare. The fund had a solid month with significant contribution from its long portfolio and only minor deduction from shorts. Overall net exposure increased by 4 points during the month (and by 8 points on a beta-adjusted basis), mainly due to short covering. Gross exposure declined by 4 points. On a sector basis, net exposure to IT increased by 3 points during the month while Financials net increased by 2 points and other sectors changed by less than a point.

**June** marked a rebound with all sectors showing positive performance, underpinned by robust U.S. economic data and a pause in the Federal Reserve's rate hikes. The Fund capitalized on this trend, gaining 0.73% net in June. During the month, long positions added 4.2% to performance while short positions detracted 3.5%, on a gross basis. At the sector level, positions in Industrials added most to performance during the month (128 bps), followed by positions in Healthcare (34 bps), Materials (34 bps), Communication Services (31 bps), and Information Technology (11 bps). Positions in Financials detracted most from performance during the month (93 bps), followed by positions in Consumer Discretionary (39 bps), Real Estate (18 bps), Energy (11 bps), and Consumer Staples (3 bps). The fund had a quiet month relative to the market rally but was positive from net long positioning, despite our short portfolio going up more than our long portfolio during the month. While certainly surprised by the magnitude of the rally, we did get more constructive on the margin coming into the month and a bit more during it, while pulling net exposure back a bit towards the end of the month and more so last week. Overall, net exposure started and ended the month at 13% net long, but averaged a few points higher during the month. Gross exposure was increased by 10 points during the month. All changes to sector net positioning during the month were less than one point, with the exception of net exposure to Financials we decreased by 1.6 points.

In **July**, moderate market activity was observed as investors awaited third-quarter economic reports with a cautious approach. Contrasting with the previous month, the Amundi Sandler US Equity Fund faced challenges, declining by 1.77%. During the month, long positions added 0.5% to performance while short positions detracted 2.7%, on a gross basis. At the sector level, positions in Information Technology added most to performance during the month, followed by positions in Consumer Discretionary and Consumer Staples. Positions in Financials detracted most from performance during the month, followed by positions in Communication Services, Materials, Industrials, Tactical Market Indices and Real Estate. The fund had a very challenging month as the short book was up dramatically more than the long portfolio during the period. Short covering was a headwind as was the risk-on appetite of investors. We initially increased gross exposure in early July as we embarked on earnings season and we felt the risk-reward for the market was lining up well with our positioning.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Sandler US Equity Fund (continued)

However, investor optimism and short covering led to a challenging environment and we began to gradually reduce exposure again as the month went on. Overall, we increased gross exposure by 6 points during the month and reduced net exposure by 4 points. On a sector basis, we reduced net exposure to IT by 3 points, to Financials by 2 points, and to Consumer Discretionary by 1 point, while all other sectors changed by less than a point. We believe it is possible that summer months may lead to more dislocations in light trading, but ultimately stocks should reflect their true risk/reward and rational bifurcation should result as the tighter financial conditions required to reach inflation targets continue. We believe July rotations are not sustainable and should be followed by a favorable environment for the portfolio.

**August's** stock market experienced low volatility, with cautious expectations dominating ahead of key economic data releases. In this context, the Amundi Sandler US Equity Fund saw an upturn of 0.90%. During the month, long positions detracted 0.7% from performance while short positions added 1.5%, on a gross basis. At the sector level, positions in Industrials added most to performance during the month (57 bps), followed by positions in Financials (53 bps), Tactical Market Indices (31 bps), Consumer Discretionary (14 bps), and Consumer Staples (4 bps). Positions in Information Technology detracted most from performance during the month (63 bps), followed by positions in Healthcare (7 bps), Materials (5 bps), Communication Services (4 bps), and Real Estate (3 bps). Positions in Energy and Utilities had minimal impact on return for the month. The fund had a positive month as the short portfolio added double what the long portfolio detracted, reversing some of July losses for the fund. We reduced net exposure by 4 points during the month (by 12 points on a beta-adjusted basis). Gross exposure declined by 11 points as we cut long positions and covered some short hedges towards the end of the month. On a sector basis, we reduced net exposure to Industrials by 3.5 points and to Financials by nearly 2 points, while we increased net exposure to Consumer Discretionary by 2.5 points. We remain very cautious and positioned bearishly during September so far.

**September** witnessed a decline in global equities, with a broader market weakness, except in the energy sector. However, U.S. economic activity remained resilient. The Fund registered a slight decline of -0.43%. During the month, long positions detracted 2.3% from performance while short positions added 1.6%, on a gross basis. At the sector level, positions in Financials added most to performance during the month (36 bps), followed by positions in Consumer Staples (15 bps) and Tactical Market Indices (13 bps). Positions in Consumer Discretionary detracted most from performance during the month (40 bps), followed by positions in Healthcare (31 bps), Information Technology (31 bps), Industrials (20 bps) and Materials (15 bps). At the sector level, we increased net exposure to IT by 2 points during the month, while reducing net exposure to Healthcare and Consumer Discretionary by about 1.5 points each. Changes to all other sector net exposures were less than a point. September seemed to be more about rate accession concerns on valuation and less about what it could do to the economy, at least in terms of relative performance among stocks. However, since there has been more focus on what rising rates mean for businesses and the economy and this has shown up in relative performance so far in October. We used September to shift further away on the long side from businesses who rely on financing and added to shorts whose businesses rely on credit financing.

Renewed concerns over inflation and interest rates led to sell-offs in various sectors in **October**. Despite this, the Fund achieved a 0.71% increase. During the month, long positions detracted 2.2% from performance while short positions added 2.8%, on a gross basis. At the sector level, positions in Consumer Discretionary added most to performance during the month (74 bps), followed by positions in Financials (64 bps), Communication Services (10 bps), Consumer Staples (10 bps), and Real Estate (9 bps). Positions in Industrials detracted most from performance during the month (37 bps), followed by positions in Healthcare (29 bps), Information Technology (26 bps), Materials (9 bps), and Tactical Market Indices (7 bps). The fund had a solid month as the short portfolio significantly outperformed the long book during the period. We increased both net and gross exposure by a few points during the month. At the sector level, we increased net exposure to Consumer Discretionary by 3 points, to IT and Financials by 1.5 points, and to Materials by 1 point while reducing net exposure to Communication Services by 1 point. In October, the markets seemed to recognize that the economy was slowing and financial conditions were not yet easing and the rotations were favourable. We began to tactically take back some shorts during the month and moved the portfolio to slightly net long, which we have since increased further in November.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Amundi Sandler US Equity Fund (continued)

**November** was marked by a market rebound, fueled by signs of easing inflation and positive holiday season outlooks. The Fund recorded a modest increase of 0.33%. During the month, long positions added 4.0% to performance while short positions detracted 3.8%, on a gross basis. At the sector level, positions in Information Technology added most to performance during the month (147 bps), followed by positions in Industrials (29 bps), Materials (25 bps), and Healthcare (21 bps). Positions in Financials detracted most from performance during the month (129 bps), followed by positions in Consumer Discretionary (31 bps), Real Estate (22 bps) and Communication Services (12 bps). The fund had a quiet month as the market ripped on improving inflation data combined with resilient economic conditions. We added 5 points to net exposure, but 19 points on a beta-adjusted basis, as we reduced higher beta shorts during the month. Gross exposure came up by about 7 points. On a sector basis, we increased net exposure to Materials by 4 points, to Industrials and IT by 3 points each, and to Financials by 1.5 points, while we reduced net exposure to Consumer Discretionary and Consumer Staples by 2 points each as we believe lower inflation and softening (though resilient) economic conditions creates risks for certain consumer business. In early December, net and gross exposure continued to move up due to better than expected economic strength (softening but so far without job loss) and faster than expected declines in inflation. In addition, the Fed seems more concerned with slowing growth than really crushing inflation and has signalled a pivot faster than we would have expected. While we still believe this can create problems down the road, for now we moved the fund's net exposure closer to its historical average.

The year concluded with investors being cautious, making adjustments in anticipation of the New Year. The Fund saw a net increase of approximately 0.29% in **December**. During the month, long positions added 5.3% to performance while short positions detracted 4.9%, on a gross basis. At the sector level, positions in Industrials added most to performance during the month, followed by positions in Materials, Communication Services, Healthcare, and Information Technology. Positions in Financials detracted most from performance during the month, followed by positions in Consumer Discretionary, Tactical Market Indices, Real Estate, and Consumer Staples. The Fund had a modest return as the market continued to rally in December. Higher net exposure helped put the fund in positive territory, while a negative spread of around 3 points between long and short positions for the month muted the Fund's return. We continued to increase net exposure during the month (by 13 points on a delta-adjusted basis and by 18 points on a beta-adjusted basis), on the heels of a pivot by the Fed. Gross exposure increased by about 10 points. On a sector basis, the biggest shift was to add just over 6 points of net exposure to Industrials, while we also added 2 points to Financials (covering some shorts there) and about 1.5 points to Materials, Consumer Discretionary, Consumer Staples, and Healthcare. We reduced net exposure to IT by nearly 3 points given the significant appreciation in the group during Q4. We were surprised at how quickly and openly the Fed not only didn't push back against the market in their December meeting, but also seemed to welcome and endorse an easing in financial conditions much sooner than prior language would have indicated, especially knowing mistakes from the late 1960s which led to the 70s inflation re-emerging. We think politics may have played a part given an election year in 2024. We do think there is still a strong chance of the economy slowing into recession from rate hikes already in the system or a re-emergence of inflation at some point, which forces the Fed to tighten financial conditions. However, the Fed is clearly trying to err on the side of preventing a recession vs. trying to put inflation to rest for good and we adjusted the portfolio to reflect that change for the time being.

#### Market outlook

Entering into 2024, equity financial markets continued on their rising trend as macro data supported hopes of soft landing in the US, while the ECB kept of more conservative stance on inflation and central policy. Globally equity long short managers performance was positive in January and for the year we expect returns to depend tightly on stocks dispersion, low equity correlation as interest rates are expected to normalize.

**AMUNDI ALTERNATIVE FUNDS PLC**

**INVESTMENT MANAGER'S REPORT (continued)  
For the year ended 31 December 2023**

**Amundi Sandler US Equity Fund (continued)**

Annual performance per share class as at 31 December 2023:

A EUR	A USD	AA USD	C EUR	C USD	EB EUR	I EUR	I GBP	I JPY
0.50%	2.47%	2.34%	0.87%	2.81%	1.63%	1.24%	3.49%	-1.76%

I SGD	I USD	IA USD	O EUR	O GBP	O USD	SI EUR	SI GBP	SI USD	SI2 GBP
3.48%	2.85%	2.76%	1.64%	2.72%	3.28%	1.44%	2.82%	3.07%	2.73%

Sandler Capital Management  
Amundi International Asset Management S.A.S.  
February 2024

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### REMUNERATION DISCLOSURE

#### COMPENSATION OF THE STAFF OF AMUNDI ASSET MANAGEMENT (2023 ACCOUNTING YEAR)

##### 1. Remuneration policy and practices of the AIFM/Management company

The remuneration policy implemented by Amundi Asset Management is compliant with the rules in terms of remuneration specified in the Directive 2011/61/UE of the European Parliament and of the Council of June 8<sup>th</sup> 2011 on Alternative Investment Fund Managers (the “AIFM Directive”), and in the Directive 2014/91/UE of July 23<sup>rd</sup> 2014 on undertakings for collective investment in transferable securities (the “UCITS V Directive”). These rules, about remuneration policies and practices, have for objective to promote sound and effective risk management of fund managers and the funds they manage.

Moreover, the remuneration policy is compliant with Regulation (EU) 2019/2088 (“SFDR”), integrating sustainability risk and ESG criteria in Amundi control framework, with responsibilities spread between the first level of controls performed by the Investment teams and second level of controls performed by the Risk teams, that can verify the compliance with ESG objectives and constraints of a fund at all time.

This policy is incorporated within the framework of the remuneration policy of Amundi reviewed each year by its Remuneration Committee. The latter checked the application of the remuneration policy in relation to the 2022 fiscal year, its compliance with the AIFM/UCITS Directives’ principles and approved the policy applicable for the 2023 exercise at its meeting held on January 30<sup>th</sup> 2023.

In 2023, the implementation of the Amundi remuneration policy was subject to an internal, central and independent audit, driven by the Amundi Internal Audit.

##### 1.1 Amounts of remuneration paid by the Management companies to its employees

During fiscal year 2023, the total amount of compensation paid by Amundi Asset Management (including fixed, deferred and non-deferred variable compensation) to its employees (1 923 beneficiaries<sup>1</sup>) is EUR 207 362 471. This amount is split as follows:

- Total amount of fixed remuneration paid by Amundi Asset Management in 2023: EUR 145 346 571, which represents 70% of the total amount of compensation paid by Amundi Asset Management to its staff, were in the form of fixed remuneration.
- Total amount of variable compensation deferred and non-deferred paid by Amundi Asset Management in 2023: EUR 62 015 900, which represents 30% of the total amount of compensation paid by Amundi Asset Management to its staff, were in this form. The entire staff is eligible for variable compensation.

Additionally, some ‘carried interest’ was paid with respect to fiscal year 2023, and is taken into account in the total amount of bonus referred to here above.

Of the total amount of remuneration paid during the fiscal year (fixed and variable compensation deferred and non-deferred), EUR 21 370 354 were paid to the ‘executives and senior managers’ of Amundi Asset Management (44 beneficiaries), and EUR 15 185 244 were paid to the ‘senior investment managers’ whose professional activities have a material impact on Amundi Asset Management’s risk profile (56 beneficiaries).

##### Alignment of remuneration policy and practices with risk profile of the AIFs/UCITS

The Amundi Group has adopted and implemented remuneration policy and practices compliant with the latest norms, rules, and guidelines issued from the regulatory authorities for its management companies (AIFM/UCITS).

The Amundi Group has also identified all of its ‘Identified Staff’, that include all the employees of the Amundi Group having a decision authority on the UCITS/AIFM management companies or the UCITS/AIFs managed and consequently likely to have a significant impact on the performance or the risk profile.

---

<sup>1</sup>Number of permanent and fixed-term employees paid during the year

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### REMUNERATION DISCLOSURE (continued)

The variable remuneration awarded to the Amundi Group staff takes into account the performance of the employee, its business unit and the Amundi Group as a whole, and is based on quantitative and qualitative criteria as well as the respect of sound risk management rules.

The criteria taken into account for performance assessment and remuneration award depends on the nature of the employee's functions :

##### 1. Management and selection of AIFs/UCITS functions

###### *Quantitative criteria:*

- IR/Sharpe over 1, 3, 5 years
- Gross/absolute/relative performance of the investment strategies (based on GIPS composites) over 1, 3, 5 years, outlook mainly focused on 1 year, adjusted with long-term figures (3,5 years)
- Performance risk adjusted based on IR/Sharpe over 1, 3, 5 years
- Competitive positioning through Morningstar rankings
- Net inflows / Successful requests for proposals, mandates
- Performance fees generation
- ESG rating of the funds according to different providers when applicable (Morningstar, CDP...)
- Respect of ESG beat the benchmark, ESG exclusion policies and climate transition index

###### *Qualitative criteria:*

- Compliance with risk policy, compliance and legal rules
- Quality of management
- Innovation/product development
- Collaboration/Sharing of best practices
- Commercial engagement – including the ESG component of commercial effort and flows
- ESG
  - o Compliance with ESG policy and participation to the ESG and net-zero offering
  - o Integration of ESG into investment processes
  - o Capacity to promote and project ESG knowledge internally and externally
  - o Extent of proposition and innovation in the ESG space
  - o Demonstrates capacity to manage well the combination of risk return and ESG (the risk and ESG adjusted return)

##### 2. Sales and marketing functions

###### *Quantitative criteria:*

- Net inflows, notably on ESG and impact denominated products
- Revenues
- Gross Inflows
- Client base development and retention; product mix
- Number of commercial activities per year, notably prospection activities
- Number of clients approached on their net zero strategy

###### *Qualitative criteria:*

- Compliance with risk policy, compliance and legal rules
- Joint consideration of Amundi's interests and of client's interests
- Securing/developing the business
- Client satisfaction
- Quality of management
- Cross-functional approach and sharing of best practices
- Entrepreneurial spirit
- Capacity to explain and promote ESG policies and capabilities as well as solutions of the firm

## **AMUNDI ALTERNATIVE FUNDS PLC**

### **INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023**

#### **REMUNERATION DISCLOSURE (continued)**

##### 3. Control and support functions

For control and support functions, performance assessment and remuneration award are independent from the performance of the business they oversee.

Common criteria taken into account are:

- Mainly criteria related to the meeting of objectives linked to their functions (risk management, quality of controls, completion of projects, tools and systems improvement etc.)
- When financial criteria are used, these are mainly related to management/ optimization of expenses.

The above-mentioned performance criteria, and specifically those applicable to Identified staff in charge of the management of AIFs/UCITS, comply with the applicable regulation as well as to the AIF's/UCITS investment policy. These internal rules of Amundi Group contribute to a sound and effective risk management.

Furthermore, Amundi Group has adopted and implemented, for its entire staff, measures aiming to align remuneration with long-term performance and risks in order to avoid conflicts of interest.

In this respect, notably:

- The deferral policy has been adapted to comply with the AIFM and UCITS V Directives' requirements.
- The deferred portion of variable compensation for identified staff members is awarded at 100% in instruments indexed on the performance of a representative basket of AIFs and/or UCITS funds.
- The actual payment of the deferred portion is linked to the financial situation of Amundi Group, to the continued employment within the group and to a sound and effective risk management over the vesting period.

##### **SANDLER CAPITAL MANAGEMENT**

The proportion of total remuneration of the staff that is attributable to SANDLER CAPITAL MANAGEMENT as the Sub-Investment Manager of "AMUNDI/SANDLER US EQUITY FUND" for the year ended 31 December 2023, is approximately USD 8.7 million which relates to 29 beneficiaries. This total remuneration is comprised of fixed remuneration of approximately USD 2.7 million and variable remuneration of approximately USD 6.0 million.

##### **TIEDEMANN CAPITAL MANAGEMENT**

TIG maintains an investment adviser role in funds managed pari passu to the UCITS strategy (which is partially derived from incentive compensation received from such funds). TIG also utilizes a long-term stock incentive plan for certain investment professionals where a portion of such person's compensation is granted in AITi Global, Inc. stock, which has a three-year vesting period. We believe this structure results in a strong alignment of interest between TIG and the funds managed.

## AMUNDI ALTERNATIVE FUNDS PLC

### INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023

#### Securities Financing Transactions Regulation Disclosure

Lyxor Newcits IRL Plc (the "Company") is subject to the Securities Financing Transactions Regulation (the "SFTR") as at 31 December 2023. The SFTR introduces mandatory reporting for securities financing transactions ("SFTs") and sets minimum disclosure and consent requirements on the re-use of collateral, with the aim of reforming shadow banking and improving transparency in the SFT market. The SFTR was formally adopted by the EU on 25 November 2015 and came into force on 13 January 2017. An SFT consists of any transaction that uses assets belonging to counterparty to generate financing means and is comprised of the following:

- repurchase transactions;
- securities or commodities lending, securities or commodities borrowing;
- any transaction having an equivalent economic effect, in particular a buy/sell-back or sell/buy-back transaction;
- margin lending transaction; and
- total return swaps

Article 2 of the SFTR covers the following entities:

- Counterparties to an SFT that are established:
  - in the EU, including all of its branches irrespective of where they are located (i.e., non-EU branches); or
  - outside the EU if the SFT is concluded in the course of the operations of an EU branch of that counterparty.
- UCITS funds and their management companies irrespective of where they are established;
- AIFMs authorised or registered in accordance under AIFMD irrespective of where their AIFs are established; and
- in relation to the Re-use Obligation only, counterparties established outside the EU, in either of the following circumstances:
  - the re-use is effected in the course of the operations of an EU branch; or
  - the re-use concerns financial instruments provided as collateral by a counterparty established in the EU or an EU branch of a third country entity (i.e. a non-EU entity re-uses an EU entity's collateral).

For the year ended 31 December 2023, the Company and its Sub-Funds did not hold any SFTs. The periodical disclosure requirements under SFT Regulation in accordance with Section A of the Annex to SFT Regulation do not apply.

## **AMUNDI ALTERNATIVE FUNDS PLC**

### **INVESTMENT MANAGER'S REPORT (continued) For the year ended 31 December 2023**

#### **Transparency of sustainable investments in periodic reports**

Regulation (EU) 2020/852 on the establishment of a framework to facilitate sustainable investment (the “Taxonomy Regulation”) sets out criteria to determine which economic activities qualify as environmentally sustainable at Union level.

According to the Taxonomy Regulation, an economic activity shall qualify as environmentally sustainable where that economic activity contributes substantially to one or more of the six environmental objectives defined by the Taxonomy Regulation (Climate change mitigation; Climate change adaptation; Sustainable use and protection of water and marine resources; Transition to a circular economy; Pollution prevention and control; Protection and restoration of biodiversity and ecosystems).

In addition, such economic activity shall not significantly harm any such environmental objectives (“do no significant harm” or “DNSH” principle) and shall be carried out in compliance with the minimum safeguards laid down in Article 18 of the Taxonomy Regulation.

In accordance with Article 7 of the Taxonomy Regulation, the management company draws the attention of investors to the fact that the investments of the below Sub-Funds do not take into account the European Union criteria for environmentally sustainable economic activities.

These Funds falls under Article 6 of regulation (EU) 2019/2088 (“SFDR”). They do not promote environmental and/or social characteristics, nor do they have sustainable investment as its objective.

- Amundi Sandler US Equity Fund
- Amundi Tiedemann Arbitrage Strategy Fund

## ***Amundi Alternative Funds plc***

### **Annual Depositary Report to Shareholders**

We, CACEIS Bank, Ireland Branch, appointed Depositary to AMUNDI Alternative Fund plc (the “Company”) provide this report solely for the shareholders of the Company for the year ended 31 December 2023 (“Annual Accounting Period”).

This report is provided in accordance with the UCITS Regulations – European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (S.I. No. 352 of 2011) (as amended) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 which implemented Directive 2009/65/EU into Irish Law (the “Regulations”). We do not, in the provision of this report, accept nor assume responsibility for any other purpose or to any other person to whom this report is shown.

In accordance with our Depositary obligations as provided for under the Regulations, we have enquired into the conduct of the Company for this Annual Accounting Period and we hereby report thereon to the shareholders of the Company as follows;

We are of the opinion that the Company has been managed during the Annual Accounting Period, in all material respects:

- (i) in accordance with the limitations imposed on the investment and borrowing powers of the Company by the constitutional documents and by the Regulations; and
- (ii) otherwise in accordance with the provisions of the constitutional documents and the Regulations.

---

**CACEIS Bank, Ireland Branch**  
**29 April 2024**



# ***Independent auditors' report to the members of Amundi Alternative Funds plc***

## **Report on the audit of the financial statements**

---

### **Opinion**

In our opinion, Amundi Alternative Funds plc's financial statements:

- give a true and fair view of the Company's and Sub-Funds' assets, liabilities and financial position as at 31 December 2023 and of their results and cash flows for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards ("IFRSs") as adopted by the European Union; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014 and the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (as amended).

We have audited the financial statements, included within the Annual Report and Audited Financial Statements, which comprise:

- the Statement of Financial Position as at 31 December 2023;
- the Statement of Comprehensive Income for the year then ended;
- the Statement of Cash Flows for the year then ended;
- the Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares for the year then ended;
- the Schedule of Investments for each of the Sub-Funds as at 31 December 2023; and
- the notes to the financial statements for the Company and for each of its Sub-Funds, which include a description of the accounting policies.

---

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) ("ISAs (Ireland)") and applicable law.

Our responsibilities under ISAs (Ireland) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Independence**

We remained independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, which includes IAASA's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

---

### **Conclusions relating to going concern**

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's and Sub-Funds' ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the Company's and Sub-Funds' ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.



---

## Reporting on other information

The other information comprises all of the information in the Annual Report and Audited Financial Statements other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Directors' Report, we also considered whether the disclosures required by the Companies Act 2014 have been included.

Based on the responsibilities described above and our work undertaken in the course of the audit, ISAs (Ireland) and the Companies Act 2014 require us to also report certain opinions and matters as described below:

- In our opinion, based on the work undertaken in the course of the audit, the information given in the Directors' Report for the year ended 31 December 2023 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.
- Based on our knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report.

---

## Responsibilities for the financial statements and the audit

### *Responsibilities of the directors for the financial statements*

As explained more fully in the Statement of Directors' responsibilities set out on page 4, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view.

The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's and Sub-Funds' ability to continue as going concerns, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

### *Auditors' responsibilities for the audit of the financial statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our audit testing might include testing complete populations of certain transactions and balances, possibly using data auditing techniques. However, it typically involves selecting a limited number of items for testing, rather than testing complete populations. We will often seek to target particular items for testing based on their size or risk characteristics. In other cases, we will use audit sampling to enable us to draw a conclusion about the population from which the sample is selected.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA website at:

[https://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description\\_of\\_auditors\\_responsibilities\\_for\\_audit.pdf](https://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf)

This description forms part of our auditors' report.



### *Use of this report*

This report, including the opinions, has been prepared for and only for the Company's members as a body in accordance with section 391 of the Companies Act 2014 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

---

## **Other required reporting**

---

### **Companies Act 2014 opinions on other matters**

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
  - In our opinion the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited.
  - The financial statements are in agreement with the accounting records.
- 

### **Companies Act 2014 exception reporting**

#### *Directors' remuneration and transactions*

Under the Companies Act 2014 we are required to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by sections 305 to 312 of that Act have not been made. We have no exceptions to report arising from this responsibility.

Aoife O'Connor  
for and on behalf of PricewaterhouseCoopers  
Chartered Accountants and Statutory Audit Firm  
Dublin  
29 April 2024

AMUNDI ALTERNATIVE FUNDS PLC

STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

	Notes	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>ASSETS</b>				
Financial assets at fair value through profit or loss:	3			
Investment in securities		1,625,722,463	1,013,167,350	612,555,113
Financial derivative instruments		47,974,704	25,855,656	22,119,048
Cash and cash equivalents	2(i)	169,961,805	121,755,134	48,206,671
Due from brokers	7	101,378,349	80,080,947	21,297,402
Dividend receivable	2(q)	65,241	7,928	57,313
Other receivables		1,931,029	-	1,931,029
Subscription receivable	2(k)	1,757,752	609,578	1,148,174
<b>Total assets</b>		<b>1,948,791,343</b>	<b>1,241,476,593</b>	<b>707,314,750</b>
<b>LIABILITIES</b>				
Financial liabilities at fair value through profit or loss:				
Financial derivative instruments	3	16,078,817	6,053,604	10,025,213
Bank overdraft	2(i)	2,981,433	2,981,433	-
Management fees payable	6	13,272,280	9,314,241	3,958,039
Performance fees payable	6	23,011,168	20,960,382	2,050,786
Due to broker	7	24,514,718	22,909,160	1,605,558
Dividend payable	2(q)	268,936	2,051	266,885
Redemption payable	2(k)	3,554,438	2,587,790	966,648
Administrative fees payable	6	2,481,859	1,507,607	974,252
Other payables		297,268	167,775	129,493
<b>Total liabilities (excluding net assets attributable to holders of redeemable participating shares)</b>		<b>86,460,917</b>	<b>66,484,043</b>	<b>19,976,874</b>
<b>Net assets attributable to holders of redeemable participating shares</b>		<b>1,862,330,426</b>	<b>1,174,992,550</b>	<b>687,337,876</b>

The Sub-Funds' abbreviated names as presented above are defined on page 2.

AMUNDI ALTERNATIVE FUNDS PLC

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 December 2023

Share Class	TIEDEMANN		SANDLER	
	No. of shares outstanding	NAV per share	No. of shares outstanding	NAV per share
Class A (USD)	84,886.28	131.51	29,477.35	113.01
Class AA (USD)	100.00	118.43	100.00	112.04
Class C (USD)	100.00	108.23	37,173.08	113.73
Class I (USD)	610,342.02	158.41	372,707.04	130.14
Class IA (USD)	1,000.00	122.15	1,000.00	114.68
Class O (USD)	1,288.98	120.03	262,979.63	117.53
Class SI (USD)	1,027,325.11	111.10	449,480.67	116.26
Hedged Class A (CHF)	1,305.01	113.78	-	-
Hedged Class A (EUR)	386,709.46	118.90	122,770.39	110.94
Hedged Class A (GBP)	2,125.00	127.82	-	-
Hedged Class C (EUR)	100.00	106.27	37,607.88	103.98
Hedged Class EB (EUR)	5,188.16	138.28	18,823.46	119.08
Hedged Class I (CHF)	37,974.09	114.51	-	-
Hedged Class I (EUR)	2,185,101.06	125.63	575,105.60	116.02
Hedged Class I (GBP)	100,144.63	135.38	1,173.35	104.69
Hedged Class ID (GBP)	734.19	104.10	-	-
Hedged Class O (EUR)	11,498.30	112.47	51,906.58	107.34
Hedged Class O (GBP)	-	-	1,423,391.73	113.71
Hedged Class SI (EUR)	1,860,154.26	108.19	1,227,599.24	106.89
Hedged Class SI (GBP)	2,503,889.98	110.07	480,755.15	114.17
Hedged Class SI2 (GBP)	-	-	95,271.20	116.40
Hedged Class I (JPY)	127.00	10,380.27	150.00	9,766.55
Hedged Class I (SGD)	-	-	138,465.89	103.48

The Sub-Funds' abbreviated names as presented above are defined on page 2.

Signed on behalf of the Board of Directors:

\_\_\_\_\_  
Bryan Tiernan  
Director

\_\_\_\_\_  
Vincent Dodd  
Director

29 April 2024

29 April 2024

AMUNDI ALTERNATIVE FUNDS PLC

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 December 2022

	Notes	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>ASSETS</b>				
Financial assets at fair value through profit or loss:	3			
Investment in securities		2,043,497,461	1,191,447,201	852,050,260
Financial derivative instruments		255,440,418	105,912,787	149,527,631
Cash and cash equivalents	2(i)	544,030,829	402,405,538	141,625,291
Due from brokers	7	121,080,672	94,163,559	26,917,113
Dividend receivable	2(q)	571,085	428,961	142,124
Subscriptions receivable	2(k)	21,436,503	19,986,475	1,450,028
Other receivables		930,350	-	930,350
<b>Total assets</b>		<b>2,986,987,318</b>	<b>1,814,344,521</b>	<b>1,172,642,797</b>
<b>LIABILITIES</b>				
Financial liabilities at fair value through profit or loss:				
Financial derivative instruments	3	17,831,329	6,307,059	11,524,270
Bank overdraft	2(i)	105	105	-
Due to brokers	7	22,312,741	21,640,341	672,400
Dividend payable	2(q)	606,222	38,819	567,403
Management fees payable	6	5,817,267	2,420,807	3,396,460
Performance fees payable	6	1,346,566	1,346,362	204
Administration fees payable	6	4,429,858	2,812,891	1,616,967
Redemptions payable	2(k)	17,760,775	3,153,905	14,606,870
Other payables	6	868,737	626,127	242,610
<b>Total liabilities (excluding net assets attributable to holders of redeemable participating shares)</b>		<b>70,973,600</b>	<b>38,346,416</b>	<b>32,627,184</b>
<b>Net assets attributable to holders of redeemable participating shares</b>		<b>2,916,013,718</b>	<b>1,775,998,105</b>	<b>1,140,015,613</b>

The Sub-Funds' abbreviated names as presented above are defined on page 2.

AMUNDI ALTERNATIVE FUNDS PLC

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 December 2022

Share Class	TIEDEMANN		SANDLER	
	No. of shares outstanding	NAV per share	No. of shares outstanding	NAV per share
Class A (USD)	66,311.56	122.19	45,323.27	110.28
Class AA (USD)	59.60	110.28	74.66	109.48
Class C (USD)	54.06	100.23	38,149.32	110.62
Class I (USD)	509,640.64	146.21	305,625.36	126.53
Class IA (USD)	610.07	112.87	760.27	111.60
Class O (USD)	2,065.51	111.32	213,793.45	113.79
Class SI (USD)	823,635.42	102.34	970,461.39	112.80
Hedged Class A (CHF)	2,678.46	109.11	-	-
Hedged Class A (EUR)	536,864.61	112.16	94,360.71	110.39
Hedged Class A (GBP)	2,060.73	119.39	-	-
Hedged Class C (EUR)	57.52	100.05	41,505.13	103.08
Hedged Class EB (EUR)	6,783.64	129.32	26,877.63	117.17
Hedged Class I (CHF)	43,232.95	108.98	-	-
Hedged Class I (EUR)	2,585,646.16	117.67	961,780.51	114.59
Hedged Class I (GBP)	469,829.12	125.56	1,588.99	101.16
Hedged Class I (NOK)	39,725.96	1,099.32	-	-
Hedged Class O (EUR)	18,151.64	105.93	44,618.73	105.61
Hedged Class O (GBP)	-	-	1,093,435.00	110.69
Hedged Class SI (EUR)	2,216,193.54	101.36	1,373,418.07	105.38
Hedged Class SI (GBP)	1,746,499.96	101.95	581,709.40	111.04
Hedged Class SI2 (GBP)	-	-	1,606,340.69	113.31
Hedged Class I (JPY)	52.38	10,048.46	76.74	9,941.96

The Sub-Funds' abbreviated names as presented above are defined on page 2.

## STATEMENT OF COMPREHENSIVE INCOME

For the year ended 31 December 2023

	Notes	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>Investment income/(loss)</b>				
Net gain/(loss) on financial assets and liabilities at fair value through profit or loss	5	185,048,285	140,063,501	44,984,784
Net gain on foreign exchange	5	2,107,853	1,668,327	439,526
Interest income on cash and cash equivalents	2(p)	16,592,069	9,634,714	6,957,355
Interest on financial assets at fair value through profit or loss	2(p)	46,357,588	24,333,822	22,023,766
Dividend income	2(q)	11,783,471	8,384,009	3,399,462
CFD financing income	2(u)	8,575,155	-	8,575,155
Other income		158,811	158,786	25
<b>Total investment income</b>		<b>270,623,232</b>	<b>184,243,159</b>	<b>86,380,073</b>
<b>Expenses</b>				
Dividend expenses	2(q)	(12,055,101)	(2,954,985)	(9,100,116)
Management fees	6	(30,238,799)	(18,881,634)	(11,357,165)
Performance fees	6	(22,942,736)	(20,904,320)	(2,038,416)
Administration fees	6	(4,419,139)	(2,682,730)	(1,736,409)
Transaction costs	2(r)	(10,792,979)	(5,756,511)	(5,036,468)
CFD financing expenses	2(u)	(1,507,936)	(1,507,936)	-
Broker fees		(24,543)	(23,251)	(1,292)
Other expenses		(2,139,972)	(1,140,838)	(999,134)
<b>Total operating expenses</b>		<b>(84,121,205)</b>	<b>(53,852,205)</b>	<b>(30,269,000)</b>
<b>Operating income</b>		<b>186,502,027</b>	<b>130,390,954</b>	<b>56,111,073</b>
<b>Finance cost</b>				
Interest expense on cash and cash equivalents	2(p)	(2,234,990)	(1,013,260)	(1,221,730)
<b>Profit before tax</b>		<b>184,267,037</b>	<b>129,377,694</b>	<b>54,889,343</b>
Withholding taxes		(2,159,062)	(1,546,097)	(612,965)
<b>Increase in net assets attributable to holders of redeemable participating shares from operations</b>		<b>182,107,975</b>	<b>127,831,597</b>	<b>54,276,378</b>

The Sub-Funds' abbreviated names as presented above are defined on page 2.

All amounts arose solely from continuing operations. There are no gains or losses other than those dealt within the Statement of Comprehensive Income.

AMUNDI ALTERNATIVE FUNDS PLC

STATEMENT OF COMPREHENSIVE INCOME (continued)

For the year ended 31 December 2022

	Notes	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>Investment income/(loss)</b>				
Net (loss)/gain on financial assets and liabilities at fair value through profit or loss	5	(261,457,036)	(153,070,699)	(108,386,337)
Net (loss)/gain on foreign exchange	5	(2,310,545)	(1,182,075)	(1,128,470)
Interest income on cash and cash equivalents	2(p)	6,028,896	3,646,403	2,382,493
Interest on financial assets at fair value through profit or loss	2(p)	11,949,916	4,380,284	7,569,632
Dividend income	2(q)	23,377,437	19,458,228	3,919,209
Other income	2(u)	1,171,012	-	1,171,012
<b>Total investment income/(loss)</b>		<b>(221,240,320)</b>	<b>(126,767,859)</b>	<b>(94,472,461)</b>
<b>Expenses</b>				
Dividend expenses	2(q)	(12,422,283)	(3,803,282)	(8,619,001)
Management fees	6	(40,241,586)	(26,671,367)	(13,570,219)
Performance fees	6	(1,347,025)	(1,346,652)	(373)
Administration fees	6	(5,394,288)	(3,449,138)	(1,945,150)
Transaction costs	2(r)	(15,736,497)	(11,038,489)	(4,698,008)
CFD Financing expenses	2(u)	(7,086,324)	(7,086,324)	-
Broker fees		(19,267)	(19,267)	-
Interest expense on financial liabilities at fair value through profit and loss	2(p)	(61,918)	(61,918)	-
Other expenses		(2,087,083)	(1,419,458)	(667,625)
<b>Total operating expenses</b>		<b>(84,396,271)</b>	<b>(54,895,895)</b>	<b>(29,500,376)</b>
<b>Operating (loss)/income</b>		<b>(305,636,591)</b>	<b>(181,663,754)</b>	<b>(123,972,837)</b>
<b>Finance cost</b>				
Interest expense on cash and cash equivalents	2(p)	(1,643,015)	(547,356)	(1,095,659)
<b>(Loss)/profit before tax</b>		<b>(307,279,606)</b>	<b>(182,211,110)</b>	<b>(125,068,496)</b>
Withholding taxes		(4,557,294)	(3,768,624)	(788,670)
<b>(Decrease)/increase in net assets attributable to holders of redeemable participating shares from operations</b>		<b>(311,836,900)</b>	<b>(185,979,734)</b>	<b>(125,857,166)</b>

The Sub-Funds' abbreviated names as presented above are defined on page 2.

All amounts arose solely from continuing operations. There are no gains or losses other than those dealt within the Statement of Comprehensive Income.

AMUNDI ALTERNATIVE FUNDS PLC

**STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE  
TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES  
For the year ended 31 December 2023**

	<b>COMPANY TOTAL USD</b>	<b>TIEDEMANN USD</b>	<b>SANDLER USD</b>
<b>Balance as at the beginning of the year</b>	<b>2,916,013,718</b>	<b>1,775,998,105</b>	<b>1,140,015,613</b>
Increase in net assets attributable to holders of redeemable participating shares from operations	182,107,975	127,831,597	54,276,378
Issuance of redeemable participating shares	724,861,574	486,294,878	238,566,696
Redemption of redeemable participating shares	(1,960,652,841)	(1,215,132,030)	(745,520,811)
<b>Balance as at the end of the year</b>	<b>1,862,330,426</b>	<b>1,174,992,550</b>	<b>687,337,876</b>

The Sub-Funds' abbreviated names as presented above are defined on page 2.

AMUNDI ALTERNATIVE FUNDS PLC

**STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE  
TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES (continued)**  
For the year ended 31 December 2022

	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>Balance as at the beginning of the year</b>	<b>3,558,169,994</b>	<b>2,292,050,984</b>	<b>1,266,119,010</b>
(Decrease)/increase in net assets attributable to holders of redeemable participating shares from operations	(311,836,900)	(185,979,734)	(125,857,166)
Issuance of redeemable participating shares	1,019,069,443	703,771,994	315,297,449
Redemption of redeemable participating shares	(1,349,388,819)	(1,033,845,139)	(315,543,680)
<b>Balance as at the end of the year</b>	<b>2,916,013,718</b>	<b>1,775,998,105</b>	<b>1,140,015,613</b>

The Sub-Funds' abbreviated names as presented above are defined on page 2.

## AMUNDI ALTERNATIVE FUNDS PLC

### STATEMENT OF CASH FLOWS For the year ended 31 December 2023

	<b>COMPANY</b>		
	<b>TOTAL</b>	<b>TIEDEMANN</b>	<b>SANDLER</b>
	<b>USD</b>	<b>USD</b>	<b>USD</b>
<b>Cash flows from operating activities:</b>			
Increase in net assets attributable to holders of redeemable participating shares from operations	182,107,975	127,831,597	54,276,378
<b>Adjustments for:</b>			
Change in financial assets and liabilities at fair value through profit or loss	(278,667,023)	(150,197,423)	(128,469,600)
Payments on purchased investments	(10,820,538,793)	(7,784,274,166)	(3,036,264,627)
Proceeds from sold investments	11,516,980,816	8,112,751,442	3,404,229,374
<b>Changes in operating assets and liabilities:</b>			
Decrease in derivatives – net	205,713,202	79,803,676	125,909,526
Decrease in due from brokers	19,702,323	14,082,612	5,619,711
Increase in other receivables	(1,000,679)	-	(1,000,679)
Increase in due to brokers	2,201,977	1,268,819	933,158
Increase in management fees payable	7,455,011	6,893,432	561,579
Increase\decrease in performance fees payable	21,664,602	19,614,020	2,050,582
Decrease in administration fees payable	(1,947,999)	(1,305,284)	(642,715)
Decrease\increase in other payables and accrued expenses	(571,469)	(458,352)	(113,117)
Decrease \increase in dividend receivable	505,844	421,033	84,811
(Decrease)\increase in dividend payable	(337,286)	(36,768)	(300,518)
<b>Net cash provided by operating activities</b>	<b>853,268,501</b>	<b>426,394,638</b>	<b>426,873,863</b>
<b>Cash flows from financing activities:</b>			
Net proceeds from subscriptions of redeemable participating shares	744,540,325	505,671,775	238,868,550
Net payments on redemptions of redeemable participating shares		(1,215,698,145)	(759,161,033)
<b>Net cash used in financing activities</b>	<b>(1,974,859,178)</b>	<b>(710,026,370)</b>	<b>(520,292,483)</b>
<b>Net change in cash and cash equivalents</b>	<b>(377,050,352)</b>	<b>(283,631,732)</b>	<b>(93,418,620)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>544,030,724</b>	<b>402,405,433</b>	<b>141,625,291</b>
<b>Net cash and cash equivalents at the end of the year</b>	<b>166,980,372</b>	<b>118,773,701</b>	<b>48,206,671</b>
<b>Net cash and cash equivalents comprised of:</b>			
Cash and cash equivalents	169,961,805	121,755,134	48,206,671
Bank overdraft	(2,981,433)	(2,981,433)	-
	<b>166,980,372</b>	<b>118,773,701</b>	<b>48,206,671</b>
<b>Supplemental disclosure of cash flow information:</b>			
	<b>Totals</b>	<b>Tiedemann</b>	<b>Sandler</b>
Interest received	62,949,657	33,968,536	28,981,121
Interest paid	(2,234,990)	(1,013,260)	(1,221,730)
Dividends received	12,289,315	8,805,042	3,484,273
Dividends paid	(12,392,387)	(2,991,753)	(9,400,634)

The Sub-Funds' abbreviated names as presented above are defined on page 2.

AMUNDI ALTERNATIVE FUNDS PLC

STATEMENT OF CASH FLOWS (continued)  
For the year ended 31 December 2022

	COMPANY		
	TOTAL	TIEDEMANN	SANDLER
	USD	USD	USD
<b>Cash flows from operating activities:</b>			
(Decrease)/ increase in net assets attributable to holders of redeemable participating shares from operations	(311,836,900)	(185,979,734)	(125,857,166)
<b>Adjustments for:</b>			
Change in financial assets and liabilities at fair value through profit or loss	215,813,283	110,692,720	105,120,563
Payments on purchased investments	(11,282,258,753)	(8,912,566,765)	(2,369,691,988)
Proceeds from sold investments	11,840,937,313	9,337,260,389	2,503,676,924
<b>Changes in operating assets and liabilities:</b>			
Increase in derivatives – net	(177,018,623)	(107,836,294)	(69,182,329)
Decrease/(increase) in due from brokers	362,744,072	362,534,201	209,871
Decrease/(increase) in dividend receivable	359,431	367,669	(8,238)
Increase in other receivables	(930,350)	-	(930,350)
Decrease/(increase) in due to brokers	(49,154,946)	(45,327,866)	(3,827,080)
Interest in dividend payable	105,964	17,328	88,636
Decrease/(increase) in management fees payable	(6,119,439)	(5,954,269)	(165,170)
Decrease/(increase) in performance fees payable	(37,253,582)	(25,613,055)	(11,640,527)
Increase in administration fees payable	2,993,150	1,550,583	1,442,567
Decrease/(increase) in other payables and accrued expenses	487,486	519,550	(32,064)
<b>Net cash provided by operating activities</b>	<b>558,868,106</b>	<b>529,664,457</b>	<b>29,203,649</b>
<b>Cash flows from financing activities:</b>			
Net proceeds from subscriptions of redeemable participating shares	1,004,758,164	688,555,780	316,202,384
Net payments on redemptions of redeemable participating shares	(1,346,713,624)	(1,038,199,620)	(308,514,004)
<b>Net cash (used in)/ provided by financing activities</b>	<b>(341,955,460)</b>	<b>(349,643,840)</b>	<b>7,688,380</b>
<b>Net change in cash and cash equivalents</b>	<b>216,912,646</b>	<b>180,020,617</b>	<b>36,892,029</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>327,118,078</b>	<b>222,384,816</b>	<b>104,733,262</b>
<b>Net cash and cash equivalents at the end of the year</b>	<b>544,030,724</b>	<b>402,405,433</b>	<b>141,625,291</b>
<b>Net cash and cash equivalents comprised of:</b>			
Cash and cash equivalents	544,030,829	402,405,538	141,625,291
Bank overdraft	(105)	(105)	-
	<b>544,030,724</b>	<b>402,405,433</b>	<b>141,625,291</b>
<b>Supplemental disclosure of cash flow information:</b>			
	<b>Totals</b>	<b>Tiedemann</b>	<b>Sandler</b>
Interest received	17,978,812	8,026,687	9,952,125
Interest paid	(1,704,933)	(609,274)	(1,095,659)
Dividends received	23,736,868	19,825,897	3,910,971
Dividends paid	(12,316,319)	(3,785,954)	(8,530,365)

The Sub-Funds' abbreviated names as presented above are defined on page 2.

---

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2023

1. GENERAL INFORMATION

Amundi Alternative Funds PLC (the “Company”) was incorporated under the laws of Ireland, pursuant to the Companies Act 2014, on 7 December 2010 with registration number 492331. It was registered as an umbrella investment company with variable capital and segregated liability between sub-funds and is authorised by the Central Bank of Ireland (“Central Bank”) as an Undertaking for Collective Investment in Transferable Securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) (“UCITS”) Regulations, 2011 (as amended) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (UCITS) Regulations 2019 (the “Central Bank UCITS Regulations” or collectively the “UCITS Regulations”). The Directors may establish additional sub-funds, subject to the prior approval of the Central Bank.

As at 31 December 2023 and 31 December 2022, the Company has three active Sub-Funds:

<b>Sub-Fund</b>	<b>Launch date</b>
Amundi Tiedemann Arbitrage Strategy Fund	21 February 2013
Amundi Sandler US Equity Fund	2 November 2016

The Sub-Funds above are referred to as “Sub-Fund” or collectively “Sub-Funds” throughout these financial statements.

Amundi Asset Management S.A.S acts as the investment manager (the “Investment Manager”) of the Company.

The investment objectives of the Sub-Funds are set out below:

**Amundi Tiedemann Arbitrage Strategy Fund**

The investment objective of the Sub-Fund is to be exposed to the Amundi Tiedemann Arbitrage Strategy (the “Strategy”) during the life of the Sub-Fund. The Strategy is based on two components, being (i) a proprietary discretionary trading strategy which has been developed by the Sub-Investment Manager (the “Trading Strategy”) and (ii) an allocation of any excess cash to liquid assets pursuant to a process defined and implemented solely by the Investment Manager (the “Cash Allocation Process”).

The Trading Strategy shall consist, primarily, of global equity investments in announced merger and acquisition transactions, based on analysis of the probability that the transactions will be consummated. In limited cases and under specific circumstances, positions in securities of companies not yet currently involved in such transactions but the price of which is or can be affected by anticipated acquisition or restructuring may also be taken from time to time.

The Sub-Fund will seek to achieve its investment objective by providing Shareholders with a return obtained from exposing up to 100% of the Sub-Fund’s net assets to the performance of the Trading Strategy.

**Amundi Sandler US Equity Fund**

The investment objective of the Sub-Fund is to be exposed to the Amundi Sandler US Equity Strategy (the “Trading Strategy”) during the life of the Sub-Fund. The Trading Strategy is based on two components, being (i) a proprietary discretionary trading strategy which has been developed by the Sub-Investment Manager (the “Trading Strategy”) and (ii) an allocation of any excess cash to liquid assets pursuant to a process defined and implemented solely by the Investment Manager (the “Cash Portfolio”).

The Trading Strategy’s investment objective is to achieve capital appreciation across shifting economic and market environments, through both long and short positions in equities which are mainly but not exclusively listed on North American Recognised Markets.

The Sub-Fund will seek to achieve its investment objective by providing Shareholders with a return obtained from exposing up to 100% of the Sub-Fund’s net assets to the performance of the Trading Strategy.

All of the Sub-Funds may achieve their investment objectives by investing in financial derivative instruments (“FDI”), which may be complex and sophisticated in nature. The detailed investment strategies of the Sub-Funds are discussed in their respective Supplements. There can be no assurance that the Sub-Funds will achieve their investment objectives.

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**2. MATERIAL ACCOUNTING POLICIES**

**(a) Basis of preparation**

The financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union (“EU”) and IFRS Interpretations Committee (“IFRS IC”) interpretations as adopted by the EU and those parts of the Companies Act 2014 applicable to companies reporting under IFRS as adopted by the EU. These financial statements are also prepared in accordance with the UCITS Regulations.

The accounting policies set out below have been consistently applied in preparing these financial statements for the year ended 31 December 2023. The comparative information for the year ended 31 December 2022 has been prepared on a consistent basis. These financial statements have been prepared on a going concern basis. The Company has the resources to continue in business for the foreseeable future (refer to Note 10 Liquidity risk section and Note 21 Subsequent events).

**(b) Basis of aggregation**

The financial statements include the aggregated assets, liabilities, revenues and expenses of the Company and its Sub-Funds. The financial statements of the Company as a whole are presented in United States Dollars (“USD”) (Note 2(g)(i)).

**(c) Basis of measurement**

The financial statements have been prepared on a historical cost basis, except for financial assets and liabilities classified at fair value through profit or loss that have been measured at fair value.

**(d) Use of judgment and estimates**

The preparation of financial statements in conformity with IFRS as adopted by the EU requires the use of certain critical accounting judgment and estimates. It also requires the Board of Directors (the “Board”), based on the advice of the Investment Manager, to exercise its judgement and make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimates are revised and in future periods affected.

Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ from those estimates materially. Key estimate relates to the determination of fair values (Note 4).

---

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

2. MATERIAL ACCOUNTING POLICIES (continued)

(e) Standards, amendments and interpretations that are effective 1 January 2023 and have been adopted by the Company

*Disclosure of Accounting Policies – Amendments to IAS 1 and IFRS Practice Statement 2 (Effective 1 January 2023)*

The IASB amended IAS 1 to require entities to disclose their material rather than their significant accounting policies. The amendments define what is ‘material accounting policy information’ and explain how to identify when accounting policy information is material. They further clarify that immaterial accounting policy information does not need to be disclosed. If it is disclosed, it should not obscure material accounting information. To support this amendment, the IASB also amended IFRS Practice Statement 2 Making Materiality Judgements to provide guidance on how to apply the concept of materiality to accounting policy disclosures. The amendments did not have a material impact on the Sub-Fund’s financial statement.

*Definition of Accounting Estimates – Amendments to IAS 8 (Effective 1 January 2023)*

The amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors clarifies how companies should distinguish changes in accounting policies from changes in accounting estimates. The distinction is important, because changes in accounting estimates are applied prospectively to future transactions and other future events, but changes in accounting policies are generally applied retrospectively to past transactions and other past events as well as the current period. The amendments did not have a material impact on the Sub-Fund’s financial statement.

There are no new standards, interpretations or amendments to existing standards that are effective that is expected to have a significant impact on the Sub-Funds.

(f) Standards, amendments and interpretations in issue that are not yet effective and have not been early adopted by the Company

*Classification of Liabilities as Current or Non-current – Amendments to IAS 1 (Effective 1 January 2024)*

The narrow-scope amendments to IAS 1 Presentation of Financial Statements clarify that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the expectations of the entity or events after the reporting date (e.g. the receipt of a waiver or a breach of covenant). The amendments also clarify what IAS 1 means when it refers to the ‘settlement’ of a liability.

The amendments could affect the classification of liabilities, particularly for entities that previously considered management’s intentions to determine classification and for some liabilities that can be converted into equity.

They must be applied retrospectively in accordance with the normal requirements in IAS 8 *Accounting Policies, Changes in Accounting Estimates and Errors*.

<sup>w</sup>

The above amendment is not expected to have material impact on the Sub-Funds.

(g) Foreign currencies

(i) Functional and presentation currency

Items included in the Sub-Funds’ financial statements are measured using the currency of the primary economic environment in which they operate (the “functional currency”). If indicators of the primary economic environment are mixed, management uses its judgment to determine the functional currency that most faithfully represents the economic effect of the underlying transactions, events and conditions. The USD is the functional and presentation currency of the Sub-Funds and the Company.

The investment transactions are primarily denominated in the Sub-Funds’ functional currency. The expenses (including management fees, performance fees and administration fees) are denominated and paid mostly in the Sub-Funds’ functional currency.

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**  
**For the year ended 31 December 2023**

**2. MATERIAL ACCOUNTING POLICIES (continued)**

**(g) Foreign currencies (continued)**

*(ii) Foreign currency transactions*

Monetary assets and liabilities denominated in currencies other than the Sub-Funds' functional currencies are translated into their functional currencies at the closing rates of exchange at each year end. Transactions during the period, including purchases and sales of securities, income and expenses, are translated at the rate of exchange prevailing on the date of the transaction. Foreign currency translation gains and losses on investments are included in net gain/(loss) on financial assets and liabilities at fair value through profit or loss in the Statement of Comprehensive Income. Other foreign exchange differences on cash and cash equivalents, if any, are included within net gain/(loss) on foreign exchange in the Statement of Comprehensive Income.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated in the Sub-Funds' functional currencies using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined.

**(h) Financial instruments**

*(i) Classification*

In accordance with IFRS 9, Financial Instruments, ("IFRS 9") the Company classifies its financial assets and financial liabilities at initial recognition into the categories of financial assets and financial liabilities discussed below.

*Financial assets*

The Company classifies its financial assets as subsequently measured at fair value through profit or loss ("FVTPL") or measured at amortised cost on the basis of both:

- (a) The Company's business model for managing the financial assets
- (b) The contractual cash flow characteristics of the financial asset

*Financial assets measured at FVTPL*

A financial asset is measured at FVTPL if any of the following is met:

- (a) Its contractual terms do not give rise to cash flows on specified dates that are solely payments of principal and interest (SPPI) on the principal amount outstanding
- (b) It is not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell
- (c) At initial recognition, it is irrevocably designated as measured at FVTPL when doing so eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases.

The Company includes in this category equity securities and debt securities which are acquired principally for the purpose of generating a profit from short-term fluctuations in price. Debt securities include investments that are held under a business model to manage them on a fair value basis for investment income and fair value gains. The collection of contractual cash flows from debt securities is only incidental to achieving the Company's business model's objective. This category also includes derivative contracts in an asset position. The equity securities, debt securities and derivative contracts are held for trading and therefore classified mandatorily at FVTPL.

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**2. MATERIAL ACCOUNTING POLICIES (continued)**

**(h) Financial instruments (continued)**

*(i) Classification (continued)*

Financial assets (continued)

*Financial assets measured at amortised cost*

A financial asset is measured at amortised cost if it is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

The Company includes in this category cash and cash equivalents, due from brokers and other short-term receivables. Their carrying value, measured at amortised cost less any expected loss, is an approximation of fair value given their short-term nature.

Financial liabilities

*Financial liabilities measured at FVTPL*

A financial liability is measured at FVTPL if it meets the definition of held for trading. The Company includes in this category, equity securities and debt securities sold short, if any, and derivative contracts in a liability position as they are classified as held for trading. The Company also includes its redeemable participating shares in this category. The Company's accounting policy regarding the redeemable participating shares is described in Note 2(m).

*Financial liabilities measured at amortised cost*

This category includes all financial liabilities other than those measured at fair value through profit or loss. The Company includes in this category bank overdraft, due to brokers and other short-term payables. Their carrying value, measured at amortised cost, is an approximation of fair value given their short-term nature.

*(ii) Recognition and initial measurement*

Financial assets and liabilities at fair value through profit and loss are recognised initially on the trade date at which the Company becomes a party to contracted provisions of the instruments. Other financial assets and liabilities are recognised on the date they originated.

Financial assets and liabilities at fair value through profit or loss are measured initially at fair value, with transaction costs recognised in the profit and loss. Financial assets or financial liabilities not at fair value through profit and loss are measured initially at fair value plus transaction costs that are directly attributable to its acquisition or issue.

*(iii) Subsequent measurement*

After initial measurement, the Company measures financial instruments which are classified as at fair value through profit or loss at fair value (Note 4).

Subsequent changes in the fair value of those financial instruments are recorded in net gain or loss on financial assets and liabilities at FVTPL in the Statement of Comprehensive Income. Dividend and interest on financial assets and liabilities at FVTPL are presented separately in the Statement of Comprehensive Income.

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**2. MATERIAL ACCOUNTING POLICIES (continued)**

**(h) Financial instruments (continued)**

*(iv) Derecognition*

A financial asset is derecognised when the Company no longer has control over the contractual rights that comprise that asset. This occurs when the contractual rights to the cash flow from the asset expire or when it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset. A financial liability is derecognised when it is extinguished or when the obligation specified in the contract is discharged, cancelled or expired.

*(v) Impairment of financial assets measured at amortised cost*

The Company holds financial assets at amortised cost, with no financing component and which have maturities of less than 12 months and as such, has chosen to apply the simplified approach for expected credit losses (ECLs) under IFRS 9 to all its financial assets at amortised cost. Therefore, the Company does not track changes in credit risk, but instead, recognises a loss allowance based on lifetime ECLs at each reporting date.

The Company's approach to ECLs reflects a probability-weighted outcome, the time value of money and reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future economic conditions. The Company assesses the ECLs of groups of financial assets based on days past due and similar loss patterns. Any historical observed loss rates are adjusted for forward-looking estimates and applied over the expected life of the financial assets (Refer to Note 10, Credit risk section).

**(i) Cash and cash equivalents/Bank overdrafts**

Cash comprises cash deposits on demand. Cash equivalents are short term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to insignificant changes in value, and are held for the purpose of meeting short-term cash commitments rather than for investments or other purposes, with original maturities of three months or less. Bank overdrafts are shown as liabilities in the Statement of Financial Position.

**(j) Due from/to brokers**

Due from brokers include margin accounts and receivables for securities sold (in a regular way transaction) that have been contracted for but not yet delivered on the Statement of Financial Position date. Margin accounts represent cash deposits held with brokers as collateral against open derivative contracts.

Due to brokers include margin accounts and payables for securities purchased (in a regular way transaction) that have been contracted for but not yet settled on the Statement of Financial Position date. Margin accounts represent cash from brokers for derivative contracts.

These amounts are recognised initially at fair value and subsequently measured at amortised cost less impairment for amounts due from brokers account, if any, at year end.

**(k) Subscriptions receivable and redemptions payable**

Subscriptions receivable represents subscriptions where shares have been issued but cash has yet been received from the investor. Redemptions payable represents redemptions where shares have been redeemed but cash has yet been paid to investor. Subscriptions receivable and redemptions payable are presented in the Statement of Financial Position.

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**2. MATERIAL ACCOUNTING POLICIES (continued)**

**(l) Net asset value per redeemable participating share**

The net asset value (“NAV”) per share disclosed on the Statement of Financial Position is calculated, in accordance with IFRS as adopted by the EU and Company’s Prospectus and Supplements, by dividing the net assets attributable to each share class by the number of redeemable participating shares outstanding at year end. Subscriber shares do not have a residual interest in the net assets of the Company and therefore do not affect the calculation of the NAV per redeemable participating share of the Sub-Funds.

**(m) Redeemable participating shares**

Redeemable participating shares are redeemable at the shareholder’s option and are classified as financial liabilities in accordance with IAS 32, Financial Instruments: Presentation. Redeemable participating shares are issued and redeemed at prices based on the Sub-Funds’ NAV per redeemable participating share at the time of issue or redemption.

Redeemable participating shares are redeemable daily for all the Sub-Funds.

**(n) Distribution to shareholders**

Dividend distribution to the shareholders is recognised as a liability in the financial statements in the year in which the dividends are declared.

It is not intended to declare any dividends in respect of any issued share classes of the Sub-Funds.

**(o) Realised and unrealised gains and losses**

All realised and unrealised gains and losses from fair value changes and foreign exchange differences on investments are recognised on a first-in-first-out basis and included within net gain/(loss) on financial assets and liabilities at fair value through profit or loss in the Statement of Comprehensive Income.

**(p) Interest income and expense, and interest on financial assets and liabilities at fair value through profit or loss**

Interest is recognised on a time-proportionate basis using the effective interest method.

Interest income and expense include interest from cash and cash equivalents. Interest on financial assets and liabilities at fair value through profit or loss includes interest from debt securities and derivatives.

**(q) Dividend income and expense**

Dividend income is recognised when the right to receive payment is established and presented in the Statement of Comprehensive Income on the dates on which the relevant securities are listed as “ex-dividend”. Dividend income is shown gross of any withholding taxes, which are disclosed separately in the Statement of Comprehensive Income.

Dividend expense on equity derivatives is disclosed separately in the Statement of Comprehensive Income.

**(r) Transaction costs**

Transaction costs are costs incurred to acquire financial assets and liabilities at fair value through profit or loss. These include broker charges and commission. Transaction costs, when incurred, are immediately recognised in profit or loss as an expense.

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**2. MATERIAL ACCOUNTING POLICIES (continued)**

**(s) Offsetting financial instruments**

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

**(t) Taxation**

Under current law and practice, the Company qualifies as an investment undertaking as defined in Section 739B of the Taxes Consolidation Act 1997, as amended. On that basis, it is not chargeable to Irish tax on its income or gains.

However, Irish tax may arise on the happening of a “chargeable event”. A chargeable event includes any distribution payments to shareholder or any encashment, redemption, cancellation or transfer of shares and the holding of shares at the end of each eight-year period beginning with the acquisition of such shares.

No Irish tax will arise on the Company in respect of chargeable events in respect of:

- A shareholder who is neither Irish resident and not ordinarily resident in Ireland for tax purposes, at the time of the chargeable event, provided appropriate valid declarations in accordance with the provisions of the Taxes Consolidation Act 1997, as amended, are held by the Company; or the Company has been authorised by the Irish Revenue to make gross payments in the absence of appropriate declarations and;
- Certain exempted Irish tax resident shareholders who have provided the Company with the necessary signed statutory declarations.

Dividends, interest and capital gains (if any) received on investments made by the Company may be subject to taxes imposed by the country from which the investment income/gains are received and such taxes may not be recoverable by the Company or its shareholders.

**(u) CFD Financing expenses/income**

This is a financing cost/income on Contract for Differences (CFD) exposure and is charged/paid by the broker. CFD positions that remain open overnight are subject to these charges.

## NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

## 3. FINANCIAL ASSETS AND LIABILITIES

The following tables detail the types of financial assets and liabilities held by the Company, through the Sub-Funds, as at year end:

31 December 2023

	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>Financial assets at fair value through profit or loss:</b>			
<i>Investment in securities</i>			
Debt securities <sup>(1)</sup>	950,251,481	700,464,604	249,786,877
Equity securities	675,470,982	312,702,746	362,768,236
Total investment in securities	<b>1,625,722,463</b>	<b>1,013,167,350</b>	<b>612,555,113</b>
<i>Financial derivative instruments</i>			
Contract for differences	7,217,410	3,625,986	3,591,424
Listed options	13,939,045	4,410,083	9,528,962
Warrants	488,920	488,920	-
Foreign currency forwards	26,329,329	17,330,667	8,998,662
Total financial derivative instruments	<b>47,974,704</b>	<b>25,855,656</b>	<b>22,119,048</b>
<b>Total held for trading</b>	<b>1,673,697,167</b>	<b>1,039,023,006</b>	<b>634,674,161</b>
<b>Financial liabilities at fair value through profit or loss:</b>			
<i>Financial derivative instruments</i>			
Contract for differences	12,490,827	3,623,961	8,866,866
Listed options	1,783,326	1,560,370	222,956
Futures contracts	739,665	-	739,665
Foreign currency forwards	1,064,999	869,273	195,726
Total financial derivative instruments	16,078,817	6,053,604	10,025,213
<b>Total held for trading</b>	<b>16,078,817</b>	<b>6,053,604</b>	<b>10,025,213</b>

<sup>(1)</sup>Debt securities include US Treasury-bills that were pledged as collateral (refer to Note 9).

**NOTES TO THE FINANCIAL STATEMENTS (continued)**  
**For the year ended 31 December 2023**

**3. FINANCIAL ASSETS AND LIABILITIES (continued)**

**31 December 2022**

	<b>COMPANY TOTAL USD</b>	<b>TIEDEMANN USD</b>	<b>SANDLER USD</b>
<b>Financial assets at fair value through profit or loss:</b>			
<i>Investment in securities</i>			
Debt securities <sup>(1)</sup>	992,303,242	491,502,305	500,800,937
Equity securities	1,051,194,219	699,944,896	351,249,323
Total investment in securities	<u>2,043,497,461</u>	<u>1,191,447,201</u>	<u>852,050,260</u>
<i>Financial derivative instruments</i>			
Contract for differences	67,603,796	6,216,064	61,387,732
Listed options	35,151,139	1,316,001	33,835,138
Warrants	488,920	488,920	-
Foreign currency forwards	152,196,563	97,891,802	54,304,761
Total financial derivative instruments	<u>255,440,418</u>	<u>105,912,787</u>	<u>149,527,631</u>
<b>Total held for trading</b>	<b><u>2,298,937,879</u></b>	<b><u>1,297,359,988</u></b>	<b><u>1,001,577,891</u></b>
<b>Financial liabilities at fair value through profit or loss:</b>			
<i>Financial derivative instruments</i>			
Contract for differences	14,101,131	3,849,048	10,252,083
Listed options	15,653	15,653	-
Futures contracts	56,915	-	56,915
Foreign currency forwards	3,657,630	2,442,358	1,215,272
Total financial derivative instruments	<u>17,831,329</u>	<u>6,307,059</u>	<u>11,524,270</u>
<b>Total held for trading</b>	<b><u>17,831,329</u></b>	<b><u>6,307,059</u></b>	<b><u>11,524,270</u></b>

<sup>(1)</sup>Debt securities include US Treasury-bills that were pledged as collateral (refer to Note 9).

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**4. FAIR VALUE ESTIMATION**

The Company adopted a hierarchical disclosure framework which prioritises and ranks the level of market price observability used in measuring investments at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Investments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

The fair value hierarchy has the following levels as defined by IFRS 13, Fair Value Measurement:

**Level 1 - Quoted market price**

Quoted prices are available in active markets for identical investments from market sources as of the reporting date. When fair values of listed equity and debt securities as well as publicly traded derivatives at 31 December 2023 and 31 December 2022 are based on quoted market prices or binding dealer price quotations, without any deduction for transaction costs, the instruments are included in Level 1 of the hierarchy.

**Level 2 - Valuation technique using observable inputs**

Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is derived from prices).

**Level 3 - Valuation technique with significant unobservable inputs**

Pricing inputs are unobservable for the investment and includes situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant judgment or estimation.

For all other financial instruments, fair value is determined using valuation techniques including the models developed internally by the independent Administrator and broker quotes. In instances where the Administrator, in the opinion of the Sub-Funds' portfolio manager, has been unable to obtain a fair value price, the Investment Manager determines the fair value of such financial instruments.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the investment. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities.

The Company invests in debt securities for which transactions may not occur on a regular basis. Investments in the debt securities are valued based on quoted market prices or binding dealer price quotations without any deduction for transaction costs.

Transfers between different levels of the fair value hierarchy are deemed to have occurred as of the beginning of the reporting period.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 4. FAIR VALUE ESTIMATION (continued)

The following tables analyse within the fair value hierarchy the Sub-Funds' financial assets and liabilities measured at fair value as at year end:

##### Amundi Tiedemann Arbitrage Strategy Fund

31 December 2023	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
<b>Financial assets at fair value through profit or loss:</b>				
<i>Investment in securities</i>				
Debt securities	700,464,604	-	-	700,464,604
Equity securities	301,674,698	-	11,028,048	312,702,746
<i>Financial derivative instruments</i>				
Contract for differences	3,625,986	-	-	3,625,986
Listed options	4,410,083	-	-	4,410,083
Foreign currency forwards	-	17,330,667	-	17,330,667
Warrants	-	-	488,920	488,920
<b>Total financial assets at fair value through profit or loss</b>	<b>1,010,175,371</b>	<b>17,330,667</b>	<b>11,516,968</b>	<b>1,039,023,006</b>
<b>Financial liabilities at fair value through profit or loss:</b>				
<i>Financial derivative instruments</i>				
Listed options	1,560,370	-	-	1,560,370
Contract for differences	3,623,961	-	-	3,623,961
Foreign currency forwards	-	869,273	-	869,273
<b>Total financial liabilities at fair value through profit or loss</b>	<b>5,184,331</b>	<b>869,273</b>	<b>-</b>	<b>6,053,604</b>
31 December 2022	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
<b>Financial assets at fair value through profit or loss:</b>				
<i>Investment in securities</i>				
Debt securities	491,502,305	-	-	491,502,305
Equity securities	694,296,611	-	5,648,285	699,944,896
<i>Financial derivative instruments</i>				
Contract for differences	6,216,064	-	-	6,216,064
Listed options	1,316,001	-	-	1,316,001
Foreign currency forwards	-	97,891,802	-	97,891,802
Warrants	-	-	488,920	488,920
<b>Total financial assets at fair value through profit or loss</b>	<b>1,193,330,981</b>	<b>97,891,802</b>	<b>6,137,205</b>	<b>1,297,359,988</b>
<b>Financial liabilities at fair value through profit or loss:</b>				
<i>Financial derivative instruments</i>				
Listed options	15,653	-	-	15,653
Contract for differences	3,849,048	-	-	3,849,048
Foreign currency forwards	-	2,442,358	-	2,442,358
<b>Total financial liabilities at fair value through profit or loss</b>	<b>3,864,701</b>	<b>2,442,358</b>	<b>-</b>	<b>6,307,059</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 4. FAIR VALUE ESTIMATION (continued)

The following tables analyse within the fair value hierarchy the Sub-Funds' financial assets and liabilities measured at fair value as at year end: (continued)

##### Amundi Sandler US Equity Fund

31 December 2023	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
<b>Financial assets at fair value through profit or loss:</b>				
<i>Investment in securities</i>				
Debt securities	249,786,877	-	-	249,786,877
Equity securities	362,768,236	-	-	362,768,236
<i>Financial derivative instruments</i>				
Listed options	9,528,962	-	-	9,528,962
Contract for differences	3,591,424	-	-	3,591,424
Foreign currency forwards	-	8,998,662	-	8,998,662
<b>Total financial assets at fair value through profit or loss</b>	<b>625,675,499</b>	<b>8,998,662</b>	<b>-</b>	<b>634,674,161</b>
<b>Financial liabilities at fair value through profit or loss:</b>				
<i>Financial derivative instruments</i>				
Futures contracts	739,665	-	-	739,665
Listed options	222,956	-	-	222,956
Contract for differences	8,866,866	-	-	8,866,866
Foreign currency forwards	-	195,726	-	195,726
<b>Total financial liabilities at fair value through profit or loss</b>	<b>9,829,487</b>	<b>195,726</b>	<b>-</b>	<b>10,025,213</b>
<b>31 December 2022</b>				
	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
<b>Financial assets at fair value through profit or loss:</b>				
<i>Investment in securities</i>				
Debt securities	500,800,937	-	-	500,800,937
Equity securities	351,249,323	-	-	351,249,323
<i>Financial derivative instruments</i>				
Listed equity options	33,835,138	-	-	33,835,138
Contract for differences	61,387,732	-	-	61,387,732
Foreign currency forwards	-	54,304,761	-	54,304,761
<b>Total financial assets at fair value through profit or loss</b>	<b>947,273,130</b>	<b>54,304,761</b>	<b>-</b>	<b>1,001,577,891</b>
<b>Financial liabilities at fair value through profit or loss:</b>				
<i>Financial derivative instruments</i>				
Futures contracts	56,915	-	-	56,915
Contract for differences	10,252,083	-	-	10,252,083
Foreign currency forwards	-	1,215,272	-	1,215,272
<b>Total financial liabilities at fair value through profit or loss</b>	<b>10,308,998</b>	<b>1,215,272</b>	<b>-</b>	<b>11,524,270</b>

## NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

## 4. FAIR VALUE ESTIMATION (continued)

The following tables present the movement in the Level 3 financial instruments for the year ended 31 December 2023 by class of financial instruments:

## Amundi Tiedemann Arbitrage Strategy Fund

31 December 2023	Equity securities USD	Contract for differences USD	Warrants USD	Total USD
<b>Financial assets</b>				
<b>Fair value as of 1 January</b>	5,648,285	-	488,920	6,137,205
Purchases	-	-	-	-
Sales	-	-	-	-
Transfers into Level 3	743,676	-	-	743,676
Realised gain	-	-	-	-
Change in unrealised gain	4,636,087	-	-	4,636,087
<b>Fair value as of 31 December</b>	<b>11,028,048</b>	<b>-</b>	<b>488,920</b>	<b>11,516,968</b>
<b>Unrealised gain on Level 3 financial instruments as of 31 December</b>	<b>4,636,087</b>	<b>-</b>	<b>-</b>	<b>4,636,087</b>
<b>31 December 2022</b>				
	Equity securities USD	Contract for differences USD	Warrants USD	Total USD
<b>Financial assets</b>				
<b>Fair value as of 1 January</b>	5,073,556	-	377,641	5,451,197
Purchases	94,097	-	-	94,097
Sales	(1,531,054)	-	-	(1,531,054)
Realised gain	1,531,054	-	-	1,531,054
Change in unrealised gain	480,632	-	111,279	591,911
<b>Fair value as of 31 December</b>	<b>5,648,285</b>	<b>-</b>	<b>488,920</b>	<b>6,137,205</b>
<b>Unrealised gain on Level 3 financial instruments as of 31 December</b>	<b>1,782,027</b>	<b>-</b>	<b>111,279</b>	<b>1,893,306</b>
<b>Financial liabilities</b>				
<b>Fair value as of 1 January</b>	-	8,631	-	8,631
Purchases	-	-	-	-
Sales	-	(58,694)	-	(58,694)
Realised gain	-	58,694	-	58,694
Change in unrealised gain	-	(8,631)	-	(8,631)
<b>Fair value as of 31 December</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Unrealised gain on Level 3 financial instruments as of 31 December</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

For the year ended 31 December 2023

**4. FAIR VALUE ESTIMATION (continued)****Amundi Tiedemann Arbitrage Strategy Fund****Sensitivity Analysis**

A sensitivity analysis on the value of the Level 3 investments as at 31 December 2023 and 31 December 2022 is as follows:

**31 December 2023**

<b>Assets Type</b>	<b>Fair Value at 31 December 2023</b>	<b>Valuation Technique</b>	<b>Unobservable Inputs</b>	<b>Ranges of Prices</b>	<b>Range of Impact for Unobservable Element on NAV</b>
	<b>USD</b>				
Equity securities	11,028,048	Broker Price	Expected realization proceeds	50%	5,514,024
Warrants	488,920	Broker Price	Expected realization proceeds	50%	244,460
<b>Total</b>	<b>11,516,968</b>				<b>5,758,484</b>

**31 December 2022**

<b>Assets Type</b>	<b>Fair Value at 31 December 2022</b>	<b>Valuation Technique</b>	<b>Unobservable Inputs</b>	<b>Ranges of Prices</b>	<b>Range of Impact for Unobservable Element on NAV</b>
	<b>USD</b>				
Equity securities	5,648,285	Broker Price	Expected realization proceeds	50%	2,824,143
Warrants	488,920	Broker Price	Expected realization proceeds	50%	244,460
<b>Total</b>	<b>6,137,205</b>				<b>3,068,603</b>

## NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

## 5. GAINS AND LOSSES ON FINANCIAL ASSETS AND LIABILITIES

The following tables detail the gains and losses on financial assets and liabilities during the year:

31 December 2023	COMPANY		
	TOTAL USD	TIEDEMANN USD	SANDLER USD
Net realised gain/(loss) on investments in securities	182,907,541	107,261,931	75,645,610
Net change in unrealised gain on investments in securities	49,743,770	18,937,144	30,806,626
Net realised loss on financial derivative instruments	(10,897,531)	(6,067,616)	(4,829,915)
Net change in unrealised loss on financial derivative instruments	(81,143,143)	(2,862,663)	(78,280,480)
Net realised gain on forward currency contracts*	167,716,106	101,786,593	65,929,513
Net change in unrealised loss on forward currency contracts*	(123,278,458)	(78,991,888)	(44,286,570)
<b>Net gain/(loss) on financial assets and liabilities at fair value through profit or loss</b>	<b>185,048,285</b>	<b>140,063,501</b>	<b>44,984,784</b>
Net realised gain on foreign exchange	1,958,014	1,590,083	367,931
Net change in unrealised gain on foreign exchange	149,839	78,244	71,595
<b>Net gain on foreign exchange</b>	<b>2,107,853</b>	<b>1,668,327</b>	<b>439,526</b>

\*The above gains and losses on forward currency contracts include those related to foreign exchange contracts placed for share class hedging purposes.

31 December 2022	COMPANY		
	TOTAL USD	TIEDEMANN USD	SANDLER USD
Net realised loss on investments in securities	(171,921,967)	(122,877,069)	(49,044,898)
Net change in unrealised gain/(loss) on investments in securities	(55,778,292)	7,867,004	(63,645,296)
Net realised gain on financial derivative instruments	167,530,133	94,959,456	72,570,677
Net change in unrealised gain/(loss) on financial derivative instruments	61,296,524	32,586,225	28,710,299
Net realized loss on forward currency contracts*	(375,764,478)	(241,189,218)	(134,575,260)
Net change in unrealised gain on forward currency contracts*	113,181,044	75,582,903	37,598,141
<b>Net (loss)/gain on financial assets and liabilities at fair value through profit or loss</b>	<b>(261,457,036)</b>	<b>(153,070,699)</b>	<b>(108,386,337)</b>
Net realised (loss)/gain on foreign exchange	(828,325)	(3,843)	(824,482)
Net change in unrealised (loss)/gain on foreign exchange	(1,482,220)	(1,178,232)	(303,988)
<b>Net (loss)/gain on foreign exchange</b>	<b>(2,310,545)</b>	<b>(1,182,075)</b>	<b>(1,128,470)</b>

\*The above gains and losses on forward currency contracts include those related to foreign exchange contracts placed for share class hedging purposes.

## NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

## 6. FEES AND EXPENSES PAYABLE

The following table details the fees and expenses payable as at year end:

31 December 2023	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
Management fees payable	13,272,280	9,314,241	3,958,039
Performance fees payable	23,011,168	20,960,382	2,050,786
Administration fees payable	2,481,859	1,507,607	974,252
Other payables and accrued expenses	297,268	167,775	129,493
<b>Total</b>	<b>39,062,575</b>	<b>31,950,005</b>	<b>7,112,570</b>

31 December 2022	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
Management fees payable	5,817,267	2,420,807	3,396,460
Performance fees payable	1,346,566	1,346,362	204
Administration fees payable	4,429,858	2,812,891	1,616,967
Other payables and accrued expenses	868,737	626,127	242,610
<b>Total</b>	<b>12,462,428</b>	<b>7,206,187</b>	<b>5,256,241</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 6. FEES AND EXPENSES PAYABLE (continued)

##### Management fees

The Sub-Funds of the Company are subject to a management fee which will be paid to Amundi Asset Management S.A.S. (the “Manager”). The management fee shall accrue daily and be payable upon instruction by the Company. The Manager will pay Amundi Asset Management S.A.S. (the “Investment Manager”) and any Sub-Investment Manager out of the management fee for the respective period as mentioned above.

The maximum management fee rates of each share class of the Sub-Funds are presented below:

Share class	% Per annum	
	TIEDEMANN	SANDLER
Hedged Class A (CHF)	1.25%	-
Hedged Class A (EUR)	1.25%	2.15%
Hedged Class A (GBP)	1.25%	-
Class A (USD)	1.25%	2.15%
Class AA (USD)	1.40%	2.30%
Hedged Class C (EUR)	1.25%	2.15%
Class C (USD)	1.25%	2.15%
Hedged Class EB (EUR)	0.10%	1.00%
Hedged Class EB (GBP)	-	1.00%
Class EB (USD)	0.10%	-
Hedged Class I (GBP)	0.50%	1.40%
Hedged Class I (JPY)	0.50%	1.40%
Hedged Class I (NOK)	0.50%	-
Class I (USD)	0.50%	1.40%
Hedged Class I (CHF)	0.50%	-
Hedged Class I (EUR)	0.50%	1.40%
Class IA (USD)	0.65%	1.80%
Hedged Class O (GBP)	-	2.15%
Hedged Class O (EUR)	1.25%	2.15%
Class O (USD)	1.25%	2.15%
Hedged Class SI (EUR)	0.15%	1.20%
Hedged Class SI (GBP)	0.15%	1.20%
Class SI (USD)	0.15%	1.20%
Hedged Class SI2 (GBP)	-	1.20%
Hedged Class I (SGD)	-	1.40%
Hedged Class ID (GBP)	0.50%	-

##### Amundi Tiedemann Arbitrage Strategy Fund

In addition, a class investment advisory fee of up to 1% per annum of the NAV of each Class of the Sub-Fund will be paid in USD out of the relevant Class. Total management fees accrued during the year amounted to USD 18,881,634 (31 December 2022: USD 26,671,367) of which USD 9,314,241 (31 December 2022: USD 2,420,807) was payable at the year end.

##### Amundi Sandler US Equity Fund

Total management fees accrued during the year amounted to USD 11,357,165 (31 December 2022: USD 13,570,219) of which USD 3,958,039 (31 December 2022: USD 3,396,460) was payable at the year end.

---

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

6. FEES AND EXPENSES PAYABLE (continued)

**Administration fees**

SS&C Financial Services (Ireland) Limited was appointed as the administrator (the “Administrator”) to the Company. For services rendered, the Administrator is entitled to receive out of the net assets of the Sub-Funds an annual fee, accrued daily and paid upon instruction by the Company.

CACEIS Ireland Limited acts as the registrar and transfer agent (the “Registrar and Transfer Agent”) to the Company and is entitled to a fee in respect of the services.

CACEIS Bank, Ireland Branch acts as depositary (the “Depositary”) to the Company. For services rendered, the Depositary is entitled to receive out of the net assets of the Sub-Funds an annual fee, accrued daily and paid upon instruction by the Company.

Amundi Tiedemann Arbitrage Strategy Fund

The Sub-Fund is subject to administration fee at a rate of up to 0.25% (effective until 2 July 2023) and 0.20% (effective from 3 July 2023) of the NAV of each Class of the Sub-Fund per annum, out of which will be paid the fees and expenses of the Depositary, the Administrator and Registrar and Transfer Agent.

Administration fee charged for the year amounted to USD 2,682,730 (31 December 2022: USD 3,449,138), of which USD 1,507,607 (31 December 2022: USD 2,821,891) was payable at the year end.

Amundi Sandler US Equity Fund

The Sub-Fund is subject to administration fee at a rate of up to 0.25% (effective until 2 July 2023) and 0.185% (effective from 3 July 2023) of the NAV of each Class of the Sub-Fund per annum, out of which will be paid the fees and expenses of the Depositary, the Administrator and Registrar and Transfer Agent.

Administration fee charged for the year amounted to USD 1,736,409 (31 December 2022: USD 1,945,150), of which USD 974,252 (31 December 2022: USD 1,616,967) was payable at the year end.

---

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

6. FEES AND EXPENSES PAYABLE (continued)

Performance fees

Amundi Tiedemann Arbitrage Strategy Fund

The Investment Manager receives from the Sub-Fund a performance fee of up to 20% per annum; calculated by multiplying the net realised and unrealised appreciation of the NAV of the relevant Class over the relevant high water- mark. The fee is calculated and payable in USD at the end of each year, at the last valuation day of December, the fee period.

Each class performance fee is subject to a high water mark mechanism whereby the class performance fee shall apply only when the gross NAV of the relevant Class exceeds the highest gross NAV ever reached by the so-said Class (by reference to the end of each fee period and adjusted by the effects of subscriptions and redemptions). For the initial fee period, the initial offer price of the relevant Class will be the starting point for the high water mark.

Performance fees charged for the year amounted to USD 20,904,320 (31 December 2022: USD 1,346,652) of which USD 20,960,382 (31 December 2022: USD 1,346,362) was payable at the year end.

Amundi Sandler US Equity Fund

The Investment Manager receives from the Sub-Fund a performance fee of up to 20% per annum; calculated by multiplying the net realised and unrealised appreciation of the NAV of the relevant Class over the relevant high water-mark. The fee is calculated and payable in USD at the end of each year, at the last valuation day of December, the fee period.

Each class performance fee is subject to a high water mark mechanism whereby the class performance fee shall apply only when the gross NAV of the relevant Class exceeds the highest gross NAV ever reached by the so-said Class (by reference to the end of each fee period and adjusted by the effects of subscriptions and redemptions). For the initial fee period, the initial offer price of the relevant Class will be the starting point for the high water mark

Performance fees charged for the year amounted to USD 2,038,416 (31 December 2022: USD 373) of which USD 2,050,786 (31 December 2022: USD 204) was payable at the year end.

The performance fee is payable to the Manager who shall be responsible for discharging from this fee the remuneration due to the Sub-Investment Managers of the Sub-Funds. The calculation of the performance fees for the Sub-Funds is verified by the Depositary.

**NOTES TO THE FINANCIAL STATEMENTS (continued)****For the year ended 31 December 2023****6. FEES AND EXPENSES PAYABLE (continued)****Directors' fees**

The Directors shall be entitled to a fee as remuneration for their services at a rate to be determined from time to time by the Directors, provided that the amount of remuneration payable to the Directors in any one year in respect of the Company shall not exceed EUR 15,000 per Sub-Fund per Director or such other amount as the Directors may from time to time determine and disclose to the shareholders in the latest annual or semi-annual report. The Directors, and any alternate Directors, shall also be entitled to be paid all travelling, hotel and other expenses properly incurred by them in attending Directors or shareholders' meetings or any other meetings in connection with the business of the Company. None of the Directors have entered into a service contract with the Company nor is any such contract proposed and none of the Directors is an executive of the Company. The Directors' fees are recognised and incurred by the Manager.

During the year, the Directors received directors' fees of EUR 29,000 (2022: EUR 29,000). The Directors, Moez Bousarsar, Colm Callally, Declan Murray, John O'Toole (resigned on 21 November 2023) and Paul Weber (resigned on 21 November 2023) are employees of the Manager (Note 11). They did not receive any Directors' fees.

**Auditor's remuneration**

Fees paid to statutory auditors, PricewaterhouseCoopers, in respect of the financial year are as follows:

	<b>31 December 2023</b>	<b>31 December 2022</b>
	<b>USD</b>	<b>USD</b>
Statutory audit of financial statements	39,309	47,131
Tax advisory services	-	-
<b>Total</b>	<b>39,309</b>	<b>47,131</b>

The fees in the above table are calculated exclusive of VAT. The fees are recognised and paid by the Manager.

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

7. DUE FROM AND TO BROKERS

The following table details the amounts due from and to brokers as at year end:

31 December 2023	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>Due from brokers</b>			
Receivable for securities sold but not yet settled	28,964,846	25,605,640	3,359,206
Margin cash	53,358,503	37,370,307	15,988,196
Cash collateral pledged	19,055,000	17,105,000	1,950,000
<b>Total</b>	<b>101,378,349</b>	<b>80,080,947</b>	<b>21,297,402</b>
<b>Due to brokers</b>			
Payables for securities purchased but not yet settled	24,514,718	22,909,160	1,605,558
<b>Total</b>	<b>24,514,718</b>	<b>22,909,160</b>	<b>1,605,558</b>

31 December 2022	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<b>Due from brokers</b>			
Receivable for securities sold but not yet settled	56,420,285	51,262,300	5,157,985
Margin cash	50,924,387	29,165,259	21,759,128
Cash collateral pledged	13,736,000	13,736,000	-
<b>Total</b>	<b>121,080,672</b>	<b>94,163,559</b>	<b>26,917,113</b>
<b>Due to brokers</b>			
Payables for securities purchased but not yet settled	21,687,682	21,640,341	47,341
Margin cash/(overdraft)	625,059	-	625,059
<b>Total</b>	<b>22,312,741</b>	<b>21,640,341</b>	<b>672,400</b>

8. SHARE CAPITAL

The authorised share capital of the Company is 500,000,000,002 shares of no par value divided into 2 subscriber shares of no par value and 500,000,000,000 shares of no par value.

The subscriber shares entitle the holders to attend and vote at general meetings of the Company but do not entitle the holders to participate in the profits or assets of the Company except for a return of capital on a winding-up. The subscriber shares are held with Amundi Asset Management (Ireland) Limited and Amundi Asset Management S.A.S.

The redeemable participating shares entitle the holders to attend and vote at general meetings of the Company and to participate equally in the profits and assets of the Sub-Fund to which the shares relate.

The Company's objective is managing the redeemable participating share capital to ensure a stable and strong base to maximise returns to all investors, and to manage liquidity risk arising from redemptions. The Company is a UCITS company and the minimum capital requirement is met by taking into account the participating and non-participating shares.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 8. SHARE CAPITAL (continued)

The movements in redeemable participating shares in the Company during the year ended 31 December 2023 are as follows:

	At 1 January 2023	Shares Issued	Shares Redeemed	At 31 December 2023
<b>Amundi Tiedemann Arbitrage Strategy Fund</b>				
Hedged Class A (CHF)	4,527	185	(3,407)	1,305
Hedged Class A (EUR)	888,371	183,381	(685,042)	386,710
Hedged Class A (GBP)	2,796	189	(860)	2,125
Class A (USD)	100,430	14,982	(30,525)	84,887
Hedged Class EB (EUR)	9,775	-	(4,587)	5,188
Hedged Class I (CHF)	72,469	5,164	(39,658)	37,974
Hedged Class I (EUR)	4,102,132	208,088	(2,125,119)	2,185,101
Hedged Class I (GBP)	601,522	21,411	(522,788)	100,145
Hedged Class I (NOK)	69,039	4,500	(73,539)	-
Class I (USD)	644,748	191,546	(225,952)	610,342
Class IA (USD)	1,000	-	-	1,000
Class AA (USD)	100	-	-	100
Hedged Class O (EUR)	31,796	2,035	(22,332)	11,499
Class O (USD)	3,428	-	(2,139)	1,289
Class SI (USD)	1,488,558	97,355	(558,587)	1,027,325
Hedged Class SI (GBP)	2,756,861	1,022,066	(1,275,037)	2,503,890
Hedged Class SI (EUR)	4,053,300	1,474,111	(3,667,257)	1,860,154
Hedged Class I (JPY)	127	-	-	127
Class C (EUR)	100	-	-	100
Class C (USD)	100	-	-	100
Class ID (GBP)	-	734	-	734
<b>Amundi Sandler US Equity Fund</b>				
Hedged Class A (EUR)	126,033	52,102	(55,365)	122,770
Class A (USD)	60,373	2,785	(33,681)	29,477
Class AA (USD)	100	-	-	100
Hedged Class C (EUR)	59,411	33	(21,836)	37,608
Class C (USD)	50,614	200	(13,641)	37,173
Hedged Class EB (EUR)	33,842	-	(15,018)	18,824
Class O (USD)	276,003	33,761	(46,784)	262,980
Hedged Class I (EUR)	1,241,190	65,841	(731,926)	575,105
Class I (USD)	354,771	282,926	(264,990)	372,707
Class IA (USD)	1,000	-	-	1,000
Hedged Class O (EUR)	62,354	2,919	(13,367)	51,907
Hedged Class O (GBP)	1,256,370	300,945	(133,923)	1,423,391
Hedged Class SI (EUR)	1,932,002	258,244	(962,646)	1,227,599
Hedged Class SI (GBP)	666,644	119,520	(305,408)	480,755
Hedged Class SI2 (GBP)	1,809,905	114,070	(1,828,704)	95,271
Class SI (USD)	1,263,748	55,880	(870,148)	449,480
Hedged Class I (GBP)	1,999	140,154	(140,979)	1,174
Hedged Class I (JPY)	150	-	-	150
Hedged Class I (SGD)	-	178,301	(39,835)	138,466

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 8. SHARE CAPITAL (continued)

The movements in redeemable participating shares in the Company during the year ended 31 December 2022 are as follows:

	At 1 January 2022	Shares Issued	Shares Redeemed	At 31 December 2022
<b>Amundi Tiedemann Arbitrage Strategy</b>				
<b>Fund</b>				
Hedged Class A (CHF)	10,900	90	(6,463)	4,527
Hedged Class A (EUR)	922,105	234,182	(267,916)	888,371
Hedged Class A (GBP)	3,597	1,284	(2,085)	2,796
Class A (USD)	112,909	12,173	(24,652)	100,430
Hedged Class EB (EUR)	9,855	-	(80)	9,775
Hedged Class I (CHF)	66,805	15,861	(10,197)	72,469
Hedged Class I (EUR)	5,412,941	947,489	(2,258,298)	4,102,132
Hedged Class I (GBP)	722,173	59,684	(180,335)	601,522
Hedged Class I (NOK)	84,175	8,313	(23,449)	69,039
Class I (USD)	1,006,551	213,126	(574,929)	644,748
Class IA (USD)	1,000	1,000	(1,000)	1,000
Class AA (USD)	100	100	(100)	100
Hedged Class O (EUR)	23,264	23,138	(14,606)	31,796
Class O (USD)	5,955	337	(2,864)	3,428
Class SI (USD)	1,634,732	205,475	(351,649)	1,488,558
Hedged Class SI (GBP)	2,900,635	142,167	(285,941)	2,756,861
Hedged Class SI (EUR)	4,876,833	2,912,396	(3,735,929)	4,053,300
Hedged Class I (JPY)	-	127	-	127
Class C (EUR)	-	100	-	100
Class C (USD)	-	100	-	100
<b>Amundi Sandler US Equity Fund</b>				
Hedged Class A (EUR)	79,782	70,555	(24,304)	126,033
Class A (USD)	99,162	10,024	(48,813)	60,373
Class AA (USD)	100	100	(100)	100
Hedged Class C (EUR)	67,996	35	(8,620)	59,411
Class C (USD)	68,332	-	(17,718)	50,614
Hedged Class EB (EUR)	111,186	-	(77,344)	33,842
Class O (USD)	370,415	1,189	(95,601)	276,003
Hedged Class I (EUR)	1,337,818	314,729	(411,357)	1,241,190
Class I (USD)	443,736	69,265	(158,230)	354,771
Class IA (USD)	1,000	1,000	(1,000)	1,000
Hedged Class O (EUR)	60,119	2,235	-	62,354
Hedged Class O (GBP)	1,048,253	284,034	(75,917)	1,256,370
Hedged Class SI (EUR)	1,404,927	902,541	(375,466)	1,932,002
Hedged Class SI (GBP)	697,491	37,005	(67,852)	666,644
Hedged Class SI2 (GBP)	1,990,734	386,886	(567,715)	1,809,905
Class SI (USD)	1,430,481	202,683	(369,416)	1,263,748
Hedged Class I (GBP)	7,822	3,248	(9,071)	1,999
Hedged Class I (JPY)	-	150	-	150

#### 9. DERIVATIVE CONTRACTS

To the extent permitted by the investment objectives and policies of the Sub-Funds of the Company and subject to the limits set down by the Central Bank from time to time and to the provisions of the Prospectus and Supplements, utilisation of financial derivative instruments and investment techniques shall be employed for efficient portfolio management purposes by the Sub-Funds. Each Sub-Fund may use these financial derivative instruments and investment techniques to hedge against changes in interest rates, non-functional currency exchange rates or securities prices or as part of their overall investment strategies. The financial derivative instruments held at year end and the Company's derivative counterparties are disclosed below. The realised gains and losses on financial instruments used for efficient portfolio management purposes are disclosed in Note 5.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 9. DERIVATIVE CONTRACTS (continued)

The following financial derivative instruments were included in the Company's Statement of Financial Position at fair value through profit or loss as at 31 December 2023:

	TIEDEMANN USD		SANDLER USD	
	Assets	Liabilities	Assets	Liabilities
<b>Financial derivative instruments</b>				
Listed options	4,410,083	1,560,370	9,528,962	222,956
Futures contracts	-	-	-	739,665
Contract for differences	3,625,986	3,623,961	3,591,424	8,866,866
Foreign currency forwards	17,330,667	869,273	8,998,662	195,726
Equity swaps	-	-	-	-
Credit default swaps	-	-	-	-
Interest rate swaps	-	-	-	-
Warrants	488,920	-	-	-
<b>Total</b>	<b>25,855,656</b>	<b>6,053,604</b>	<b>22,119,048</b>	<b>10,025,213</b>

The following financial derivative instruments were included in the Company's Statement of Financial Position at fair value through profit or loss as at 31 December 2022:

	TIEDEMANN USD		SANDLER USD	
	Assets	Liabilities	Assets	Liabilities
<b>Financial derivative instruments</b>				
Listed options	1,316,001	15,653	33,835,138	-
Futures contracts	-	-	-	56,915
Contract for differences	6,216,064	3,849,048	61,387,732	10,252,083
Foreign currency forwards	97,891,802	2,442,358	54,304,761	1,215,272
Equity swaps	-	-	-	-
Credit default swaps	-	-	-	-
Interest rate swaps	-	-	-	-
Warrants	488,920	-	-	-
<b>Total</b>	<b>105,912,787</b>	<b>6,307,059</b>	<b>149,527,631</b>	<b>11,524,270</b>

#### Options

When the Sub-Funds write or purchase put or call options, an amount equal to the premium received or paid is recorded as an asset or liability and is subsequently re-measured at fair value in the Statement of Financial Position. Premiums received or paid from writing or purchasing put or call options that expire or were unexercised are recognised on the expiration date as realised gains or losses in the Statement of Comprehensive Income. If an option is exercised, the premium received or paid is included with the proceeds or the cost of the transaction to determine whether the Sub-Funds have realised a gain or loss on the related investment transaction in the Statement of Comprehensive Income. When the Sub-Funds enter into a closing transaction, the Sub-Funds will realise a gain or loss in the Statement of Comprehensive Income depending upon whether the amount from the closing transaction is greater or less than the premium received or paid. The resulting unrealised gains and losses on open options are included in the Statement of Financial Position and the change in unrealised gains and losses for the year are included in the Statement of Comprehensive Income.

The Investment Manager considered the option positions held by the Sub-Funds to be covered option positions.

---

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

**9. DERIVATIVE CONTRACTS (continued)**

*Contract for differences*

Contract for differences is a contract between two parties, typically described as "buyer" and "seller", stipulating that the seller will pay to the buyer the difference between the current value of an asset and its value at contract time. Contract for differences are valued on the date of valuation by reference to the underlying instrument. The unrealised gains or losses on open contract for differences are included in the Statement of Financial Position with the related change during the year included in the Statement of Comprehensive Income. Upon expiry or settlement of the obligation under the contracts, realised gains or losses are recorded in the Statement of Comprehensive Income.

*Futures contracts*

Future contracts are exchange traded derivative contracts whereby the seller agrees to make delivery at a specified future date of the respective asset or liability (e.g. a commodity or instrument) at a specified price.

During a year in which future contracts are open, changes in the value of the contracts are recognised as unrealised gains or losses by marking-to-market on a daily basis to reflect the value of the contracts at the end of each day's trading. Futures contracts are valued at the settlement price established each day by the exchange on which they are traded. Gains and losses are recognised in the Statement of Comprehensive Income and the unrealised gains or losses on open positions are included in the Statement of Financial Position. Upon expiry or settlement of the obligation under the contracts, realised gains or losses are recorded in the Statement of Comprehensive Income. Commission charges to open such contracts are expensed at the time that the contracts are opened.

*Foreign currency forwards*

Foreign currency forwards are over the counter derivative contracts whereby the seller agrees to make delivery at a specified future date certain currency at a specified rate. Foreign currency forwards are fair valued by reference to the forward price at which a new forward contract of the same size and maturity could be undertaken at the valuation date. The unrealised gain or loss on open foreign currency forwards is calculated as the difference between the forward rate for the transaction specified in the contract and the forward rate on the valuation date as reported in published sources, multiplied by the face amount of the forward contract.

The unrealised gains or losses on open foreign currency forwards are included in the Statement of Financial Position with the related change during the year included in the Statement of Comprehensive Income. Upon expiry or settlement of the obligation under the contracts, realised gains or losses are recorded in the Statement of Comprehensive Income.

*Warrants*

The Sub-Funds may invest in warrants through listed exchanges and OTC markets. The listed warrants are traded on recognised exchanges and valued at the last traded price. OTC traded warrants are valued by reference to quoted prices. Realised and change in unrealised gains and losses are recorded in the Statement of Comprehensive Income.

All positions are valued according to the pricing policy and compared to prime broker and Manager valuation. For the OTC positions, the Administrator prices the positions using its own model and reconciles the price with counterparties and Manager prices.

---

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

9. DERIVATIVE CONTRACTS (continued)

*Credit default swaps*

Credit default swaps may be centrally cleared or traded on the over-the-counter (“OTC”) market. The fair value of credit default swaps is determined using prices from one or more pricing services, recently executed transactions, quotations (where observable) provided by one or more dealers, or an income or market approach that considers multiple inputs including specific contract terms, interest rate yield curves, interest rates, credit curves, recovery rates, current credit spreads, and the counterparty's creditworthiness. Many inputs into the model do not require material subjectivity as they are observable in the marketplace or set per the contract. Other than the contract terms, valuation is affected by the difference between the contract spread and the current market spread. The contract spread (or rate) is generally fixed and the market spread is determined by the credit risk of the underlying debt or reference entity. The unrealised gains or losses on open credit default swaps are included in the Statement of Financial Position with the related change during the year included in the Statement of Comprehensive Income. Upon expiry or settlement of the obligation under the contracts, realised gains or losses are recorded in the Statement of Comprehensive Income.

*Interest rate swaps*

An interest rate swap is a forward contract in which one stream of future interest payments is exchanged for another based on a specified principal amount. Interest rate swaps usually involve the exchange of a fixed interest rate for a floating rate, or vice versa, to reduce or increase exposure to fluctuations in interest rates or to obtain a marginally lower interest rate than would have been possible without the swap. Gains and losses are recognised in the Statement of Comprehensive Income and the unrealised gains or losses on open positions are included in the Statement of Financial Position. Upon expiry or settlement of the obligation under the contracts, realised gains or losses are recorded in the Statement of Comprehensive Income.

*Equity swaps*

An equity swap is an exchange of future cash flows between two parties that allows each party to diversify its income for a specified period of time while still holding its original assets. An equity swap is similar to an interest rate swap, but rather than one leg being the “fixed” side, it is based on the return of an equity index. The two sets of nominally equal cash flows are exchanged as per the terms of the swap, which may involve an equity-based cash flow (such as from a stock asset, called the reference equity) that is traded for fixed-income cash flow (such as a benchmark interest rate). Equity swaps are valued on the date of valuation by reference to the underlying instrument. The unrealised gains or losses on open equity swaps are included in the Statement of Financial Position with the related change during the year included in the Statement of Comprehensive Income. Upon expiry or settlement of the obligation under the contracts, realised gains or losses are recorded in the Statement of Comprehensive Income.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 9. DERIVATIVE CONTRACTS (continued)

The counterparties to the OTC financial derivative instruments as at 31 December 2023 are as follows:

	TIEDEMANN USD	SANDLER USD
<b>Contract for differences</b>		
Goldman Sachs & Co.	647,897	(1,597,491)
Bnp Paribas	40,290	-
Berenberg Bank	(266,983)	-
Ubs Limited	198,281	-
MS Etf Creation	(125,457)	-
Investment Technology Group Inc	-	2,355,559
Kempen & Co Usa Inc (New York)	364,349	-
Investec Henderson Crosthwaite Securities	2,327,069	-
Davy	18,838	-
JP Morgan Chase Bank	(3,201,150)	(2,488,621)
Morgan Stanley & Co.	(1,109)	(3,543,743)
BTIG LLC - SF	-	(1,146)
<b>Listed Options</b>		
Goldman Sachs International	12,462	-
Goldman, Sachs & Co.	666,526	-
BTIG LLC – SF	1,759,436	-
Ubs Limited	303,412	1,025,268
Mkm Partners	3,207	-
United First Partners LLP	104,670	-
Barclays Bank Plc	-	609,551
Citigroup Inc.	-	446,850
Cowen And Company	-	1,396,890
Jefferies Inc	-	25,040
Merrill Lynch, Pierce	-	575,817
Morgan Stanley & Co.	-	1,160,767
Nomura Inc.	-	1,120,768
Sanford LLC	-	2,204,235
Susquehanna SFG	-	740,820
<b>Warrants</b>		
Ubs Limited	488,920	-
<b>Futures</b>		
Morgan Stanley & Co.	-	(739,665)

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 9. DERIVATIVE CONTRACTS (continued)

The counterparties to the OTC financial derivative instruments as at 31 December 2023 are as follows (continued):

	TIEDEMANN USD	SANDLER USD
<b>Foreign currency forwards</b>		
Morgan Stanley & Co.	(350,639)	-
Societe General Paris	9,282,331	8,923,835
Credit Agricole CIB	7,529,702	(745)
Goldman Sachs International	-	(3,653)
Morgan Stanley Capital New York	-	(116,501)
<b>Total</b>	<b>19,802,052</b>	<b>12,093,835</b>

The counterparties to the OTC financial derivative instruments as at 31 December 2022 are as follows:

	TIEDEMANN USD	SANDLER USD
<b>Contract for differences</b>		
Goldman Sachs & Co.	104,782	25,364,860
Cazenove Capital Management Limited	1,514,683	-
Merrill Lynch Pierce	147,575	-
Cowen & Company	(109,506)	-
MS Etf Creation	(2,255,620)	-
Numis Securities Ltd	(93,495)	-
Credit Suisse AG	4,100,065	-
Bloomberg Tradebook LLC	(794,283)	-
Investment Technology Group Inc	-	(4,973,054)
JP Morgan Chase Bank	(247,185)	5,065,472
Morgan Stanley & Co.	-	25,678,371
<b>Foreign currency forwards</b>		
Morgan Stanley & Co.	44,677	-
JP Morgan Chase Bank	90,146,736	11,354,263
Societe General Paris	5,258,031	23,492,237
Credit Agricole CIB	-	75,236
Goldman Sachs International	-	18,167,753
<b>Total</b>	<b>97,816,460</b>	<b>104,225,138</b>

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**9. DERIVATIVE CONTRACTS (continued)**

*Collateral pledged*

Pledged accounts are maintained by the Sub-Funds of the Company as guarantee in case of default with certain counterparties. Certain US Government Treasury-bills (“US T-bills”) are pledged as collateral in favour of the counterparties which are kept in segregated accounts at the Depository. At 31 December 2023, the Amundi Tiedemann Arbitrage Strategy Fund pledged a total of USD 34,672,565 (31 December 2022: USD 59,659,150) of US T-bills to Goldman Sachs International, USD 66,707,753 (31 December 2022: USD 96,234,448) of US T-bills to Morgan Stanley and Amundi Sandler US Equity Fund pledged a total of USD 19,973,730 (31 December 2022: USD 19,847,240) of US T-bills to Goldman Sachs International, USD 54,754,000 (31 December 2022: USD 54,270,240) of US T-bills to JP Morgan, USD 81,516,698 (31 December 2022: USD 81,189,864) of US T-bills to Morgan Stanley. When the US T-bills come close to maturity, they are rolled by the Investment Manager to avoid any cash settlement.

The US T-bills are included within investment in securities in the Statement of Financial Position.

**10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS**

Risk is inherent in the Company’s activities, but it is managed through a process of ongoing identification, measurement and monitoring, subject to risks limits and other controls. The Sub-Funds are exposed to market risk (which can include interest rate risk, currency risk and price risk), credit risk and liquidity risk arising from the financial instruments they hold.

**Risk mitigation**

The Company and the Sub-Funds are subject to a process for assessing, controlling and periodically re-evaluating the adequacy and efficiency of the risk management policy. Investments guidelines are set up at the launch of each sub-fund to frame each risk factor in accordance with the Investment Manager’s strategy, the liquidity of the Fund and the global fund risk level. Prior to any investment, the Investment Manager shall ensure the compliance with investment guidelines as agreed and is accountable for performing a pre-trade monitoring when allocating. Using the transparency of the Amundi Managed Account Platform, Amundi Risk Management also realises post trade a full second level control. A comprehensive range of portfolio limits are monitored on a daily or weekly basis including stress tests, volatility, leverage, diversification and liquidity. In case of breach, a procedure is in place to notify the Investment Manager and find a solution in the best interests of investors (cure request, one-off agreement).

**Investment strategy**

The detailed investment strategies of the Sub-Funds are documented in their respective Prospectus Supplements.

**Market risk**

Market risk embodies the potential for both gains and losses and includes interest rate risk, currency risk and price risk. Each Sub-Fund’s market risk is managed on a daily basis by the Investment Manager subject to the investment objective and investment policies set out in each Sub-Fund’s Prospectus Supplement.

*Interest rate risk*

Interest rate risk arises from the possibility that changes in interest rates will affect future cash flows or the fair values of financial instruments. Amundi Risk team set up limits and performs stress-test of interest rate to manage interest rate risk. Stress-test scenarios include parallel shift on rate curve, interest rate steepening and interest rate flattening.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Market risk (continued)

##### Interest rate risk (continued)

The following tables detail the Sub-Funds' exposure to interest rate risk at 31 December 2023 and 31 December 2022. It includes the Sub-Funds' assets and liabilities at fair values, categorised by the earlier of contractual repricing or maturity date measured by the carrying value of assets and liabilities.

##### Amundi Tiedemann Arbitrage Strategy Fund

##### 31 December 2023

	Less than 3 months USD	3 months to 1 year USD	1 to 5 years USD	Greater than 5 years USD	Non-interest bearing USD	Total USD
<b>Assets</b>						
Financial assets at fair value through profit or loss:						
Debt securities	700,464,604	-	-	-	-	700,464,604
Equity securities	-	-	-	-	312,702,746	312,702,746
Listed options	-	-	-	-	4,410,083	4,410,083
Warrants	-	-	-	-	488,920	488,920
Contract for differences	-	-	-	-	3,625,986	3,625,986
Foreign currency forwards	-	-	-	-	17,330,667	17,330,667
Cash and cash equivalents	121,755,134	-	-	-	-	121,755,134
Due from brokers	54,475,307	-	-	-	25,605,640	80,080,947
Dividend receivable	-	-	-	-	7,928	7,928
Subscriptions receivable	-	-	-	-	609,578	609,578
<b>Total assets</b>	<b>876,695,045</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>364,781,548</b>	<b>1,241,476,593</b>
<b>Liabilities</b>						
Financial liabilities at fair value through profit or loss:						
Listed options	-	-	-	-	1,560,370	1,560,370
Credit default swaps	-	-	-	-	3,623,961	3,623,961
Foreign currency forwards	-	-	-	-	869,273	869,273
Bank overdraft	2,981,433	-	-	-	-	2,981,433
Due to brokers	-	-	-	-	22,909,160	22,909,160
Dividend payable	-	-	-	-	2,051	2,051
Management fees payable	-	-	-	-	9,314,241	9,314,241
Performance fees payable	-	-	-	-	20,960,382	20,960,382
Administration fees payable	-	-	-	-	1,507,607	1,507,607
Redemptions payable	-	-	-	-	2,587,790	2,587,790
Other payable and accrued expenses	-	-	-	-	167,775	167,775
<b>Total liabilities</b>	<b>2,981,433</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>63,502,610</b>	<b>66,484,043</b>
<b>Total interest sensitivity gap</b>	<b>873,713,612</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>301,278,938</b>	<b>1,174,992,550</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Market risk (continued)

*Interest rate risk (continued)*

##### Amundi Tiedemann Arbitrage Strategy Fund (continued)

31 December 2022

	Less than 3 months USD	3 months to 1 year USD	1 to 5 years USD	Greater than 5 years USD	Non-interest bearing USD	Total USD
<b>Assets</b>						
Financial assets at fair value through profit or loss:						
Debt securities	436,619,606	54,882,699	-	-	-	491,502,305
Equity securities	-	-	-	-	699,944,896	699,944,896
Listed options	-	-	-	-	1,316,001	1,316,001
Warrants	-	-	-	-	488,920	488,920
Contract for differences	-	-	-	-	6,216,064	6,216,064
Foreign currency forwards	-	-	-	-	97,891,802	97,891,802
Cash and cash equivalents	402,405,538	-	-	-	-	402,405,538
Due from brokers	42,901,259	-	-	-	51,262,300	94,163,559
Dividend receivable	-	-	-	-	428,961	428,961
Subscriptions receivable	-	-	-	-	19,986,475	19,986,475
<b>Total assets</b>	<b>881,926,403</b>	<b>54,882,699</b>			<b>877,535,419</b>	<b>1,814,344,521</b>
<b>Liabilities</b>						
Financial liabilities at fair value through profit or loss:						
Listed options	-	-	-	-	15,653	15,653
Credit default swaps	-	-	-	-	3,849,048	3,849,048
Foreign currency forwards	-	-	-	-	2,442,358	2,442,358
Bank overdraft	105	-	-	-	-	105
Due to brokers	-	-	-	-	21,640,341	21,640,341
Dividend payable	-	-	-	-	38,819	38,819
Management fees payable	-	-	-	-	2,420,807	2,420,807
Performance fees payable	-	-	-	-	1,346,362	1,346,362
Administration fees payable	-	-	-	-	2,812,891	2,812,891
Redemptions payable	-	-	-	-	3,153,905	3,153,905
Other payable and accrued expenses	-	-	-	-	626,127	626,127
<b>Total liabilities</b>	<b>105</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>38,346,311</b>	<b>38,346,416</b>
<b>Total interest sensitivity gap</b>	<b>881,926,298</b>	<b>54,882,699</b>	<b>-</b>	<b>-</b>	<b>839,189,108</b>	<b>1,775,998,105</b>

##### *Sensitivity analysis*

Amundi Tiedemann Arbitrage Strategy Fund is an equity fund, the only interest rate instruments are short term T-bills (for cash management purpose) which are less sensitive to the evolution of interest rate. As a result, the Management determines that a fluctuation of interest rate of 50 basis points is reasonably possible, considering the economic environment in which the Sub-Fund operates. As at 31 December 2023, if interest rate had been 50 basis points lower/higher with all other variables held constant, the increase/(decrease) in net assets attributable to holders of redeemable participating shares would have been USD 4,368,568 (2022: USD 4,684,045) higher/lower.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Market risk (continued)

*Interest rate risk (continued)*

##### Amundi Sandler US Equity Fund

31 December 2023

	Less than 3 months USD	3 months to 1 year USD	1 to 5 years USD	Greater than 5 years USD	Non-interest bearing USD	Total USD
<b>Assets</b>						
Financial assets at fair value through profit or loss:						
Debt securities	249,786,877	-	-	-	-	249,786,877
Equity securities	-	-	-	-	362,768,236	362,768,236
Listed options	-	-	-	-	9,528,962	9,528,962
Contract for differences	-	-	-	-	3,591,424	3,591,424
Foreign currency forwards	-	-	-	-	8,998,662	8,998,662
Cash and cash equivalents	48,206,671	-	-	-	-	48,206,671
Due from brokers	17,938,196	-	-	-	3,359,206	21,297,402
Dividend receivable	-	-	-	-	57,313	57,313
Subscriptions receivable	-	-	-	-	1,148,174	1,148,174
Other receivables	-	-	-	-	1,931,029	1,931,029
<b>Total assets</b>	<b>315,931,744</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>391,383,006</b>	<b>707,314,750</b>
<b>Liabilities</b>						
Financial liabilities at fair value through profit or loss:						
Credit default swaps	-	-	-	-	8,866,866	8,866,866
Listed options	-	-	-	-	222,956	222,956
Futures contracts	-	-	-	-	739,665	739,665
Foreign currency forwards	-	-	-	-	195,726	195,726
Due to brokers	-	-	-	-	1,605,558	1,605,558
Dividend payable	-	-	-	-	266,885	266,885
Redemptions payable	-	-	-	-	966,648	966,648
Management fees payable	-	-	-	-	3,958,039	3,958,039
Performance fees payable	-	-	-	-	2,050,786	2,050,786
Administration fees payable	-	-	-	-	974,252	974,252
Other payables and accrued expenses	-	-	-	-	129,493	129,493
<b>Total liabilities</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>19,976,874</b>	<b>19,976,874</b>
<b>Total interest sensitivity gap</b>	<b>315,931,744</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>371,406,132</b>	<b>687,337,876</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Market risk (continued)

*Interest rate risk (continued)*

##### Amundi Sandler US Equity Fund (continued)

31 December 2022

	Less than 3 months USD	3 months to 1 year USD	1 to 5 years USD	Greater than 5 years USD	Non-interest bearing USD	Total USD
<b>Assets</b>						
Financial assets at fair value through profit or loss:						
Debt securities	382,644,309	118,156,628	-	-	-	500,800,937
Equity securities	-	-	-	-	351,249,323	351,249,323
Listed equity options	-	-	-	-	33,835,138	33,835,138
Contract for differences	-	-	-	-	61,387,732	61,387,732
Foreign currency forwards	-	-	-	-	54,304,761	54,304,761
Cash and cash equivalents	141,625,291	-	-	-	-	141,625,291
Due from brokers	21,759,128	-	-	-	5,157,985	26,917,113
Dividend receivable	-	-	-	-	142,124	142,124
Subscriptions receivable	-	-	-	-	1,450,028	1,450,028
Other receivables	-	-	-	-	930,350	930,350
<b>Total assets</b>	<b>546,028,728</b>	<b>118,156,628</b>	<b>-</b>	<b>-</b>	<b>508,457,441</b>	<b>1,172,642,797</b>
<b>Liabilities</b>						
Financial liabilities at fair value through profit or loss:						
Futures contracts	-	-	-	-	56,915	56,915
Credit default swaps	-	-	-	-	10,252,083	10,252,083
Foreign currency forwards	-	-	-	-	1,215,272	1,215,272
Due to brokers	625,059	-	-	-	47,341	672,400
Dividend payable	-	-	-	-	567,403	567,403
Management fees payable	-	-	-	-	3,396,460	3,396,460
Performance fees payable	-	-	-	-	204	204
Administration fees payable	-	-	-	-	1,616,967	1,616,967
Redemptions payable	-	-	-	-	14,606,870	14,606,870
Other payable and accrued expenses	-	-	-	-	242,610	242,610
<b>Total liabilities</b>	<b>625,059</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>32,002,125</b>	<b>32,627,184</b>
<b>Total interest sensitivity gap</b>	<b>545,403,669</b>	<b>118,156,628</b>	<b>-</b>	<b>-</b>	<b>476,455,316</b>	<b>1,140,015,613</b>

##### *Sensitivity analysis*

Amundi Sandler US Equity Fund is an equity fund, the only interest rate instruments are short term T-bills (for cash management purpose) which are less sensitive to the evolution of interest rate. As a result, the Management determines that a fluctuation of interest rate of 50 basis points is reasonably possible, considering the economic environment in which the Sub-Fund operates. As at 31 December 2023, if interest rates had been 50 basis points lower/higher with all other variables held constant, the increase/(decrease) in net assets attributable to holders of redeemable participating shares would have been USD 1,579,659 (2022: USD 3,317,801) higher/lower.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Market risk (continued)

##### Currency risk

Each Sub-Fund may invest in financial instruments and enter into transactions denominated in currencies other than its functional currency. Consequently, each Sub-Fund is exposed to the risk that the exchange rate of its functional currency relative to other foreign currencies may change in a manner that has an adverse effect on the value of that portion of the Sub-Fund's assets or liabilities denominated in currencies other than the functional currency. Currency risk is managed either by controlling the exposure of "unhedged currency" under the predefined limit (using FX trades, hedging derivatives and other instruments), or by doing stress test of foreign exchange and controlling the compliance with the predefined limit. The Sub-Funds' currency risk is managed and monitored on a daily basis by the Investment Manager.

The Sub-Funds had the following currency risk exposures:

##### Amundi Tiedemann Arbitrage Strategy Fund

##### 31 December 2023

Currency Monetary/Non Monetary	Total Exposure USD	Hedging USD	Net Exposure USD
USD	1,114,028,500	885,084,379	1,999,112,879
EUR	27,399,970	(546,647,578)	(519,247,608)
CAD	8,961,106	5,241,786	14,202,892
GBP	21,231,815	(343,362,859)	(322,131,044)
JPY	(64,878)	(9,323)	(74,201)
Others	3,436,037	(306,405)	3,129,632
	<b>1,174,992,550</b>	<b>-</b>	<b>1,174,992,550</b>

##### 31 December 2022

Currency Monetary/Non Monetary	Total Exposure USD	Hedging USD	Net Exposure USD
USD	1,600,088,729	1,442,742,085	3,042,830,814
EUR	108,814,081	(1,027,663,992)	(918,849,911)
JPY	(784,196)	-	(784,196)
GBP	31,031,096	(427,131,998)	(396,100,902)
CAD	35,806,402	28,715,281	64,521,683
Others	1,041,993	(16,661,376)	(15,619,383)
	<b>1,775,998,105</b>	<b>-</b>	<b>1,775,998,105</b>

##### Sensitivity analysis

Management deems that a +/-5% threshold is reasonable for the Sub-Fund. If exchange rates at 31 December 2023 had changed by +/-5% with all other variables held constant, this would have changed net assets attributable to holders of redeemable shares by approximately USD +/- 41,206,016 (2022: USD +/- 63,341,635).

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Market risk (continued)

*Currency risk (continued)*

##### Amundi Sandler US Equity Fund

31 December 2023

Currency Monetary/Non Monetary	Total Exposure USD	Hedging USD	Net Exposure USD
USD	669,624,943	537,297,308	1,206,922,251
CAD	12,350,453	8,715,994	21,066,447
EUR	4,649,262	(246,228,134)	(241,578,872)
GBP	622,774	(288,999,161)	(288,376,387)
Others	90,444	(10,786,007)	(10,695,563)
	<b>687,337,876</b>	<b>-</b>	<b>687,337,876</b>

31 December 2022

Currency Monetary/Non Monetary	Total Exposure USD	Hedging USD	Net Exposure USD
USD	1,103,968,065	913,832,912	2,017,800,977
GBP	21,247,099	(502,184,033)	(480,936,934)
EUR	14,800,340	(411,637,456)	(396,837,116)
JPY	65	(11,423)	(11,358)
Others	44	-	44
	<b>1,140,015,613</b>	<b>-</b>	<b>1,140,015,613</b>

##### *Sensitivity analysis*

Management deems that a +/-5% threshold is reasonable for the Sub-Fund. If exchange rates at 31 December 2023 had changed by +/-5% with all other variables held constant, this would have changed net assets attributable to holders of redeemable shares by approximately USD +/- 25,979,219 (2022: USD +/- 43,889,268).

---

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

Market risk (continued)

*Price risk*

Price risk is the risk that the value of the instrument will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer or all factors affecting all instruments traded in the market.

As the majority of the Company's financial instruments are carried at fair value with fair value changes recognised in the Statement of Comprehensive Income, all changes in market conditions will directly affect change in net assets attributable to holders of redeemable participating shares.

The Investment Manager manages price risk in accordance with the investment objectives and policies set out in the Sub-Funds' Prospectus Supplements. This risk is managed by ensuring appropriate processes and procedures are in place to effectively manage the Sub-Funds' risks.

Value at risk (VaR)

Global exposure for each Sub-Fund is calculated using a Value at Risk (VaR) model. VaR will be monitored in terms of absolute VaR, as defined below:

- Absolute VaR is defined as percentage of NAV, the VaR of the Sub-Fund is limited as a percentage of NAV. The absolute VaR of each Sub-Fund cannot be greater than 20% of the NAV.
- The market risks of each Sub-Fund's financial asset and liability positions are monitored by the Investment Manager on a daily basis. VaR analysis represents the interdependencies between risk variables, unlike a traditional sensitivity analysis. VaR represents a statistical estimate of the potential losses from adverse changes in market factors for a specified time year and confidence level.

*Limitation of VaR calculation*

Whilst in the opinion of the Investment Manager VaR is a good general risk measure, it is acknowledged that it does have certain limitations, including:

- The measure is a point-in-time calculation, reflecting positions as recorded at that date, which do not necessarily reflect the risk positions held at any other time.
- If a 99% confidence interval is applied, losses are not expected to exceed the calculated VaR on 99% of occasions, but on the other 1%, losses are expected to be greater and may substantially exceed the calculated VaR. VaR is a statistical estimation and therefore it is possible that there could be, in any period, a greater number of days in which losses could exceed the calculated VaR.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Market risk (continued)

Price risk (continued)

VaR analysis (historical simulation)

##### 31 December 2023

Sub-Fund	Absolute VaR%	Average VaR%	Minimum VaR%	Maximum VaR%	VaR% Limit	Leverage employed during the year ended 31 December 2023 (%)
	(% of NAV)	(Limit utilisation)	(Limit utilisation)	(Limit utilisation)		
TIEDEMANN	4.43%	31.00%	20.87%	43.74%	20.00%	33.21%
SANDLER	3.25%	14.49%	8.85%	23.02%	20.00%	56.31%

##### 31 December 2022

Sub-Fund	Absolute VaR%	Average VaR%	Minimum VaR%	Maximum VaR%	VaR% Limit	Leverage employed during the year ended 31 December 2022 (%)
	(% of NAV)	(Limit utilisation)	(Limit utilisation)	(Limit utilisation)		
TIEDEMANN	6.84%	32.20%	18.07%	52.42%	20.00%	35.28%
SANDLER	4.33%	17.98%	11.33%	42.29%	20.00%	37.49%

##### Credit risk

Credit risk is the risk that the counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Company. The below value of financial assets best represent the maximum credit risk exposure at the balance sheet date.

##### 31 December 2023

	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<i>Investment in securities</i>			
Debt securities	950,251,481	700,464,604	249,786,877
Equity securities	675,470,982	312,702,746	362,768,236
Total investment in securities	<b>1,625,722,463</b>	<b>1,013,167,350</b>	<b>612,555,113</b>
<i>Financial derivative instruments<sup>(1)</sup></i>			
Listed options	15,722,371	5,970,453	9,751,918
Futures contracts	25,194,780	-	25,194,780
Warrants	488,920	488,920	-
Contract for differences	420,314,960	207,368,195	212,946,765
Foreign currency forwards	1,662,597,255	1,091,964,856	570,632,399
Total financial derivative instruments	<b>2,124,318,286</b>	<b>1,305,792,424</b>	<b>818,525,862</b>
Cash and cash equivalents	169,961,805	121,755,134	48,206,671
Due from brokers	101,378,349	80,080,947	21,297,402
Dividend receivable	65,241	7,928	57,313
Subscriptions receivable	1,757,752	609,578	1,148,174
Other receivables	1,931,029	-	1,931,029
<b>Total</b>	<b>4,025,134,925</b>	<b>2,521,413,361</b>	<b>1,503,721,564</b>

<sup>(1)</sup>The financial derivative instruments are stated at their notional amounts. The other financial assets are stated at their fair value as presented in the Statement of Financial Position.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Credit risk (continued)

31 December 2022

	COMPANY TOTAL USD	TIEDEMANN USD	SANDLER USD
<i>Investment in securities</i>			
Debt securities	992,303,242	491,502,305	500,800,937
Equity securities	1,051,194,219	699,944,896	351,249,323
Total investment in securities	<b>2,043,497,461</b>	<b>1,191,447,201</b>	<b>852,050,260</b>
<i>Financial derivative instruments<sup>(1)</sup></i>			
Listed options	35,166,792	1,331,654	33,835,138
Futures contracts	8,549,100	-	8,549,100
Warrants	488,920	488,920	-
Contract for differences	725,063,752	317,776,882	407,286,870
Foreign currency forwards	2,825,521,308	1,777,645,529	1,047,875,779
Total financial derivative instruments	<b>3,594,789,872</b>	<b>2,097,242,985</b>	<b>1,497,546,887</b>
Cash and cash equivalents	544,030,829	402,405,538	141,625,291
Due from brokers	121,080,672	94,163,559	26,917,113
Dividend receivable	571,085	428,961	142,124
Subscriptions receivable	21,436,503	19,986,475	1,450,028
Other receivables	930,350	-	930,350
<b>Total</b>	<b>6,326,336,772</b>	<b>3,805,674,719</b>	<b>2,520,662,053</b>

<sup>(1)</sup>The financial derivative instruments are stated at their notional amounts. The other financial assets are stated at their fair value as presented in the Statement of Financial Position.

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Credit risk (continued)

The following table details the name and credit rating of the financial institutions holding the net cash and cash equivalents of each Sub-Fund:

##### 31 December 2023

	<b>Credit Rating</b>	<b>TIEDEMANN USD</b>	<b>SANDLER USD</b>
Caceis Bank, Ireland Branch	A+	76,486,006	33,428,946
Morgan Stanley Capital Services Inc	A+	-	5,836,749
Goldman Sachs and Co.	A+	42,287,695	8,940,976
<b>Total</b>		<b>118,773,701</b>	<b>48,206,671</b>

##### 31 December 2022

	<b>Credit Rating</b>	<b>TIEDEMANN USD</b>	<b>SANDLER USD</b>
Caceis Bank, Ireland Branch	AA-	362,769,076	96,006,046
Morgan Stanley Capital Services Inc	A+	-	30,238,316
Goldman Sachs and Co.	A+	39,636,357	15,380,929
<b>Total</b>		<b>402,405,433</b>	<b>141,625,291</b>

The following table details the name and credit rating of the financial institutions holding the net due from/to brokers balances of each Sub-Fund.

##### 31 December 2023

	<b>Credit Rating</b>	<b>TIEDEMANN USD</b>	<b>SANDLER USD</b>
Goldman Sachs & Co.	A+	(35,577)	678,730
Goldman Sachs International	A+	7,008,694	-
JP Morgan Chase Bank	A+	361,157	3,048,978
Caceis Bank, Ireland Branch	A+	24,496,278	2,577,742
Morgan Stanley & Co.	A+	(19,768)	13,386,394
Morgan Stanley New York	A+	(2,634,674)	-
Merrill Lynch Bank & Trust Co. (Cayman) Ltd	A+	22,734	-
UBS AG	A+	27,972,943	-
<b>Total</b>		<b>57,171,787</b>	<b>19,691,844</b>

AMUNDI ALTERNATIVE FUNDS PLC

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

Credit risk (continued)

31 December 2022

	Credit Rating	TIEDEMANN USD	SANDLER USD
Bank of America, NA	A-	13,736,000	-
Goldman Sachs & Co.	A+	(172,149)	764,468
Goldman Sachs International	A+	28,028,383	-
JP Morgan Chase Bank	A+	2,048,353	1,857,598
Caceis Bank, Ireland Branch	AA-	28,545,690	3,768,457
Morgan Stanley & Co.	A+	-	19,854,190
Morgan Stanley New York	A+	314,775	-
Merrill Lynch Bank & Trust Co. (Cayman) Ltd	A+	22,166	-
<b>Total</b>		<b>72,523,218</b>	<b>26,244,713</b>

The following table details the name and credit rating of the OTC derivative counterparties of each Sub-Fund.

31 December 2023

	Credit Rating	TIEDEMANN USD	SANDLER USD
Cowen & Company	BB-	-	1,396,890
Barclays Bank Plc	A+	-	609,551
Berenberg Bank	NR	(266,983)	-
BTIG LLC - SF	NR	1,759,436	(1,146)
Bnp Paribas, London	A+	40,290	-
Citigroup Global Markets Inc.	A+	-	446,850
DAVY	NR	18,838	-
External - London	A+	488,920	-
Goldman Sachs & Co.	A+	1,314,423	(1,597,491)
Goldman Sachs International	A+	-	(3,653)
Investec Henderson Crosthwaite Securities	NR	2,327,069	-
JP Morgan Chase Bank	A+	(3,182,617)	-
J.P. Morgan Europe Limited	A+	(18,533)	-
J.P. Morgan Securities Asia Pacific	A+	-	(2,488,621)
Jefferies & Company, Inc	BBB	-	25,040
Kempen & Co Usa Inc (New York)	NR	364,349	-
Merrill Lynch Pierce	A+	-	575,817
MKM Partners	NR	3,207	-
Morgan Stanley & Co.	A+	-	(3,122,641)
Morgan Stanley Capital New York	A+	-	(116,501)
Morgan Stanley Senior Fund	A-	(1,109)	-
Morgan Stanley (PB)	A-	(350,639)	-
Nomura Global Financial Products Inc.	BBB+	-	1,120,768
Sanford C. Bernstein & Co., Llc	NR	-	2,204,235
Societe General Paris	A	9,282,331	8,923,835
Susquehanna Financial Group LLLP (SFG)	NR	-	740,820
Test Ny	A+	12,462	-
Ubs Ag	A+	501,693	-
Ubs Securities Incorporated-Ny	A+	-	1,025,268
United First Partners Llp	NR	104,670	-
Credit Agricole CIB	A+	7,529,702	(745)
Investment Technology Group Inc	BBB	-	2,355,559
MS Etf Creation	NR	(125,457)	-
<b>Total</b>		<b>19,802,052</b>	<b>12,093,835</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Credit risk (continued)

31 December 2022

	Credit Rating	TIEDEMANN USD	SANDLER USD
Cowen & Company	BB-	-	(109,506)
Credit Suisse AG	A	-	4,100,065
Goldman Sachs & Co.	A+	25,364,860	104,782
Goldman Sachs International	A+	18,167,753	-
JP Morgan Chase Bank	A+	16,419,735	89,899,551
Merrill Lynch Pierce	A+	-	147,575
Morgan Stanley & Co.	A+	25,678,371	44,677
Societe General Paris	A+	23,492,237	5,258,031
Credit Agricole CIB	AA-	75,236	-
Bloomberg Tradebook LLC	NR	-	(794,283)
Cazenove Capital Management Ltd	NR	-	1,514,683
Investment Technology Group Inc	BBB+	(4,973,054)	-
MS Etf Creation	NR	-	(2,255,620)
Numis Securities Ltd	NR	-	(93,495)
<b>Total</b>		<b>104,225,138</b>	<b>97,816,460</b>

The tables below analyse the Sub-Funds' portfolio of debt securities by rating agency category.

##### Amundi Tiedemann Arbitrage Strategy Fund

31 December 2023

Credit rating	Debt securities	
	Fair value USD	% of NAV
AAA	700,464,604	59.61%
<b>Total</b>	<b>700,464,604</b>	<b>59.61%</b>

31 December 2022

Credit rating	Debt securities	
	Fair value USD	% of NAV
AAA	491,502,305	27.67%
<b>Total</b>	<b>491,502,305</b>	<b>27.67%</b>

##### Amundi Sandler US Equity Fund

31 December 2023

Credit rating	Debt securities	
	Fair value USD	% of NAV
AAA	249,786,877	36.34%
<b>Total</b>	<b>249,786,877</b>	<b>36.34%</b>

31 December 2022

Credit rating	Debt securities	
	Fair value USD	% of NAV
AAA	500,800,937	43.93%
<b>Total</b>	<b>500,800,937</b>	<b>43.93%</b>

---

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)**

**Credit risk (continued)**

The Depositary network holds securities (i.e. bonds and equities), cash, and/or collateral for the Company. Bankruptcy, insolvency or other credit default events of the Depositary or its Sub-Depositary network (“Institution”) may cause the Company’s rights with respect to securities and other assets (including collateral) held by the Depositary to be delayed or limited. In the event of the insolvency or bankruptcy of the Institution, the Company will be treated as a general creditor with respect to cash. The maximum exposure to this risk at the 31 December 2023 and 31 December 2022 is the carrying value of the relevant assets other than derivatives. Substantially all of the assets and cash held by the Company are held with Goldman Sachs and Co., CACEIS and Morgan Stanley and Co. Bankruptcy or insolvency by these banks may cause the Company’s rights with respect to the cash held or assets to be delayed or may result in the Company not receiving the full value of such cash or assets.

The Sub-Funds monitor their risk by periodically reviewing the credit quality of the Depositary and its parent company, Credit Agricole S.A. At 31 December 2023, the long term senior debt credit rating of Credit Agricole S.A. from Standard & Poor’s was A (31 December 2022: A+). In respect of the cash held with any institution, including the Depositary, the Company will be exposed to the credit risk of that institution.

The Company is required to disclose the impact of offsetting assets and liabilities represented in the Statement of Financial Position to enable users of the financial statements to evaluate the effect or potential effect of netting arrangements on its financial position for recognised assets and liabilities. These recognised assets and liabilities are financial instruments and derivative instruments that are either subject to an enforceable master netting agreement or similar agreement or meet the following right of set off criteria: if the Company currently has a legally enforceable right to set off the recognised amounts; and if it intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

As of 31 December 2023 and 31 December 2022, the Company does not hold financial instruments and derivative instruments that are eligible for offset in the Statement of Financial Position but does hold those which are subject to a master netting arrangement or similar agreements.

AMUNDI ALTERNATIVE FUNDS PLC

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

Credit risk (continued)

Offsetting financial instruments

31 December 2023

Financial assets subject to enforceable master netting arrangements and similar agreements:

Sub-Fund	Sub-Fund's functional currency	Description of type of financial asset	Gross amount of recognised financial asset	Gross amount of financial liabilities offset in the Statement of Financial Position	Net amount of financial assets presented in the Statement of Financial Position	Gross amounts not offset in the Statement of Financial Position		Net amount
						Financial instrument	Collateral received	
TIEDEMANN	USD	Derivative financial instruments	25,855,656	-	25,855,656	(2,108,269)	-	23,747,387
SANDLER	USD	Derivative financial instruments	22,119,048	-	22,119,048	(2,694,421)	-	19,424,627

Financial liabilities subject to enforceable master netting arrangements and similar agreements:

Sub-Fund	Sub-Fund's functional currency	Description of type of financial asset	Gross amount of recognised financial asset	Gross amount of financial liabilities offset in the Statement of Financial Position	Net amount of financial assets presented in the Statement of Financial Position	Gross amounts not offset in the Statement of Financial Position		Net Amount
						Financial instrument	Collateral pledged	
TIEDEMANN	USD	Derivative financial instruments	(6,053,604)	-	(6,053,604)	2,108,269	3,533,251	(412,084)
SANDLER	USD	Derivative financial instruments	(10,025,213)	-	(10,025,213)	2,694,421	10,000	(7,320,792)

The cash collateral balances of the Sub-Funds are disclosed in Note 7.

AMUNDI ALTERNATIVE FUNDS PLC

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

Credit risk (continued)

Offsetting financial instruments (continued)

31 December 2022

Financial assets subject to enforceable master netting arrangements and similar agreements:

Sub-Fund	Sub-Fund's functional currency	Description of type of financial asset	Gross amount of recognised financial asset	Gross amount of financial liabilities offset in the Statement of Financial Position	Net amount of financial assets presented in the Statement of Financial Position	Gross amounts not offset in the Statement of Financial Position		Net amount
						Financial instrument	Collateral received	
TIEDEMANN	USD	Derivative financial instruments	105,912,787	-	105,912,787	(2,830,139)	-	103,082,648
SANDLER	USD	Derivative financial instruments	149,527,631	-	149,527,631	(5,963,907)	-	143,563,724

Financial liabilities subject to enforceable master netting arrangements and similar agreements:

Sub-Fund	Sub-Fund's functional currency	Description of type of financial asset	Gross amount of recognised financial asset	Gross amount of financial liabilities offset in the Statement of Financial Position	Net amount of financial assets presented in the Statement of Financial Position	Gross amounts not offset in the Statement of Financial Position		Net amount
						Financial instrument	Collateral pledged	
TIEDEMANN	USD	Derivative financial instruments	(6,307,059)	-	(6,307,059)	2,830,139	-	(3,476,920)
SANDLER	USD	Derivative financial instruments	(11,524,270)	-	(11,524,270)	5,963,907	-	(5,560,363)

**NOTES TO THE FINANCIAL STATEMENTS (continued)**  
**For the year ended 31 December 2023**

**10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)**

**Credit risk (continued)**

*Offsetting financial instruments (continued)*

The cash collateral balances of the Sub-Funds are disclosed in Note 7.

*Expected credit losses*

At 31 December 2023 and 31 December 2022, the cash and cash equivalents, due from brokers and other short-term receivables are held with most counterparties with a credit rating of A+ or higher and are due to be settled within one week. Management considers the probability of default to be close to zero as the counterparties have a strong capacity to meet their contractual obligations in the near term. As a result, no loss allowance has been recognised based on 12-month expected credit losses as any such impairment would be wholly insignificant to the Company.

**Liquidity risk**

**Residual contractual maturities of assets and liabilities**

The tables below analyse the Company's financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within twelve months equal their carrying balances, as the impact of discounting is not significant. Note the liquidity analysis does not take account of the secondary market liquidity of investments.

If redemption applications on any dealing day exceed 10% of the redeemable participating shares in a Sub-Fund, the Company may defer the excess redemption applications to subsequent dealing days.

The period over which positions are expected to be held may differ to the actual period of holding thereby impacting the calculated VaR. Inputs are restricted to conditions or events occurring in the past 12 months. Therefore, any condition or event outside this time period will not have been included in the calculation.

**Amundi Tiedemann Arbitrage Strategy Fund**

**31 December 2023**

	<b>Less than 3 months</b>	<b>3 months</b>	<b>1 to 5</b>	<b>Greater</b>	<b>No stated</b>	<b>Total</b>
<b>Liabilities</b>	<b>USD</b>	<b>to 1 year</b>	<b>years</b>	<b>than 5</b>	<b>maturity</b>	<b>USD</b>
	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>years</b>	<b>USD</b>	<b>USD</b>
Financial liabilities at fair value through profit or loss	2,429,647	-	-	-	3,623,957	6,053,604
Bank overdraft	2,981,433	-	-	-	-	2,981,433
Due to brokers	22,909,160	-	-	-	-	22,909,160
Dividend payable	2,051	-	-	-	-	2,051
Management fees payable	9,314,241	-	-	-	-	9,314,241
Performance fees payable	20,960,382	-	-	-	-	20,960,382
Administration fees payable	1,507,607	-	-	-	-	1,507,607
Redemptions payable	2,587,790	-	-	-	-	2,587,790
Other payable and accrued expenses	167,775	-	-	-	-	167,775
Net assets attributable to holders of redeemable participating shares	1,174,992,550	-	-	-	-	1,174,992,550
<b>Total liabilities</b>	<b>1,237,852,636</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,623,957</b>	<b>1,241,476,593</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Liquidity risk (continued)

##### Amundi Tiedemann Arbitrage Strategy Fund (continued)

31 December 2022

	Less than 3 months	3 months to 1 year	1 to 5 years	Greater than 5 years	No stated maturity	Total
	USD	USD	USD	USD	USD	USD
<b>Liabilities</b>						
Financial liabilities at fair value through profit or loss	2,458,011	-	-	-	3,849,048	6,307,059
Bank overdraft	105	-	-	-	-	105
Due to brokers	21,640,341	-	-	-	-	21,640,341
Dividend payable	38,819	-	-	-	-	38,819
Management fees payable	2,420,807	-	-	-	-	2,420,807
Performance fees payable	1,346,362	-	-	-	-	1,346,362
Administration fees payable	2,812,891	-	-	-	-	2,812,891
Redemptions payable	3,153,905	-	-	-	-	3,153,905
Other payable and accrued expenses	626,127	-	-	-	-	626,127
Net assets attributable to holders of redeemable participating shares	1,775,998,105	-	-	-	-	1,775,998,105
<b>Total liabilities</b>	<b>1,810,495,473</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,849,048</b>	<b>1,814,344,521</b>

##### Amundi Sandler US Equity Fund

31 December 2023

	Less than 3 months	3 months to 1 year	1 to 5 years	Greater than 5 years	No stated maturity	Total
	USD	USD	USD	USD	USD	USD
<b>Liabilities</b>						
Financial liabilities at fair value through profit or loss	1,158,346	-	-	-	8,866,867	10,025,213
Due to brokers	1,605,558	-	-	-	-	1,605,558
Dividend payable	266,885	-	-	-	-	266,885
Management fees payable	3,958,039	-	-	-	-	3,958,039
Performance fees payable	2,050,786	-	-	-	-	2,050,786
Administration fees payable	974,252	-	-	-	-	974,252
Redemptions payable	966,648	-	-	-	-	966,648
Other payable and accrued expenses	129,493	-	-	-	-	129,493
Net assets attributable to holders of redeemable participating shares	687,337,876	-	-	-	-	687,337,876
<b>Total liabilities</b>	<b>698,447,883</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>8,866,867</b>	<b>707,314,750</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

#### 10. FINANCIAL INSTRUMENTS AND ASSOCIATED RISKS (continued)

##### Liquidity risk (continued)

##### Amundi Sandler US Equity Fund

31 December 2022

	Less than 3 months USD	3 months to 1 year USD	1 to 5 years USD	Greater than 5 years USD	No stated maturity USD	Total USD
<b>Liabilities</b>						
Financial liabilities at fair value through profit or loss	1,272,187	-	-	-	10,252,083	11,524,270
Due to brokers	672,400	-	-	-	-	672,400
Dividend payable	567,403	-	-	-	-	567,403
Management fees payable	3,396,460	-	-	-	-	3,396,460
Performance fees payable	204	-	-	-	-	204
Administration fees payable	1,616,967	-	-	-	-	1,616,967
Redemptions payable	14,606,870	-	-	-	-	14,606,870
Other payable and accrued expenses	242,610	-	-	-	-	242,610
Net assets attributable to holders of redeemable participating shares	1,140,015,613	-	-	-	-	1,140,015,613
<b>Total liabilities</b>	<b>1,162,390,714</b>	-	-	-	<b>10,252,083</b>	<b>1,172,642,797</b>

#### 11. RELATED PARTY DISCLOSURES

IAS 24, Related Party Disclosures – Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

##### Directors and dependents thereof are considered related parties.

Mr. Moez Bousarsar is the Sales Director EMEA, Alternative Assets at Amundi Asset Management.

Mr. Colm Callaly is Head of Legal Ireland at Amundi Ireland Ltd.

Mr. Declan Murray is Director of Management Company Services at Amundi Ireland Ltd.

Mr. John O'Toole (resigned on 21 November 2023) is Global Head of Multi-Asset Fund Solutions at Amundi Ireland Ltd.

Mr. Paul Weber (resigned on 21 November 2023) is Head of Fund Research & Manager Selection, Multi-Asset Fund Solutions at Amundi Ireland Ltd.

The Directors' fees are recognised and paid by the Manager (Note 6).

None of the Directors hold shares in any of the Company's Sub-Funds during the period ended 31 December 2023 (31 December 2022: Nil).

##### Significant shareholders

The number of significant shareholders and the percentage of their shareholdings per Sub-Fund at the year end date follow:

31 December 2023

Sub-Fund	No. of	
	shareholders	Holdings %
Amundi Sandler US Equity Fund	1	32.68%
Amundi Tiedemann Arbitrage Strategy Fund	1	23.20%

## NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

## 11. RELATED PARTY DISCLOSURES (continued)

## Significant shareholders (continued)

31 December 2022

Sub-Fund	No. of shareholders	Holdings %
Amundi Sandler US Equity Fund	1	21.61%

**Manager, Distributor and Investment Manager**

Amundi Asset Management, the Manager, is a wholly-owned subsidiary of Amundi, a credit institution authorized by the *Autorité de contrôle prudentiel et de résolution* (ACPR) and European Central Bank under n°19530. Amundi's majority shareholder is Credit Agricole SA. Credit Agricole SA is controlled by SAS Rue La Boetie. The Manager and Crédit Agricole SA are related by virtue therefore, all subsidiary companies of Crédit Agricole SA are considered as related and connected party.

The Manager is responsible for the day to day management, administration and investment management of the Company. The Manager provides or procures the provision of management, administration, accounting, registration, transfer agency, distribution, investment management or advisory and shareholder services to or for the benefit of the Company.

Until 1st June 2022, date of the merger between Lyxor Asset Management and Amundi Asset Management, Lyxor Asset Management was Manager and Investment Manager of the Company. Therefore, it was entitled to management and performance fees during the period from 1st January 2022 to 31 May 2022.

The management fees recognised during the year were disclosed in Note 6.

The Manager also acts as the Distributor of the Company.

**Depositary**

The Company has appointed CACEIS Bank, Ireland Branch to act as depositary of the assets of the Company (the "Depositary"). Pursuant to the depositary agreement, the Depositary will provide safekeeping for the Company's assets in accordance with the UCITS Regulations and will collect any income arising on such assets on the Company's behalf.

The Depositary may delegate the performance of its safekeeping duties to third parties (hereinafter referred to as "Sub-custodians") in accordance with the requirements of UCITS V. Sub-custodians may be considered as related and connected party as subsidiary companies of Crédit Agricole SA. The list of the entities to whom safekeeping of the Company's assets have been sub-delegated is set out in Annex II of the Prospectus, and any updates to the list are available via the website: [www.caceis.com/en/regulatory-watch/ucits-v/overview.html](http://www.caceis.com/en/regulatory-watch/ucits-v/overview.html) or such other website as may be notified by the Depositary to the Company from time to time and notified to the Shareholders or made available to investors upon request.

Depositary fees are included within administration fees as disclosed in Note 6.

**Registrar and Transfer Agent**

The Manager has appointed CACEIS Ireland Limited to act as registrar and transfer agent to the Company pursuant to the Registrar and Transfer Agency Agreement. The Registrar and Transfer Agent is owned by CACEIS which is a joint venture between Credit Agricole S.A. (85%) and Natixis S.A. (15%). The Registrar and Transfer Agent is engaged in the provision of fund administration, accounting, registration, transfer agency and related shareholder services to collective investment schemes and investment funds.

During the continuance of its appointment, the Registrar and Transfer Agent shall, subject to the overall supervision and direction of the Manager, be responsible for providing registrar and transfer agency services required in connection with the Company's operations including, but not limited to, shareholder registration, maintaining the Company's share register, processing subscriptions, exchanges, transfers and redemptions, and arranging for payments to Shareholders (or to their order) of dividends and other distributions, if any, declared by the Company.

Registrar and transfer agent fees are included within administration fees as disclosed in Note 6.

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

11. RELATED PARTY DISCLOSURES (continued)

Other related parties

The Amundi Sandler US Equity Fund held NIL shares (31 December 2022: NIL) in a related fund, Amundi Smart Overnight Return, the related balances follow:

Amundi Smart Overnight Return	31 December 2023 USD	31 December 2022 USD
Fair value at year end		-
Unrealised gain at year end		-
Change in unrealised gain during the year		(713,549)

During the period, the Company recognised and paid a fee of USD 2,274,808 (31 December 2022: USD 2,554,086), relating to a trade execution platform provided by Amundi Intermediation which is owned by Amundi Asset Management (42%), by Amundi France (38.53%) and by Société Générale Gestion (19.47%).

12. DIVIDEND AND DISTRIBUTION POLICY

It is not intended to declare dividends in respect of any redeemable participating share class of the Sub-Funds.

13. CROSS INVESTMENTS

As at 31 December 2023 and 31 December 2022, the Company's Sub-Funds did not hold any cross investments.

14. EXCHANGE RATES

The following exchange rates (against the USD) were used to convert the investments and other assets and liabilities denominated in currencies other than USD as at year end:

Currency	31 December 2023	31 December 2022
AUD	0.6815	0.6810
CAD	0.7547	0.7385
CHF	1.1889	1.0814
CNH	0.1403	0.1445
EUR	1.1041	1.0706
GBP	1.2748	1.2090
HKD	0.1281	0.1281
JPY	0.0071	0.0076
SEK	0.0992	0.0958
NOK	0.0984	0.1021
SGD	0.7577	0.7466

15. SOFT COMMISSION ARRANGEMENTS

The following table details the soft commission arrangements that are in place on each Sub-Fund as at year end.

Sub-Funds	Sub-Investment Manager	31 December 2023 USD	31 December 2022 USD
Amundi Tiedemann Arbitrage Strategy Fund	TIG Advisors LLC	2,085,287	1,783,805
Amundi Sandler US Equity Fund	Sandler Capital Management	2,559,000	2,242,000

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the year ended 31 December 2023

16. TOTAL NAV AND NAV PER SHARE HISTORY

The net asset value and net asset value per redeemable participating share of the Sub-Funds are presented below:

	TIEDEMANN			SANDLER		
	31 December 2023 USD	31 December 2022 USD	31 December 2021 USD	31 December 2023 USD	31 December 2022 USD	31 December 2021 USD
<b>Net asset value</b>	1,174,992,550	1,775,998,105	2,292,050,984	687,337,876	1,140,015,613	1,266,119,010
<b>NAV per redeemable participating share:</b>						
Class A (USD)	131.51	122.19	121.98	113.01	110.28	113.65
Class AA (USD)	118.43	110.28	110.24	112.04	109.48	112.98
Class C (USD)	108.23	100.23	-	113.73	110.62	113.60
Class I (USD)	158.41	146.21	145.01	130.14	126.53	129.42
Class IA (USD)	122.15	112.87	112.07	114.68	111.60	114.49
Class O (USD)	120.03	111.32	110.90	117.53	113.79	115.94
Class SI (USD)	111.10	102.34	101.29	116.26	112.80	115.15
Hedged Class A (CHF)	113.78	109.11	111.05	-	-	-
Hedged Class A (EUR)	118.90	112.16	114.38	110.94	110.39	-
Hedged Class A (GBP)	127.82	119.39	120.04	-	-	-
Hedged Class C (EUR)	106.27	100.05	-	103.98	103.08	108.12
Hedged Class EB (EUR)	138.28	129.32	130.51	119.08	117.17	122.00
Hedged Class I (CHF)	114.51	108.98	110.75	-	-	-
Hedged Class I (EUR)	125.63	117.67	119.04	116.02	114.59	119.73
Hedged Class I (GBP)	135.38	125.56	125.31	104.69	101.16	104.08
Hedged Class I (JPY)	10,380.27	10,048.46	-	9,766.55	9,941.96	-
Hedged Class I (NOK)	-	1,099.32	1,096.02	-	-	-
Hedged Class O (EUR)	112.47	105.93	107.78	107.34	105.61	109.91
Hedged Class O (GBP)	-	-	-	113.71	110.69	113.48
Hedged Class SI (EUR)	108.19	101.36	102.25	106.89	105.38	109.85
Hedged Class SI (GBP)	110.07	101.95	101.48	114.17	111.04	114.05
Hedged Class SI2 (GBP)	-	-	-	116.40	113.31	116.02
Hedged Class I (SGD)	-	-	-	103.48	-	-
Hedged Class ID (GBP)	104.10	-	-	-	-	-

**NOTES TO THE FINANCIAL STATEMENTS (continued)**

**For the year ended 31 December 2023**

**17. PROSPECTUS CHANGES**

The details of changes in the Prospectus and Supplements during the year are disclosed in Note 20, significant events during the year.

**18. CHARGES OVER ASSETS**

There are no liens or encumbrances on the Company's assets other than:

- (i) standard general liens that the Company, in relation to the Sub-Funds, has provided to the Depositary under the terms of the market standard agreement for the provision of certain depositary services in respect of any fees and expenses or credit exposures incurred in the performance of services under such agreement and;
- (ii) standard security interests over assets of certain Sub-Funds of the Company that the Company has provided to relevant counterparties pursuant to the standard market terms of the relevant trading agreements in place for such Sub-Funds.

Refer to Note 7 for collateral and margin posted by each of the Sub-Funds against financial derivative instruments.

**19. COMMITMENT AND CONTINGENCIES**

The Company and the Sub-Funds did not have commitments and contingencies as at 31 December 2023 (2022: none).

**20. SIGNIFICANT EVENTS DURING THE YEAR**

On 29 September 2023, the Company has changed its legal entity name from Lyxor Newcits IRL Public Limited Company to Amundi Alternative Funds PLC. In addition, sub funds names change from Lyxor/Tiedemann Arbitrage Strategy Fund to Amundi Tiedemann Arbitrage Strategy Fund and Lyxor/Sandler US Equity Fund to Amundi Sandler US Equity Fund. Consequently, supplements were updated for Amundi Tiedemann Arbitrage Strategy Fund and Amundi Sandler US Equity Fund on 29 September 2023.

On 3 November 2023, the Administrator's registered office address changed to Bishop Square, Redmond's Hill, Dublin, D02 TD99, Ireland.

Russia's invasion of Ukraine caused a closure of the Moscow stock exchange and then the closure of the market for Global Depositary Receipts replicating Russian assets and has had an impact on energy and other commodity costs. Although this has not had a material effect on the fund, we have seen bouts of volatility arising as a result. We continue to monitor developments in this crisis and its impact on the management of the fund.

Following Directors resigned during the year:

<b>Name of the Director</b>	<b>Date of resignation</b>
John O'Toole (Irish)	21 November 2023
Paul Webber (Irish)	21 November 2023

There have been no other significant events during the financial period to report.

**21. SUBSEQUENT EVENTS**

There have been no significant events subsequent to years end.

**22. APPROVAL OF THE FINANCIAL STATEMENTS**

The financial statements were approved by the Board of Directors on 29 April 2024.

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Transferrable securities traded on a regulated market</b>			
<b>Equity securities</b>			
Australia			
Origin Energy Ltd	248,024	1,431,670	0.12%
Belgium			
Euronav NV	6,802	119,647	0.01%
British Virgin Islands			
Capri Holdings Ltd	726,401	36,494,386	3.11%
Canada			
Neighbourly Pharmacy Inc	445,757	5,648,072	0.48%
Resolute Forest Procuts Inc	371,838	743,676	0.06%
Sigma Lithium Corp	114,219	3,601,324	0.31%
Xenon Pharmaceuticals Inc	47	2,165	0.00%
Cayman Islands			
Gracell Biotechnologies Inc	498,776	5,007,711	0.43%
Helix Acquisition Corp	47	2,838	0.00%
Manchester United Plc	13,724	279,695	0.02%
Silicon Motion Technology Corp	76,483	4,686,113	0.40%
Finland			
Musti Group Oyj	138,877	4,004,905	0.34%
Germany			
Covestro AG	451,368	26,252,174	2.23%
MorphoSys AG	703	6,960	0.00%
Telefonica Deutschland Holding AG	99,017	257,120	0.02%
Netherlands			
Argenx SE	47	17,880	0.00%
Norway			
Adevinta ASA	278	3,075	0.00%
Sweden			
Olink Holding AB	150,799	3,792,595	0.32%
Switzerland			
Softwareone Holding AG	160	3,120	0.00%
United Kingdom			
Amryt Pharma Holdings Ltd	7,337,860	3,668,930	0.31%
Network International Holdings PLC	1,933,187	9,606,336	0.82%
Smart Metering Systems PLC	609,329	7,301,663	0.62%
United States of America			
Abiomed Inc	370,299	648,024	0.06%
Achillion Pharmaceuticals Inc	230,794	115,397	0.01%
ANSYS Inc	50,326	18,262,299	1.55%
Alaska Air Group Inc	365	14,261	0.00%
Albertsons Cos Inc	666,134	15,321,082	1.30%
Apellis Pharmaceuticals Inc	8,008	479,359	0.04%
BioMarin Pharmaceutical Inc	234	22,562	0.00%
Bristol-Myers Squibb Co	2,641,352	5,282,704	0.45%
Concert Pharmaceuticaxpnparent	1,594,597	478,379	0.04%

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets (continued)</b>			
<b>Transferrable securities traded on a regulated market (continued)</b>			
<b>Equity securities (continued)</b>			
United States of America (continued)			
Cerevel Therapeutics Holdings Inc	8	339	0.00%
Chevron Corp	54,190	8,082,980	0.69%
Cleveland-Cliffs Inc	725,383	14,812,321	1.26%
Cytokinetics Inc	5,903	492,841	0.04%
Endeavor Group Holdings Inc	614,593	14,584,292	1.24%
Hawaiian Holdings Inc	3,735	53,037	0.00%
Hess Corp	14,054	2,026,025	0.17%
Icosavax Inc	197,672	3,115,311	0.27%
ImmunoGen Inc	901,849	26,739,823	2.28%
Intra-Cellular Therapies Inc	17	1,218	0.00%
Karuna Therapeutics Inc	2,554	808,367	0.07%
Kroger Co/The	37	1,691	0.00%
Lantheus Holdings Inc	521	32,302	0.00%
Macy's Inc	23,591	474,651	0.04%
Nucor Corp	2,762	480,698	0.04%
PGT Innovations Inc	7,939	323,117	0.03%
Pfizer Inc	2,102	60,517	0.01%
Prevail Therapeutics Inc	454,689	90,938	0.01%
Quantum-Si Inc	38,686	77,759	0.01%
Sovos Brands Inc	36,232	798,191	0.07%
Splunk Inc	209,885	31,975,980	2.72%
Tapestry Inc	174	6,405	0.00%
United States Steel Corp	1,087,235	52,893,984	4.50%
Westrock Co	29,235	1,213,837	0.10%
<b>Total Equity securities (31 December 2022: USD 699,944,896 - 39.41%)</b>		<b>312,702,746</b>	<b>26.61%</b>
<b>Debt securities</b>			
United States of America			
United States of America , 0.00% , 11 January 2024	65,000,000	64,914,623	5.52%
United States of America , 0.00% , 18 January 2024	60,000,000	59,859,510	5.09%
United States of America , 0.00% , 25 January 2024	60,000,000	59,797,752	5.09%
United States of America , 0.00% , 1 February 2024	65,000,000	64,715,203	5.51%
United States of America , 0.00% , 8 February 2024	65,000,000	64,648,292	5.50%
United States of America , 0.00% , 15 February 2024	65,000,000	64,583,929	5.50%
United States of America , 0.00% , 22 February 2024	65,000,000	64,517,525	5.49%
United States of America , 0.00% , 29 February 2024	65,000,000	64,448,781	5.49%
United States of America , 0.00% , 7 March 2024	65,000,000	64,391,904	5.48%
United States of America , 0.00% , 14 March 2024	65,000,000	64,326,579	5.47%
United States of America , 0.00% , 21 March 2024	65,000,000	64,260,506	5.47%
<b>Total Debt securities (31 December 2022: USD 491,502,305 - 27.68%)</b>		<b>700,464,604</b>	<b>59.61%</b>
<b>Total Transferable securities traded on a regulated market (Assets)</b> <b>(31 December 2022 : USD 1,191,447,201 – 67.09%)</b>		<b>1,013,167,350</b>	<b>86.23%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial derivative instruments (Assets)</b>			
<b>Financial derivative instruments - Dealt in on a regulated market (Assets)</b>			
<b>Warrants</b>			
United States of America			
Adamas Pharmaceuticals Call Option, Strike Price USD 0.5000 , Expiry 12 January 2023	67,071	3,354	0.00%
Adamas Pharmaceuticals Call Option, Strike Price USD 0.5000 , Expiry 31 January 2023	67,071	3,354	0.00%
Flexion Therape Call Option, Strike Price USD 0.5000 , Expiry 14 November 2022	741,865	482,212	0.04%
<b>Total Warrants (31 December 2022: 488,920 - 0.03%)</b>		<b>488,920</b>	<b>0.04%</b>
<b>Listed equity options</b>			
Canada			
Xenon Pharmaceuticals Inc Call Option, Strike Price USD 50.0000 , Expiry 19 January 2024	302	52,850	0.00%
Xenon Pharmaceuticals Inc Call Option, Strike Price USD 50.0000 , Expiry 16 February 2024	1	268	0.00%
Cayman Islands			
Moonlake Immunotherapeutics Call Option, Strike Price USD 70.0000 , Expiry 19 January 2024	499	199,600	0.02%
Germany			
Covestro Ag Put Option, Strike Price EUR 48.0000 , Expiry 19 January 2024	1,462	137,200	0.01%
Covestro Ag Put Option, Strike Price EUR 48.0000 , Expiry 15 March 2024	2,407	568,694	0.05%
Morphosys Ag ADR Call Option, Strike Price USD 10.0000 , Expiry 19 April 2024	424	79,500	0.01%
Morphosys Ag ADR Call Option, Strike Price USD 12.5000 , Expiry 19 January 2024	234	4,680	0.00%
Morphosys Ag ADR Call Option, Strike Price USD 15.0000 , Expiry 19 April 2024	187	13,090	0.00%
Morphosys Ag ADR Call Option, Strike Price USD 7.5000 , Expiry 19 April 2024	307	95,938	0.01%
Netherlands			
Argenx se - ADR Call Option, Strike Price USD 390.0000 , Expiry 19 January 2024	118	124,608	0.01%
Argenx se - ADR Call Option, Strike Price USD 410.0000 , Expiry 19 January 2024	60	36,000	0.00%
Switzerland			
Softwareone Holding Ag Put Option, Strike Price CHF 16.0000 , Expiry 15 March 2024	1,949	282,699	0.02%

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets (continued)</b>			
<b>Financial derivative instruments (Assets) (continued)</b>			
<b>Financial derivative instruments - Dealt in on a regulated market (Assets) (continued)</b>			
<b>Listed equity options (continued)</b>			
United States of America			
Albertsons Cos Inc - Class a Put Option, Strike Price USD 20.0000 , Expiry 19 January 2024	123	1,230	0.00%
Ansys Inc(nsm) Call Option, Strike Price USD 390.0000 , Expiry 19 January 2024	61	37,027	0.00%
Ansys Inc(nsm) Put Option, Strike Price USD 340.0000 , Expiry 19 January 2024	98	59,780	0.01%
Apellis pharmaceuticals Inc Call Option, Strike Price USD 65.0000 , Expiry 19 January 2024	736	349,600	0.03%
Apellis pharmaceuticals Inc Put Option, Strike Price USD 45.0000 , Expiry 19 January 2024	251	32,630	0.00%
Biomarin pharmaceutical Inc Call Option, Strike Price USD 100.0000 , Expiry 19 January 2024	160	24,000	0.00%
Biomarin pharmaceutical Inc Call Option, Strike Price USD 105.0000 , Expiry 19 January 2024	47	3,055	0.00%
Biomarin pharmaceutical Inc Call Option, Strike Price USD 105.0000 , Expiry 19 April 2024	42	15,330	0.00%
Cleveland-Cliffs Inc Put Option, Strike Price USD 18.0000 , Expiry 19 January 2024	458	3,206	0.00%
Cytokinetics Inc Call Option, Strike Price USD 50.0000 , Expiry 19 January 2024	188	638,260	0.05%
Cytokinetics Inc Call Option, Strike Price USD 75.0000 , Expiry 19 January 2024	94	119,850	0.01%
Cytokinetics Inc Put Option, Strike Price USD 60.0000 , Expiry 19 January 2024	141	11,280	0.00%
Cytokinetics Inc Put Option, Strike Price USD 65.0000 , Expiry 19 January 2024	436	65,400	0.01%
Endeavor Group Hold-Class a Put Option, Strike Price USD 21.0000 , Expiry 19 January 2024	1,407	26,733	0.00%
Endeavor Group Hold-Class A Put Option, Strike Price USD 22.0000 , Expiry 19 January 2024	2,494	37,410	0.00%
Intra-Cellular therapies Inc Call Option, Strike Price USD 60.0000 , Expiry 19 January 2024	46	56,580	0.00%
Intra-Cellular therapies Inc Call Option, Strike Price USD 60.0000 , Expiry 16 February 2024	120	168,000	0.01%
Intra-Cellular therapies Inc Call Option, Strike Price USD 65.0000 , Expiry 19 January 2024	399	315,210	0.03%
Intra-Cellular therapies Inc Call Option, Strike Price USD 70.0000 , Expiry 19 January 2024	49	23,520	0.00%
Macy's Inc (nys) Put Option, Strike Price USD 19.5000 , Expiry 19 January 2024	236	8,732	0.00%
Neurocrine Biosciences Inc Call Option, Strike Price USD 140.0000 , Expiry 19 January 2024	293	32,230	0.00%
Neurocrine Biosciences Inc Call Option, Strike Price USD 140.0000 , Expiry 16 February 2024	141	47,940	0.00%
Pfizer Inc Call Option, Strike Price USD 30.0000 , Expiry 16 February 2024	201	12,462	0.00%
Pfizer Inc Call Option, Strike Price USD 35.0000 , Expiry 19 January 2024	207	414	0.00%

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets (continued)</b>			
<b>Financial derivative instruments (Assets) (continued)</b>			
<b>Financial derivative instruments - Dealt in on a regulated market (Assets) (continued)</b>			
<b>Listed equity options (continued)</b>			
United States of America (continued)			
Point Biopharma Global in Call Option, Strike Price USD 12.5000 , Expiry 19 January 2024	2,650	-	0.00%
Spirit Airlines Inc Put Option, Strike Price USD 10.0000 , Expiry 19 January 2024	1,228	127,712	0.01%
United States Steel Corp(NYS) Put Option, Strike Price USD 40.0000 , Expiry 16 February 2024	203	2,639	0.00%
United States Steel Corp(NYS) Put Option, Strike Price USD 40.0000 , Expiry 15 March 2024	8	220	0.00%
United States Steel Corp(NYS) Put Option, Strike Price USD 40.0000 , Expiry 19 April 2024	592	34,928	0.00%
United States Steel Corp(NYS) Put Option, Strike Price USD 41.0000 , Expiry 19 April 2024	24	2,868	0.00%
<b>Total Listed equity options (31 December 2022: USD 1,316,001 – 0.07%)</b>		<b>3,853,373</b>	<b>0.33%</b>
<b>Index Options</b>			
United States of America			
S&P 500 index Put Option, Strike Price USD 4620.0000 , Expiry 15 March 2024	99	484,110	0.04%
S&P 500 index Put Option, Strike Price USD 4760.0000 , Expiry 19 January 2024	20	72,600	0.01%
<b>Total index options</b>		<b>556,710</b>	<b>0.05%</b>
<b>Total Financial derivative instruments - Dealt in on a regulated market (Assets) (31 December 2022: USD 1,804,921 – 0.10%)</b>			
		<b>4,899,003</b>	<b>0.42%</b>
<b>Financial derivative instruments - Over-the-counter (OTC) (Assets)</b>			
<b>Contracts for difference</b>			
Belgium	148,947	40,290	0.00%
Ireland	(29,235)	18,838	0.00%
Spain	1,408,201	364,348	0.03%
United Kingdom	9,029,235	2,974,967	0.25%
United States of America	(654,265)	227,543	0.02%
<b>Total Contracts for difference (31 December 2022: USD 6,216,064 – 0.35%)</b>		<b>3,625,986</b>	<b>0.30%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund (continued)

Financial assets (continued)

Financial derivative instruments - Over-the-counter (OTC) (Assets) (continued)

Foreign currency forwards

Bought Currency	Amount Bought	Sold Currency	Amount Sold	Settlement Date	Unrealised Loss	% of Net Assets
CHF	4,740,183	USD	5,448,226	12 January 2024	191,768	0.02%
EUR	561,262,986	USD	606,967,448	12 January 2024	12,882,717	1.10%
GBP	93,754	USD	119,162	03 January 2024	356	0.00%
GBP	284,879,073	USD	358,948,226	12 January 2024	4,224,388	0.36%
JPY	1,315,970	USD	8,997	12 January 2024	344	0.00%
USD	1,472,112	EUR	1,324,855	12 January 2024	8,880	0.00%
USD	508	GBP	397	02 January 2024	2	0.00%
USD	912,677	GBP	715,100	12 January 2024	1,021	0.00%
USD	7,288,248	GBP	5,700,000	19 January 2024	21,191	0.00%
<b>Total Foreign currency forwards (31 December 2022: USD 97,891,802 – 5.51%)</b>					<b>17,330,667</b>	<b>1.48%</b>
<b>Total Financial derivative instruments - Over-the-counter (OTC) (31 December 2022: USD 104,107,866 – 5.86%)</b>					<b>20,956,653</b>	<b>1.78%</b>
<b>Total Financial derivative instruments (31 December 2022: USD 105,912,787 – 5.96%)</b>					<b>25,855,656</b>	<b>1.9%</b>
<b>Total Financial Assets at Fair Value Through Profit or Loss (31 December 2022: USD 1,297,359,988 – 73.05%)</b>					<b>1,039,023,006</b>	<b>88.43%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial liabilities</b>			
<b>Financial derivative instruments - Dealt in on a regulated market (Liabilities)</b>			
<b>Listed equity options</b>			
Germany			
Covestro AG Call Option, Strike Price EUR 60.0000 , Expiry 19 January 2024	(1,462)	(27,440)	0.00%
Covestro AG Call Option, Strike Price EUR 60.0000 , Expiry 15 March 2024	(2,407)	(217,911)	(0.02)%
Covestro AG Put Option, Strike Price EUR 40.0000 , Expiry 19 January 2024	(1,462)	(24,212)	0.00%
Covestro AG Put Option, Strike Price EUR 42.0000 , Expiry 15 March 2024	(2,407)	(241,828)	(0.02)%
Switzerland			
Softwareone Holding AG Call Option, Strike Price CHF 20.0000 , Expiry 15 March 2024	(1,949)	(90,371)	(0.01)%
Softwareone Holding AG Put Option, Strike Price CHF 13.0000 , Expiry 15 March 2024	(1,949)	(83,419)	(0.01)%
United States of America			
Cytokinetics INC Call Option, Strike Price USD 70.0000 , Expiry 19 January 2024	(188)	(300,800)	(0.03)%
Endeavor Group Hold-Class A Call Option, Strike Price USD 25.0000 , Expiry 16 February 2024	(1,316)	(75,012)	(0.01)%
Endeavor Group Hold-Class A Call Option, Strike Price USD 26.0000 , Expiry 16 February 2024	(1,903)	(55,187)	0.00%
Point Biopharma Global In Call Option, Strike Price USD 15.0000 , Expiry 19 January 2024	(149)	0	0.00%
United States Steel Corp(NYS) Call Option, Strike Price USD 38.0000 , Expiry 19 January 2024	(328)	(354,240)	(0.03)%
United States Steel Corp(NYS) Call Option, Strike Price USD 39.0000 , Expiry 19 January 2024	(88)	(87,560)	(0.01)%
United States Steel Corp(NYS) Call Option, Strike Price USD 50.0000 , Expiry 19 January 2024	(133)	(2,390)	0.00%
<b>Total Listed equity options (31 December 2022: USD (15,653) – (0.00) %)</b>		<b>(1,560,370)</b>	<b>(0.14)%</b>
<b>Total Financial derivative instruments - Dealt in on a regulated market (Liabilities)</b> <b>(31 December 2022: USD (15,653) – (0.00) %)</b>		<b>(1,560,370)</b>	<b>(0.14)%</b>
<b>Financial derivative instruments - Over-the-counter (OTC) (Liabilities)</b>			
<b>Contracts for difference</b>			
Germany	(35,241)	(266,982)	(0.02)%
Japan	2,262	(1,109)	0.00%
United States of America	(1,266,999)	(3,355,870)	(0.29)%
<b>Total Contracts for difference (31 December 2022: USD (3,849,048) – (0.22)%)</b>		<b>(3,623,961)</b>	<b>(0.31)%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Tiedemann Arbitrage Strategy Fund (continued)

Financial liabilities (continued)

Financial derivative instruments (Liabilities) (continued)

Financial derivative instruments - Over-the-counter (OTC) (continued)

Foreign currency forwards

Bought Currency	Amount Bought	Sold Currency	Amount Sold	Settlement Date	Unrealised Loss	% of Net Assets
EUR	1,119,889	USD	1,245,005	02 January 2024	(8,831)	0.00%
EUR	204,967	USD	226,535	03 January 2024	(242)	0.00%
GBP	37,063	USD	47,427	02 January 2024	(180)	0.00%
GBP	193,581	USD	247,042	12 January 2024	(252)	0.00%
USD	2,708,580	AUD	4,000,000	19 January 2024	(18,784)	0.00%
USD	5,258,176	CAD	7,000,000	19 January 2024	(25,708)	0.00%
USD	8,206	CHF	6,923	03 January 2024	(20)	0.00%
USD	293,978	CHF	252,327	12 January 2024	(6,255)	0.00%
USD	2,327,801	CHF	2,000,000	19 January 2024	(53,577)	0.00%
USD	41,611,466	EUR	38,104,478	12 January 2024	(471,373)	(0.04)%
USD	30,501,882	EUR	27,800,000	19 January 2024	(209,038)	(0.02)%
USD	1,198,414	GBP	948,124	12 January 2024	(10,290)	0.00%
USD	10,134,360	GBP	8,000,000	19 January 2024	(64,723)	(0.01)%
<b>Total Foreign currency forwards (31 December 2022: USD (2,442,358) – (0.14)%)</b>					<b>(869,273)</b>	<b>(0.07)%</b>
<b>Total Financial derivative instruments - Over-the-counter (OTC) (31 December 2022: USD (6,291,406) – (0.36)%)</b>					<b>(4,493,234)</b>	<b>(0.07)%</b>
<b>Total Financial Liabilities at Fair Value Through Profit or Loss (31 December 2022: USD (6,307,059)– (0.36)%)</b>					<b>(6,053,604)</b>	<b>(0.52)%</b>
<b>Cash and cash equivalents and Other assets and liabilities (31 December 2022: USD 484,945,176– 27.31%)</b>					<b>142,023,148</b>	<b>12.09%</b>
<b>Net assets attributable to holders of redeemable participating shares (31 December 2022: USD 1,775,998,105– 100.00%)</b>					<b>1,174,992,550</b>	<b>100.00%</b>

Analysis of Total Assets (unaudited)	Fair Value USD	% of Total Assets
Transferable securities traded on a regulated market	1,013,167,350	81.60%
Financial derivative instruments - Dealt in on a regulated market (Assets)	4,899,003	0.39%
Financial derivative instruments - Over-the-counter (OTC) (Assets)	20,956,653	1.69%
Cash and cash equivalents	121,755,134	9.81%
Other assets	80,793,270	6.51%
<b>Total Assets</b>	<b>1,241,571,410</b>	<b>100.00%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS

As at 31 December 2023

Amundi Sandler US Equity Fund

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets</b>			
<b>Transferrable securities traded on a regulated market</b>			
<b>Equity securities</b>			
Canada			
CAE Inc	572,231	12,350,620	1.80%
Shopify Inc	30,284	2,359,124	0.34%
Jersey			
Ferguson Plc	6,552	1,264,995	0.18%
Netherlands			
Elastic Nv	12,883	1,451,914	0.21%
United Kingdom			
Rio Tinto PLC	68,052	5,067,152	0.74%
United States of America			
A. O. Smith Corp	87,600	7,221,744	1.05%
AAON Inc	71,385	5,273,210	0.77%
AECOM	37,531	3,468,990	0.50%
Alphabet Inc	26,699	3,762,690	0.55%
Amazon.com Inc	43,203	6,564,264	0.96%
Applied Materials Inc	43,419	7,036,917	1.02%
Arista Networks Inc	25,318	5,962,642	0.87%
Axon Enterprise Inc	46,435	11,995,554	1.75%
Bio-Techne Corp	32,033	2,471,666	0.36%
BlackRock Inc	6,768	5,494,262	0.80%
Blackstone Inc	17,573	2,300,657	0.33%
Booz Allen Hamilton Holding Corp	20,368	2,605,271	0.38%
Boston Scientific Corp	199,369	11,525,522	1.68%
Caterpillar Inc	16,337	4,830,361	0.70%
Charles River Laboratories International Inc	14,766	3,490,682	0.51%
Clean Harbors Inc	89,218	15,569,434	2.27%
Crowdstrike Holdings Inc	14,306	3,652,608	0.53%
Curtiss-Wright Corp	10,308	2,296,519	0.33%
DR Horton Inc	44,755	6,801,865	0.99%
Datadog Inc	82,278	9,986,904	1.45%
Eli Lilly & Co	10,785	6,286,792	0.91%
Entegris Inc	66,593	7,979,173	1.16%
Exponent Inc	26,509	2,333,852	0.34%
Fair Isaac Corp	1,171	1,363,056	0.20%
Floor & Decor Holdings Inc	9,636	1,074,992	0.16%
Howmet Aerospace Inc	78,416	4,243,874	0.62%
Hubbell Inc	23,697	7,794,654	1.13%
Intuitive Surgical Inc	13,044	4,400,524	0.64%
JB Hunt Transport Services Inc	29,569	5,906,112	0.86%
KLA Corp	3,748	2,178,712	0.32%
Lennox International Inc	7,645	3,421,290	0.50%

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Sandler US Equity Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets (continued)</b>			
<b>Transferrable securities traded on a regulated market (continued)</b>			
<b>Equity securities (continued)</b>			
United States of America (continued)			
Liberty Media Corp-Liberty Formula One	49,441	3,121,210	0.45%
Martin Marietta Materials Inc	20,511	10,233,143	1.49%
Meritage Homes Corp	29,916	5,211,367	0.76%
Meta Platforms Inc	14,711	5,207,106	0.76%
Microsoft Corp	16,406	6,169,312	0.90%
MongoDB Inc	3,459	1,414,212	0.21%
NVIDIA Corp	8,471	4,195,009	0.61%
Nucor Corp	27,673	4,816,209	0.70%
Onto Innovation Inc	65,007	9,939,570	1.45%
Palo Alto Networks Inc	10,773	3,176,742	0.46%
RH	3,744	1,091,301	0.16%
RTX Corp	62,287	5,240,828	0.76%
Rockwell Automation Inc	15,493	4,810,267	0.70%
The Sherwin-Williams Co	32,977	10,285,526	1.50%
Steel Dynamics Inc	71,822	8,482,178	1.23%
Synopsys Inc	14,674	7,555,789	1.10%
Teledyne Technologies Inc	5,154	2,300,179	0.33%
Tetra Tech Inc	32,481	5,422,053	0.79%
The Home Depot Inc	9,802	3,396,883	0.49%
The Procter & Gamble Co	10,945	1,603,880	0.23%
The TJX Cos Inc	82,824	7,769,719	1.13%
Toll Brothers Inc	27,179	2,793,729	0.41%
Union Pacific Corp	12,635	3,103,409	0.45%
Vertiv Holdings Co	184,192	8,846,742	1.29%
Vulcan Materials Co	47,936	10,881,951	1.58%
West Pharmaceutical Services Inc	21,672	7,631,145	1.11%
Xylem Inc/NY	107,721	12,318,974	1.79%
Zillow Group Inc	96,624	5,590,665	0.81%
Zoom Video Communications Inc	116,403	8,370,540	1.22%
<b>Total equity securities (31 December 2022: USD 351,249,323 -30.81%)</b>		<b>362,768,236</b>	<b>52.78%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Sandler US Equity Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets (continued)</b>			
<b>Transferrable securities traded on a regulated market (continued)</b>			
<b>Debt Securities</b>			
United States of America			
United States of America , 0% , 11 January 2024	50,000,000	49,934,325	7.26%
United States of America , 0% , 25 January 2024	50,000,000	49,831,460	7.25%
United States of America , 0% , 01 February 2024	7,000,000	6,969,330	1.01%
United States of America , 0% , 08 February 2024	55,000,000	54,702,401	7.96%
United States of America , 0% , 15 February 2024	60,000,000	59,615,934	8.67%
United States of America , 0% , 29 February 2024	10,000,000	9,915,197	1.44%
United States of America , 0% , 07 March 2024	15,000,000	14,859,671	2.16%
United States of America , 0% , 14 March 2024	4,000,000	3,958,559	0.58%
<b>Total Debt Securities (31 December 2022: USD 500,800,937 -43.93%)</b>		<b>249,786,877</b>	<b>36.33%</b>
<b>Total Transferrable securities traded on a regulated market (Assets)</b> <b>(31 December 2022 : USD 852,050,260 - 74.74%)</b>		<b>612,555,113</b>	<b>89.11%</b>
<b>Financial derivative instruments - Dealt in on a regulated market (Assets)</b>			
<b>Index Options</b>			
United States of America			
NASDAQ 100 STOCK INDEX Put Option, Strike Price USD 16900.0000 , Expiry 19 January 2024	28	612,360	0.09%
<b>Total index options</b>		<b>612,360</b>	<b>0.09%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Sandler US Equity Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets (continued)</b>			
<b>Financial derivative instruments (Assets) (continued)</b>			
<b>Financial derivative instruments – Dealt in on a regulated market (Assets) (continued)</b>			
<b>Listed Equity Options</b>			
Canada			
Magna International Inc(Nys) Put Option, Strike Price Usd 55.0000 , Expiry 15 March 2024	703	115,995	0.02%
Ireland			
Seagate Technology Holdings Put Option, Strike Price Usd 75.0000 , Expiry 16 February 2024	717	73,134	0.01%
Seagate Technology Holdings Put Option, Strike Price Usd 77.5000 , Expiry 16 February 2024	717	110,777	0.02%
Taiwan Province of China			
Taiwan Semiconductor-Sp Adr Call Option, Strike Price Usd 105.0000 , Expiry 19 January 2024	1,167	319,175	0.05%
United States of America			
Albemarle Corp Put Option, Strike Price Usd 135.0000 , Expiry 15 March 2024	468	411,840	0.06%
Bank Of America Corp(Nys) Call Option, Strike Price Usd 30.0000 , Expiry 19 January 2024	936	358,488	0.05%
Capital One Financial Corp Put Option, Strike Price Usd 110.0000 , Expiry 16 February 2024	2,237	145,405	0.02%
Coinbase Global Inc -Class A Put Option, Strike Price Usd 125.0000 , Expiry 16 February 2024	284	105,364	0.02%
Cryptoport Inc (Nas) Put Option, Strike Price Usd 10.0000 , Expiry 16 February 2024	1,252	25,040	0.00%
Ford Motor Co(Nys) Put Option, Strike Price Usd 12.0000 , Expiry 15 March 2024	5,758	356,996	0.05%
Freeport-Memoran Inc(Nys) Call Option, Strike Price Usd 43.0000 , Expiry 16 February 2024	702	136,890	0.02%
Gamestop Corp-Class A Put Option, Strike Price Usd 10.0000 , Expiry 19 April 2024	7,263	210,627	0.03%
Gamestop Corp-Class A Put Option, Strike Price Usd 12.0000 , Expiry 19 April 2024	7,263	435,780	0.06%
Gogo Inc(Nsm) Put Option, Strike Price Usd 10.0000 , Expiry 15 March 2024	4,965	446,850	0.07%
Guess? Inc(Nys) Put Option, Strike Price Usd 23.0000 , Expiry 19 January 2024	3,193	223,510	0.03%
The Hershey Co Call Option, Strike Price Usd 200.0000 , Expiry 16 February 2024	480	122,400	0.02%
Hologic Inc(Nsm) Call Option, Strike Price Usd 75.0000 , Expiry 15 March 2024	701	115,665	0.02%
Live Nation Entertainment In Call Option, Strike Price Usd 85.0000 , Expiry 19 January 2024	933	881,685	0.13%
Live Nation Entertainment In Call Option, Strike Price Usd 92.5000 , Expiry 15 March 2024	1,401	987,705	0.14%
Lucid Group Inc Put Option, Strike Price Usd 4.0000 , Expiry 16 February 2024	2,207	99,315	0.01%
Lucid Group Inc Put Option, Strike Price Usd 4.0000 , Expiry 19 April 2024	956	70,744	0.01%
Mercury Systems Inc Call Option, Strike Price Usd 35.0000 , Expiry 02/16/2024	936	327,600	0.05%
Pure Storage Inc - Class A Call Option, Strike Price Usd 40.0000 , Expiry 15 March 2024	1,639	190,124	0.03%
Synchrony Financial Put Option, Strike Price Usd 35.0000 , Expiry 15 March 2024	3,189	334,845	0.05%
Upstart Holdings Inc Put Option, Strike Price Usd 35.0000 , Expiry 15 March 2024	2,805	1,396,890	0.20%
Valley National Bancorp Put Option, Strike Price Usd 8.0000 , Expiry 15 March 2024	4,668	70,020	0.01%
Yum China Holdings Inc Put Option, Strike Price Usd 55.0000 , Expiry 19 January 2024	516	670,800	0.10%
Zoom Video Communications-A Call Option, Strike Price Usd 80.0000 , Expiry 15 March 2024	703	172,938	0.03%
<b>Total Listed Equity Options</b>		<b>8,916,602</b>	<b>1.21%</b>
<b>Total Financial derivative instruments - Dealt in on a regulated market (Asset)</b> <b>(31 December 2022: USD 33,835,138 -2.97%)</b>		<b>9,528,962</b>	<b>1.30%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Sandler US Equity Fund (continued)

				No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets
<b>Financial assets (continued)</b>						
<b>Financial derivative instruments - Over-the-counter (OTC) (Assets)</b>						
<b>Contracts for Differences</b>						
	France			28,828	962,157	0.14%
	Germany			48,158	401,148	0.06%
	Spain			142,292	837,780	0.12%
	Sweden			140,628	154,474	0.02%
	United States of America			(853,183)	1,235,865	0.18%
<b>Total Contracts for Differences (31 December 2022: USD 61,387,732- 5.38%)</b>					<b>3,591,424</b>	<b>0.52%</b>
<b>Foreign currency forwards</b>						
Bought Currency	Amount Bought	Sold Currency	Amount Sold	Settlement Date	Unrealised Gain	% of Net Assets
EUR	227,648,652	USD	246,092,762	12 January 2024	5,318,695	0.77%
GBP	3,686	USD	4,685	03 January 2024	13	0.00%
GBP	228,476,721	USD	287,750,775	12 January 2024	3,518,110	0.51%
JPY	1,462,086	USD	9,993	12 January 2024	385	0.00%
SGD	8,038	USD	6,084	03 January 2024	7	0.00%
SGD	14,545,431	USD	10,867,467	12 January 2024	158,604	0.02%
USD	6,677	EUR	6,006	02 January 2024	47	0.00%
USD	982,011	EUR	888,488	03 January 2024	1,075	0.00%
USD	180,380	EUR	162,396	12 January 2024	1,023	0.00%
USD	9,243	GBP	7,225	02 January 2024	34	0.00%
USD	266,008	GBP	208,131	12 January 2024	669	0.00%
<b>Total Foreign Currency Forwards (31 December 2022: USD 54,304,761 -4.77%)</b>					<b>8,998,662</b>	<b>1.3%</b>
<b>Total Financial derivative instruments - Over-the-counter (OTC) (Assets)</b> <b>(31 December 2022: USD 115,692,493 -10.15%)</b>					<b>12,590,086</b>	<b>1.82%</b>
<b>Total Financial derivative instruments - (Assets)</b> <b>(31 December 2022: USD 149,527,631 – 13.12%)</b>					<b>22,119,048</b>	<b>3.12%</b>
<b>Total Financial Assets at Fair Value Through Profit or Loss</b> <b>(31 December 2022: USD 1,001,577,891 – 87.86%)</b>					<b>634,674,161</b>	<b>92.23%</b>

AMUNDI ALTERNATIVE FUNDS PLC

SCHEDULE OF INVESTMENTS (continued)

As at 31 December 2023

Amundi Sandler US Equity Fund (continued)

	No. of shares/ Nominal value/ No. of contracts	Fair Value USD	% of Net Assets			
<b>Financial liabilities</b>						
<b>Financial derivative instruments - Dealt in on a regulated market (Liabilities)</b>						
<b>Futures</b>						
United States of America						
NASDAQ 100 STOCK INDEX Expiry 15 March 2024	(74)	(739,665)	(0.11)%			
<b>Total Futures (31 December 2022: USD (56,915) -0.00%)</b>		<b>(739,665)</b>	<b>(0.11)%</b>			
<b>Index Options</b>						
United States of America						
NASDAQ 100 STOCK INDEX Put Option, Strike Price USD 16100.0000 , Expiry 19 January 2024	(28)	(98,000)	(0.01)%			
<b>Total Index options</b>		<b>(98,000)</b>	<b>(0.01)%</b>			
<b>Listed Equity Options</b>						
United States of America						
Albemarle Corp Put Option, Strike Price Usd 110.0000 , Expiry 15 March 2024	(468)	(124,956)	(0.02)%			
<b>Total Listed equity options</b>		<b>(124,956)</b>	<b>(0.02)%</b>			
<b>Total Financial derivative instruments – Dealt in on a regulated market (Liabilities)</b>		<b>(962,621)</b>	<b>(0.14)%</b>			
<b>Financial derivative instruments - Over-the-counter (OTC) (Liabilities)</b>						
<b>Contracts for Differences</b>						
United States of America	(1,953,499)	(8,866,866)	(1.29)%			
<b>Total Contracts for Differences (31 December 2022: USD (10,252,083) -(0.90)%</b>		<b>(8,866,866)</b>	<b>(1.29)%</b>			
<b>Foreign currency forwards</b>						
Bought Currency	Amount Bought	Sold Currency	Amount Sold	Settlement Date	Unrealised Gain	% of Net Assets
EUR	126,715	USD	140,871	02 January 2024	(999)	0.0%
EUR	35,681	USD	39,439	03 January 2024	(45)	0.0%
EUR	894,494	USD	989,031	12 January 2024	(1,120)	0.0%
GBP	109,016	USD	139,498	02 January 2024	(529)	0.0%
GBP	52,869	USD	67,484	12 January 2024	(83)	0.0%
USD	8,776,949	CAD	11,778,665	14 February 2024	(116,502)	(0.02)%
USD	4,677,855	EUR	4,288,144	12 January 2024	(57,989)	(0.01)%
USD	25,016	GBP	19,678	03 January 2024	(69)	0.0%
USD	1,585,205	GBP	1,256,062	12 January 2024	(16,065)	0.0%
USD	234,374	SGD	312,245	12 January 2024	(2,325)	0.0%
<b>Total Foreign Currency Forwards (31 December 2022: USD (1,215,272)- (0.11)%</b>					<b>(195,726)</b>	<b>(0.03)%</b>
<b>Total Financial derivative instruments - Over-the-counter (OTC) (Liabilities)</b> <b>(31 December 2022 USD (11,467,355) – (1.01)%</b>					<b>(9,062,592)</b>	<b>(1.32)%</b>
<b>Total Financial derivative instruments (Liabilities)</b> <b>(31 December 2022: USD (11,524,270) –(1.01)%</b>					<b>(10,025,213)</b>	<b>(1.46)%</b>
<b>Cash and cash equivalents and Other assets and liabilities – net</b> <b>(31 December 2022: USD 106,149,961,992 – 13.15%)</b>					<b>62,688,928</b>	<b>9.12%</b>
<b>Net assets attributable to holders of redeemable participating shares</b> <b>(31 December 2022: USD 1,140,015,613 – 100.00%)</b>					<b>687,337,876</b>	<b>100.00%</b>

**AMUNDI ALTERNATIVE FUNDS PLC****SCHEDULE OF INVESTMENTS (continued)****As at 31 December 2023****Amundi Sandler US Equity Fund (continued)**

<b>Analysis of Total Assets (unaudited)</b>	<b>Fair Value USD</b>	<b>% of Total Assets</b>
Transferable securities traded on a regulated market	612,555,113	86.60%
Financial derivative instruments - Dealt in on a regulated market (Assets)	9,528,962	1.35%
Financial derivative instruments - Over-the-counter (OTC) (Assets)	12,590,086	1.78%
Cash and cash equivalents	48,206,671	6.82%
Other assets	24,433,918	3.45%
<b>Total Assets</b>	<b>707,314,750</b>	<b>100.00%</b>

## AMUNDI ALTERNATIVE FUNDS PLC

### APPENDIX A: SCHEDULE OF PURCHASES AND SALES OF INVESTMENTS (UNAUDITED)

For the year ended 31 December 2023

#### Amundi Tiedemann Arbitrage Strategy Fund

<b>MAJOR PURCHASES</b>	<b>PURCHASE VALUE USD</b>
Activision Blizzard Inc(Nsm)	416,050,839
Horizon Therapeutics Plc	303,870,945
Seagen Inc (Acq)	291,944,559
Vmware Inc-Class A(Nys)	198,826,686
National Instruments Corp	192,989,864
United States Steel Corp(Nys)	157,119,847
Broadcom Inc	153,580,561
Shaw Communications Inc-B	132,047,740
Black Knight Inc (Acq)	120,958,752
Abcam Plc-Spon Adr	115,599,914
Life Storage Inc	114,153,700
United States Treasury Bill-B 0% 11 Jan 2024	97,261,449
United States Treasury Bill-B 0% 08 Jun 2023	95,861,802
Univar Solutions Inc	94,378,850
Oak Street Health Inc	92,962,170
United States Treasury Bill-B 0% 25 Jan 2024	88,151,495
United States Treasury Bill-B 0% 20 Apr 2023	86,165,314
Capri Holdings Ltd	81,190,891
Iveric Bio Inc (Acq)	75,981,217
Prometheus Biosciences In (Acq)	75,025,577

All purchases and sales exceeding 1% of the total value of purchases and sales, respectively, have been disclosed such that, as a minimum, the largest 20 purchases and sales have been disclosed.

**AMUNDI ALTERNATIVE FUNDS PLC**

**APPENDIX A: SCHEDULE OF PURCHASES AND SALES OF INVESTMENTS (UNAUDITED) (continued)**

**For the year ended 31 December 2023**

**Amundi Tiedemann Arbitrage Strategy Fund (continued)**

<b>MAJOR SALES</b>	<b>SALE VALUE USD</b>
Activision Blizzard Inc(Nsm)	(368,403,417)
Horizon Therapeutics Plc	(343,453,467)
Vmware Inc-Class A(Nys)	(260,112,558)
Seagen Inc (Acq)	(232,117,620)
National Instruments Corp	(181,150,894)
Broadcom Inc	(158,954,816)
United States Steel Corp(Nys)	(146,888,585)
Black Knight Inc (Acq)	(130,385,318)
Life Storage Inc	(122,822,341)
Globus Medical Inc - A	(97,871,800)
United States Treasury Bill-B 0% 08 Jun 2023	(83,626,314)
Tegna Inc(Nys)	(81,756,610)
Tower Semiconductor Ltd(Nsm)	(74,406,068)
Ritchie Bros Auctioneers( Old)	(73,990,209)
Silicon Motion Technol-Adr(Nsm)	(65,483,908)
United States Treasury Bill-B 0% 26 Oct 2023	(64,329,387)
Oak Street Health Inc	(63,038,873)
First Horizon Corp	(57,740,329)
Simcorp A/S	(55,246,285)
Public Storage(Nys)	(54,369,992)
Sierra Wireless Inc(Del) (Acq)	(54,318,675)

All purchases and sales exceeding 1% of the total value of purchases and sales, respectively, have been disclosed such that, as a minimum, the largest 20 purchases and sales have been disclosed.

**AMUNDI ALTERNATIVE FUNDS PLC**

**APPENDIX A: SCHEDULE OF PURCHASES AND SALES OF INVESTMENTS (UNAUDITED) (continued)**

**For the year ended 31 December 2023**

**Amundi Sandler US Equity Fund**

<b>MAJOR PURCHASES</b>	<b>PURCHASE VALUE USD</b>
United States Treasury Bill-B 0% 07 Sep 2023	113,911,901
United States Treasury Bill-B 0% 04 May 2023	84,252,240
United States Treasury Bill-B 0% 07 Dec 2023	69,140,153
United States Treasury Bill-B 0% 08 Feb 2024	60,862,228
United States Treasury Bill-B 0% 01 Jun 2023	59,873,988
United States Treasury Bill-B 0% 25 May 2023	59,632,500
United States Treasury Bill-B 0% 09 Nov 2023	59,185,469
United States Treasury Bill-B 0% 03 Aug 2023	59,131,038
United States Treasury Bill-B 0% 12 Oct 2023	59,121,641
United States Treasury Bill-B 0% 05 Oct 2023	59,107,588
United States Treasury Bill-B 0% 19 Oct 2023	59,092,713
United States Treasury Bill-B 0% 22 Jun 2023	59,077,651
United States Treasury Bill-B 0% 26 Oct 2023	59,038,648
United States Treasury Bill-B 0% 15 Feb 2024	58,887,420
United States Treasury Bill-B 0% 06 Jul 2023	58,058,016
United States Treasury Bill-B 0% 06 Apr 2023	54,503,682
United States Treasury Bill-B 0% 20 Jul 2023	54,421,158
United States Treasury Bill-B 0% 21 Sep 2023	54,285,750
United States Treasury Bill-B 0% 14 Sep 2023	54,222,488
United States Treasury Bill-B 0% 08 Jun 2023	54,211,263
United States Treasury Bill-B 0% 13 Jul 2023	54,173,007
United States Treasury Bill-B 0% 13 Apr 2023	49,536,268
United States Treasury Bill-B 0% 29 Jun 2023	49,502,762
United States Treasury Bill-B 0% 11 Jan 2024	49,129,069
United States Treasury Bill-B 0% 25 Jan 2024	49,106,357
United States Treasury Bill-Microsoft Corp	48,284,220
United States Treasury Bill-B 0% 07 Mar 2024	44,218,304
United States Treasury Bill-B 0% 14 Mar 2024	44,173,813
Meta Platforms Inc-Class A	42,522,491
United States Treasury Bill-B 0% 09 Feb 2023	39,896,184
United States Treasury Bill-B 0% 15 Jun 2023	37,640,053
Boston Scientific Corp	36,294,341
Live Nation Entertainment In	34,235,467
Amazon.Com Inc	31,750,423

All purchases and sales exceeding 1% of the total value of purchases and sales, respectively, have been disclosed such that, as a minimum, the largest 20 purchases and sales have been disclosed.

AMUNDI ALTERNATIVE FUNDS PLC

APPENDIX A: SCHEDULE OF PURCHASES AND SALES OF INVESTMENTS (UNAUDITED) (continued)

For the year ended 31 December 2023

Amundi Sandler US Equity Fund (continued)

MAJOR SALES	SALE VALUE USD
United States Treasury Bill-B 0% 07 Dec 2023	(69,673,172)
United States Treasury Bill-B 0% 07 Sep 2023	(54,573,491)
United States Treasury Bill-B 0% 25 May 2023	(49,919,296)
Hubbell Inc	(45,465,265)
Microsoft Corp	(44,879,890)
Nvidia Corp	(44,463,009)
United States Treasury Bill-B 0% 14 Mar 2024	(40,431,058)
Meta Platforms Inc-Class A	(38,460,447)
Live Nation Entertainment In	(37,675,964)
Synopsys Inc(NSM)	(30,839,304)
United States Treasury Bill-B 0% 04 May 2023	(29,783,000)
United States Treasury Bill-B 0% 07 Mar 2024	(29,611,588)
Charles River Laboratories(NYS)	(29,532,078)
Eaton Corp Plc	(27,276,659)
Boston Scientific Corp	(26,315,566)
Hologic Inc(NSM)	(25,777,582)
Amazon.Com Inc	(25,690,455)
Dr Horton Inc	(25,374,596)
Advanced Micro Devices	(24,642,418)
Martin Marietta Materials	(23,509,346)
Rockwell Automation Inc	(23,001,819)
Vulcan Materials Co	(22,552,540)
Tetra Tech Inc	(22,330,666)
United States Treasury Bill-B 0% 19 Oct 2023	(20,996,917)
United States Treasury Bill-B 0% 29 Feb 2024	(20,787,238)
Pure Storage Inc - Class A	(20,540,291)
United States Treasury Bill-B 0% 03 Aug 2023	(19,974,265)
On Semiconductor	(19,881,813)
Alphabet Inc-CL C	(19,796,395)
Nxp Semiconductors NV	(19,391,228)
Nextracker Inc-CL A	(19,058,486)
United States Treasury Bill-B 0% 26 Oct 2023	(18,977,700)
Intuitive Surgical Inc	(18,950,896)

All purchases and sales exceeding 1% of the total value of purchases and sales, respectively, have been disclosed such that, as a minimum, the largest 20 purchases and sales have been disclosed.

## AMUNDI ALTERNATIVE FUNDS PLC

### APPENDIX B: TOTAL EXPENSE RATIO (UNAUDITED) (Annualised)

For the year ended 31 December 2023

This appendix makes the annual report with the FINMA requirements for the marketing in Switzerland. **It has not been certified by the accountants.**

#### Country of origin of the Fund

Ireland.

#### Representative of the Fund in Switzerland

Société Générale, Paris, Zurich Branch, has been authorised by the FINMA as the Fund's representative in Switzerland while also assuming the payment service. The prospectus, articles of association, annual and semi-annual reports of the Fund, the KIIDs as well as the list of purchases and sales made by the Fund during the fiscal year can be obtained on request and at no cost from the representative's head office in Switzerland, Société Générale, Paris, Zurich Branch, Talacker 50, PO Box 5070, 8021 Zurich.

The total Expense Ratio (TER) are calculated according to the recommendations of the Asset Management Association Switzerland (AMAS).

Share class	Total expense ratio	Management fee expense %	Investment advisory fee %	Performance fee expense %	Administrative expenses %
<b>Amundi Tiedemann Arbitrage Strategy Fund</b>					
Hedged Class I (EUR)	2.71%	1.00%	0.40%	1.12%	0.19%
Class I (USD)	3.63%	1.00%	0.40%	2.04%	0.19%
Hedged Class I (CHF)	2.39%	1.00%	0.40%	0.80%	0.19%
Hedged Class I (GBP)	2.27%	1.00%	0.40%	0.69%	0.18%
Hedged Class A (EUR)	3.38%	1.00%	1.25%	0.94%	0.19%
Class A (USD)	4.24%	1.00%	1.25%	1.80%	0.19%
Hedged Class A (CHF)	2.93%	1.00%	1.25%	0.49%	0.19%
Hedged Class A (GBP)	3.83%	1.00%	1.25%	1.39%	0.19%
Hedged Class EB (EUR)	2.60%	1.00%	0.10%	1.31%	0.19%
Hedged Class I (JPY)	2.54%	1.00%	0.40%	0.95%	0.19%
Class AA (USD)	4.43%	1.00%	1.41%	1.83%	0.19%
Class IA (USD)	3.76%	1.00%	0.55%	2.02%	0.19%
Hedged Class I (NOK)	0.82%	0.50%	0.22%	0.01%	0.09%
Hedged Class O (EUR)	3.02%	1.00%	1.00%	0.84%	0.18%
Class O (USD)	3.49%	1.00%	1.00%	1.30%	0.19%
Hedged Class SI (EUR)	2.47%	1.00%	0.15%	1.14%	0.18%
Hedged Class SI (GBP)	3.34%	1.00%	0.15%	2.00%	0.19%
Class SI (USD)	3.21%	1.00%	0.15%	1.87%	0.19%
Hedged Class C (EUR)	3.57%	1.01%	0.81%	1.56%	0.19%
Class C (USD)	4.02%	1.00%	0.81%	2.02%	0.19%
Class ID GBP	2.93%	1.03%	0.41%	1.28%	0.21%
<b>Amundi Sandler US Equity Fund</b>					
Hedged Class SI (GBP)	1.48%	1.20%	0.00%	0.10%	0.18%
Hedged Class A (EUR)	2.33%	2.15%	0.00%	0.00%	0.18%
Hedged Class EB (EUR)	1.18%	1.00%	0.00%	0.00%	0.18%
Class A (USD)	2.35%	2.15%	0.00%	0.02%	0.18%
Class I (USD)	1.96%	1.40%	0.00%	0.38%	0.18%
Class AA (USD)	2.48%	2.30%	0.00%	0.00%	0.18%
Class IA (USD)	2.06%	1.70%	0.00%	0.18%	0.18%
Hedged Class SI2 (GBP)	1.44%	0.94%	0.00%	0.33%	0.17%
Hedged Class O (GBP)	1.51%	1.00%	0.00%	0.33%	0.18%
Hedged Class I (EUR)	1.58%	1.40%	0.00%	0.00%	0.18%
Class O (USD)	1.56%	1.00%	0.00%	0.38%	0.18%
Hedged Class C (EUR)	1.98%	1.80%	0.00%	0.00%	0.18%
Hedged Class O (EUR)	1.18%	1.00%	0.00%	0.00%	0.18%
Class C (USD)	2.01%	1.80%	0.00%	0.03%	0.18%
Hedged Class SI (EUR)	1.38%	1.20%	0.00%	0.00%	0.18%
Class SI (USD)	1.75%	1.20%	0.00%	0.37%	0.18%

## AMUNDI ALTERNATIVE FUNDS PLC

### APPENDIX B: TOTAL EXPENSE RATIO (UNAUDITED) (Annualised) (Continued)

For the year ended 31 December 2023

Hedged Class I (GBP)	1.74%	1.50%	0.00%	0.06%	0.18%
Hedged Class I (JPY)	1.53%	1.40%	0.00%	0.00%	0.13%
Hedged Class I (SGD)	1.61%	1.40%	0.00%	0.02%	0.19%

### APPENDIX B: TOTAL EXPENSE RATIO (UNAUDITED) (Annualised)

For the year ended 31 December 2022

Share class	Total expense ratio	Management fee expense %	Investment advisory fee %	Performance fee expense %	Administrative expenses %
<b>Amundi Tiedemann Arbitrage Strategy Fund</b>					
Hedged Class I (EUR)	1.58%	0.40%	1.00%	0.01%	0.17%
Class I (USD)	1.75%	0.40%	1.00%	0.18%	0.17%
Hedged Class I (CHF)	1.57%	0.40%	1.00%	0.00%	0.17%
Hedged Class I (GBP)	1.64%	0.40%	1.00%	0.07%	0.17%
Hedged Class A (EUR)	2.42%	1.25%	1.00%	0.00%	0.17%
Class A (USD)	2.49%	1.25%	1.00%	0.07%	0.17%
Hedged Class A (CHF)	2.42%	1.25%	1.00%	0.00%	0.17%
Hedged Class A (GBP)	2.44%	1.25%	1.00%	0.02%	0.17%
Hedged Class EB (EUR)	1.27%	0.10%	1.00%	0.00%	0.17%
Hedged Class I (JPY)	1.57%	0.40%	1.00%	0.00%	0.17%
Class AA (USD)	2.60%	1.40%	1.00%	0.03%	0.17%
Class IA (USD)	1.92%	0.55%	1.00%	0.20%	0.17%
Hedged Class I (NOK)	1.64%	0.40%	1.00%	0.07%	0.17%
Hedged Class O (EUR)	2.17%	1.00%	1.00%	0.00%	0.17%
Class O (USD)	2.23%	1.00%	1.00%	0.06%	0.17%
Hedged Class SI (EUR)	1.33%	0.15%	1.00%	0.01%	0.17%
Hedged Class SI (GBP)	1.45%	0.15%	1.00%	0.13%	0.17%
Class SI (USD)	1.59%	0.15%	1.00%	0.27%	0.17%
Hedged Class C (EUR)	1.96%	0.80%	1.00%	0.00%	0.16%
Class C (USD)	1.96%	0.80%	1.00%	0.00%	0.16%
<b>Amundi Sandler US Equity Fund</b>					
Hedged Class SI (GBP)	1.37%	0.00%	1.20%	0.00%	0.17%
Hedged Class A (EUR)	2.32%	0.00%	2.15%	0.00%	0.17%
Hedged Class EB (EUR)	1.17%	0.00%	1.00%	0.00%	0.17%
Class A (USD)	2.32%	0.00%	2.15%	0.00%	0.17%
Class I (USD)	1.57%	0.00%	1.40%	0.00%	0.17%
Class AA (USD)	2.47%	0.00%	2.30%	0.00%	0.17%
Class IA (USD)	1.87%	0.00%	1.70%	0.00%	0.17%
Hedged Class SI2 (GBP)	1.07%	0.00%	0.90%	0.00%	0.17%
Hedged Class O (GBP)	1.17%	0.00%	1.00%	0.00%	0.17%
Hedged Class I (EUR)	1.57%	0.00%	1.40%	0.00%	0.17%
Class O (USD)	1.17%	0.00%	1.00%	0.00%	0.17%
Hedged Class C (EUR)	1.97%	0.00%	1.80%	0.00%	0.17%
Hedged Class O (EUR)	1.17%	0.00%	1.00%	0.00%	0.17%
Class C (USD)	1.97%	0.00%	1.80%	0.00%	0.17%
Hedged Class SI (EUR)	1.37%	0.00%	1.20%	0.00%	0.17%
Class SI (USD)	1.37%	0.00%	1.20%	0.00%	0.17%
Hedged Class I (GBP)	1.57%	0.00%	1.40%	0.00%	0.17%
Hedged Class I (JPY)	1.40%	0.00%	1.40%	0.00%	0.00%